PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31703731-4	2019	RESULTS: We performed CCK-8 assay to detect apoptosis rates in response to CAM alone or in combination with cisplatin, which were further confirmed by Annexin V and PI staining methods and western blotting.	Clarithromycin	75-78	annexin A5	Mus musculus	151-160
31881688-9	2019	The overall H. pylori eradication rate was 83.7%, and the seven-day PAM-treated clarithromycin-resistance group showed a significantly lower eradication rate than the seven-day PAC-treated nonresistance group (ITT; 55.4% (51/92) vs. 74.3% (252/339), p = 0.001, PP; 66.2% (51/77) vs. 88.4% (252/285), p = 0.0001).	Clarithromycin	80-94	peptidylglycine alpha-amidating monooxygenase	Homo sapiens	68-71
31881688-10	2019	CONCLUSIONS: There were significantly lower eradication rates in the patients with clarithromycin-resistant H. pylori when treated with PAM for seven days.	Clarithromycin	83-97	peptidylglycine alpha-amidating monooxygenase	Homo sapiens	136-139
31129789-0	2019	Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.	Clarithromycin	203-217	solute carrier organic anion transporter family member 1B1	Homo sapiens	82-89
31129789-0	2019	Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.	Clarithromycin	203-217	solute carrier organic anion transporter family member 1B1	Homo sapiens	91-98
32879197-7	2020	Thus, these results indicate that the NADPH-dependent CPR/CYP4 system is responsible for CLA formation.	Clarithromycin	89-92	cytochrome p450 oxidoreductase	Mus musculus	54-57
32879197-10	2020	Therefore, we conclude that the CYP4F13 enzyme is the major enzyme involved in CLA formation.	Clarithromycin	79-82	cytochrome P450, family 4, subfamily f, polypeptide 13	Mus musculus	32-39
31030414-5	2019	Oral clarithromycin IR 500 mg bid was given alone on days 9 and 10.	Clarithromycin	5-19	BH3 interacting domain death agonist	Homo sapiens	30-33
31656654-0	2019	Effect of rifampicin and clarithromycin on the CYP3A activity in patients with Mycobacterium avium complex.	Clarithromycin	25-39	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	47-52
31157746-4	2019	clarithromycin, a P-gp inhibitor.	Clarithromycin	0-14	ATP binding cassette subfamily B member 1	Homo sapiens	18-22
30973998-11	2019	In conclusion, the P-gp inhibitor clarithromycin significantly increases distribution volumes but not oral absorption of trospium.	Clarithromycin	34-48	ATP binding cassette subfamily B member 1	Homo sapiens	19-23
31656654-3	2019	The cytochrome P450 (CYP) enzyme inducer, rifampicin, and the CYP inhibitor, clarithromycin, have clinical activity against MAC and key drugs in the treatment of MAC infection.	Clarithromycin	77-91	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-65
31283028-10	2019	There was a significant decrease in the serum interleukin-8(IL-8), interleukin-4(IL-4), and eotaxin levels following 3 weeks of clarithromycin therapy.	Clarithromycin	128-142	C-X-C motif chemokine ligand 8	Homo sapiens	46-59
31656654-12	2019	Conclusions: Coadministration of rifampicin and clarithromycin may increase CYP3A enzymatic activity.	Clarithromycin	48-62	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	76-81
31283028-10	2019	There was a significant decrease in the serum interleukin-8(IL-8), interleukin-4(IL-4), and eotaxin levels following 3 weeks of clarithromycin therapy.	Clarithromycin	128-142	C-X-C motif chemokine ligand 8	Homo sapiens	60-64
31283028-10	2019	There was a significant decrease in the serum interleukin-8(IL-8), interleukin-4(IL-4), and eotaxin levels following 3 weeks of clarithromycin therapy.	Clarithromycin	128-142	interleukin 4	Homo sapiens	67-80
31283028-10	2019	There was a significant decrease in the serum interleukin-8(IL-8), interleukin-4(IL-4), and eotaxin levels following 3 weeks of clarithromycin therapy.	Clarithromycin	128-142	interleukin 4	Homo sapiens	81-85
31283028-10	2019	There was a significant decrease in the serum interleukin-8(IL-8), interleukin-4(IL-4), and eotaxin levels following 3 weeks of clarithromycin therapy.	Clarithromycin	128-142	C-C motif chemokine ligand 11	Homo sapiens	92-99
31382897-11	2019	Using published data and MPC90, we calculated the time inside the MSW (TMSW) for low- and high-dose (200 or 500 mg bid) clarithromycin that were 6 and 0 h, 24 and 4 h, 15 and 2 h, 5 and 17 h for the strains with MICs (mg/L) of 0.016, 0.031, 0.062-0.125, and 0.25, respectively.	Clarithromycin	120-134	BH3 interacting domain death agonist	Homo sapiens	115-118
30892121-4	2019	Cabergoline and clarithromycin significantly lowered VEGF-2 levels.	Clarithromycin	16-30	vascular endothelial growth factor A	Rattus norvegicus	53-57
30892121-5	2019	Clarithromycin significantly reduced IL-1b and TNF-a and significantly increased IL-10 levels.	Clarithromycin	0-14	interleukin 1 beta	Rattus norvegicus	37-42
30892121-5	2019	Clarithromycin significantly reduced IL-1b and TNF-a and significantly increased IL-10 levels.	Clarithromycin	0-14	tumor necrosis factor	Rattus norvegicus	47-52
30892121-5	2019	Clarithromycin significantly reduced IL-1b and TNF-a and significantly increased IL-10 levels.	Clarithromycin	0-14	interleukin 10	Rattus norvegicus	81-86
30892121-10	2019	Clarithromycin is known to suppress the production of some pro-inflammatory molecules such as VEGF, IL-8, IL-1, IL-6 and TNF-a.	Clarithromycin	0-14	vascular endothelial growth factor A	Rattus norvegicus	94-98
30892121-10	2019	Clarithromycin is known to suppress the production of some pro-inflammatory molecules such as VEGF, IL-8, IL-1, IL-6 and TNF-a.	Clarithromycin	0-14	interleukin 6	Rattus norvegicus	112-116
30892121-10	2019	Clarithromycin is known to suppress the production of some pro-inflammatory molecules such as VEGF, IL-8, IL-1, IL-6 and TNF-a.	Clarithromycin	0-14	tumor necrosis factor	Rattus norvegicus	121-126
31095708-12	2019	Milk fat from FLX cows had greater (P < 0.01) CLA and CLnA concentrations than that of CAN cows during the first 42 d of lactation.	Clarithromycin	49-52	Weaning weight-maternal milk	Bos taurus	0-4
31212682-12	2019	The nutrigenomic effect of C16:0 is not via PPARgamma but likely via unknown transcription factor(s) while PPARgamma plays an indirect role on the nutrigenomic effect of polyunsaturated LCFA (PUFA) on milk fat related genes, particularly for CLA (permitting effect) and DHA (blocking effect).	Clarithromycin	242-245	peroxisome proliferator-activated receptor gamma	Capra hircus	107-116
31212682-12	2019	The nutrigenomic effect of C16:0 is not via PPARgamma but likely via unknown transcription factor(s) while PPARgamma plays an indirect role on the nutrigenomic effect of polyunsaturated LCFA (PUFA) on milk fat related genes, particularly for CLA (permitting effect) and DHA (blocking effect).	Clarithromycin	242-245	LCFA	Bos taurus	186-190
30920135-7	2019	The up-regulation of CYP3A4 associated with disease control was reversed by clarithromycin, a potent inhibitor of CYP3A4.	Clarithromycin	76-90	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	21-27
30920135-7	2019	The up-regulation of CYP3A4 associated with disease control was reversed by clarithromycin, a potent inhibitor of CYP3A4.	Clarithromycin	76-90	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	114-120
30936099-5	2019	In addition, more C. gattii cells were phagocytosed by murine macrophages, resulting in increased production of tumor necrosis factor alpha (TNF-alpha) by CAM exposure.	Clarithromycin	155-158	tumor necrosis factor	Mus musculus	112-139
30936099-5	2019	In addition, more C. gattii cells were phagocytosed by murine macrophages, resulting in increased production of tumor necrosis factor alpha (TNF-alpha) by CAM exposure.	Clarithromycin	155-158	tumor necrosis factor	Mus musculus	141-150
31233128-13	2019	Milk fat from FLX cows had greater (P < 0.01) CLA and CLnA concentrations than that of CAN cows during the first 42 d of lactation.	Clarithromycin	49-52	Weaning weight-maternal milk	Bos taurus	0-4
30642055-4	2019	Addition of CLA to the differentiation medium further increased the mRNA level of Wnt3a, Wnt10b, Frizzled 4, LRP5, and beta-catenin, inferring that CLA worked by stimulating Wnt/LRP5/beta-catenin signaling.	Clarithromycin	12-15	Wnt family member 3A	Homo sapiens	82-87
31149626-7	2019	All initial isolates were resistant to clarithromycin (minimum inhibitory concentration (MIC) >=8 microg mL-1).	Clarithromycin	39-53	L1 cell adhesion molecule	Mus musculus	108-112
30898762-7	2019	Furthermore, clarithromycin, a clinically active CYP3A4 inhibitor, significantly reversed the protective effects of BMSCs.	Clarithromycin	13-27	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	49-55
30642055-4	2019	Addition of CLA to the differentiation medium further increased the mRNA level of Wnt3a, Wnt10b, Frizzled 4, LRP5, and beta-catenin, inferring that CLA worked by stimulating Wnt/LRP5/beta-catenin signaling.	Clarithromycin	12-15	Wnt family member 10B	Homo sapiens	89-95
30642055-4	2019	Addition of CLA to the differentiation medium further increased the mRNA level of Wnt3a, Wnt10b, Frizzled 4, LRP5, and beta-catenin, inferring that CLA worked by stimulating Wnt/LRP5/beta-catenin signaling.	Clarithromycin	12-15	frizzled class receptor 4	Homo sapiens	97-107
30642055-4	2019	Addition of CLA to the differentiation medium further increased the mRNA level of Wnt3a, Wnt10b, Frizzled 4, LRP5, and beta-catenin, inferring that CLA worked by stimulating Wnt/LRP5/beta-catenin signaling.	Clarithromycin	12-15	LDL receptor related protein 5	Homo sapiens	109-113
30642055-4	2019	Addition of CLA to the differentiation medium further increased the mRNA level of Wnt3a, Wnt10b, Frizzled 4, LRP5, and beta-catenin, inferring that CLA worked by stimulating Wnt/LRP5/beta-catenin signaling.	Clarithromycin	12-15	catenin beta 1	Homo sapiens	119-131
30642055-4	2019	Addition of CLA to the differentiation medium further increased the mRNA level of Wnt3a, Wnt10b, Frizzled 4, LRP5, and beta-catenin, inferring that CLA worked by stimulating Wnt/LRP5/beta-catenin signaling.	Clarithromycin	12-15	LDL receptor related protein 5	Homo sapiens	178-182
30642055-4	2019	Addition of CLA to the differentiation medium further increased the mRNA level of Wnt3a, Wnt10b, Frizzled 4, LRP5, and beta-catenin, inferring that CLA worked by stimulating Wnt/LRP5/beta-catenin signaling.	Clarithromycin	12-15	catenin beta 1	Homo sapiens	183-195
30642055-4	2019	Addition of CLA to the differentiation medium further increased the mRNA level of Wnt3a, Wnt10b, Frizzled 4, LRP5, and beta-catenin, inferring that CLA worked by stimulating Wnt/LRP5/beta-catenin signaling.	Clarithromycin	148-151	Wnt family member 3A	Homo sapiens	82-87
30642055-4	2019	Addition of CLA to the differentiation medium further increased the mRNA level of Wnt3a, Wnt10b, Frizzled 4, LRP5, and beta-catenin, inferring that CLA worked by stimulating Wnt/LRP5/beta-catenin signaling.	Clarithromycin	148-151	Wnt family member 10B	Homo sapiens	89-95
30642055-4	2019	Addition of CLA to the differentiation medium further increased the mRNA level of Wnt3a, Wnt10b, Frizzled 4, LRP5, and beta-catenin, inferring that CLA worked by stimulating Wnt/LRP5/beta-catenin signaling.	Clarithromycin	148-151	frizzled class receptor 4	Homo sapiens	97-107
30642055-4	2019	Addition of CLA to the differentiation medium further increased the mRNA level of Wnt3a, Wnt10b, Frizzled 4, LRP5, and beta-catenin, inferring that CLA worked by stimulating Wnt/LRP5/beta-catenin signaling.	Clarithromycin	148-151	LDL receptor related protein 5	Homo sapiens	109-113
30642055-4	2019	Addition of CLA to the differentiation medium further increased the mRNA level of Wnt3a, Wnt10b, Frizzled 4, LRP5, and beta-catenin, inferring that CLA worked by stimulating Wnt/LRP5/beta-catenin signaling.	Clarithromycin	148-151	catenin beta 1	Homo sapiens	119-131
30642055-4	2019	Addition of CLA to the differentiation medium further increased the mRNA level of Wnt3a, Wnt10b, Frizzled 4, LRP5, and beta-catenin, inferring that CLA worked by stimulating Wnt/LRP5/beta-catenin signaling.	Clarithromycin	148-151	LDL receptor related protein 5	Homo sapiens	178-182
30642055-4	2019	Addition of CLA to the differentiation medium further increased the mRNA level of Wnt3a, Wnt10b, Frizzled 4, LRP5, and beta-catenin, inferring that CLA worked by stimulating Wnt/LRP5/beta-catenin signaling.	Clarithromycin	148-151	catenin beta 1	Homo sapiens	183-195
30642055-5	2019	Wnt inhibitor dickkopf-1 antagonized CLA-promoted osteoblastogenesis, indicating that CLA did not target the downstream of canonical Wnt signaling pathway.	Clarithromycin	37-40	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	14-24
30318006-15	2019	Of all mutations in bacterial genome, the prominent mutations responsible for bacterial resistance to Clarithromycin included A2142C, A2142G, and A2143G nucleotide polymorphism on 23S rRNA gene.	Clarithromycin	102-116	mitochondrially encoded 12S RNA	Homo sapiens	182-188
30403784-9	2019	Conclusions: Consequently, fluoroquinolones/metronidazole/clarithromycin-based triple therapies can be used to eradicate H. pylori infection, if one does not know the CYP2C19 genotype of the patient.	Clarithromycin	58-72	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	167-174
30393041-0	2019	Clarithromycin suppresses IL-13-induced goblet cell metaplasia via the TMEM16A-dependent pathway in guinea pig airway epithelial cells.	Clarithromycin	0-14	interleukin-13	Cavia porcellus	26-31
30393041-2	2019	Clarithromycin (CAM) is reported to inhibit IL-13-induced goblet cell metaplasia.	Clarithromycin	0-14	interleukin-13	Cavia porcellus	44-49
30393041-2	2019	Clarithromycin (CAM) is reported to inhibit IL-13-induced goblet cell metaplasia.	Clarithromycin	16-19	interleukin-13	Cavia porcellus	44-49
30393041-16	2019	CAM may thus improve airway mucociliary differentiation by attenuating TMEM16A expression in IL-13-related asthma.	Clarithromycin	0-3	interleukin-13	Cavia porcellus	93-98
30091221-0	2018	PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.	Clarithromycin	96-110	phosphoglycolate phosphatase	Homo sapiens	27-31
30647742-4	2018	Clarithromycin is a macrolide with anti-inflammatory activity through blockage of the p38 MAPK signal cascade, which is involved in methotrexate-induced pulmonary toxicity.	Clarithromycin	0-14	mitogen activated protein kinase 14	Rattus norvegicus	86-89
30496270-10	2018	Acquired clarithromycin resistance explicable by the A2271G/C mutation of rrl was seen in only 7/16 (43.75%) of strains.	Clarithromycin	9-23	rrl	Mycobacterium abscessus	74-77
30262139-1	2018	In vitro, the rat Fatty Acid Desaturase 3 (FADS3) gene was shown to code for an enzyme able to catalyze the unexpected Delta13-desaturation of trans-vaccenic acid, producing the trans11,cis13-conjugated linoleic acid (CLA) isomer.	Clarithromycin	218-221	fatty acid desaturase 3	Rattus norvegicus	18-41
30262139-1	2018	In vitro, the rat Fatty Acid Desaturase 3 (FADS3) gene was shown to code for an enzyme able to catalyze the unexpected Delta13-desaturation of trans-vaccenic acid, producing the trans11,cis13-conjugated linoleic acid (CLA) isomer.	Clarithromycin	218-221	fatty acid desaturase 3	Rattus norvegicus	43-48
29550174-11	2018	CONCLUSIONS: CAM suppressed the progression and rupture of AA through the suppression of inflammatory macrophage infiltration, a reduction in MMP-2 and MMP-9 activity, and the inhibition of elastin degradation associated with the suppression of NF-kappaB phosphorylation.	Clarithromycin	13-16	matrix metallopeptidase 2	Mus musculus	142-147
29550174-11	2018	CONCLUSIONS: CAM suppressed the progression and rupture of AA through the suppression of inflammatory macrophage infiltration, a reduction in MMP-2 and MMP-9 activity, and the inhibition of elastin degradation associated with the suppression of NF-kappaB phosphorylation.	Clarithromycin	13-16	matrix metallopeptidase 9	Mus musculus	152-157
29550174-11	2018	CONCLUSIONS: CAM suppressed the progression and rupture of AA through the suppression of inflammatory macrophage infiltration, a reduction in MMP-2 and MMP-9 activity, and the inhibition of elastin degradation associated with the suppression of NF-kappaB phosphorylation.	Clarithromycin	13-16	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	245-254
30032669-2	2018	OBJECTIVE(S): The objective was to describe the characteristics of hearing losses documented in patients treated with clarithromycin alone for nontuberculous mycobacterial NTM lymphadenitis in a pediatric tertiary care center over a 12-year period.	Clarithromycin	118-132	neurotrimin	Homo sapiens	172-175
30250474-0	2018	Clarithromycin Enhances the Antibacterial Activity and Wound Healing Capacity in Type 2 Diabetes Mellitus by Increasing LL-37 Load on Neutrophil Extracellular Traps.	Clarithromycin	0-14	cathelicidin antimicrobial peptide	Homo sapiens	120-125
30077071-4	2018	Furthermore, the treatment of HaCaT cells with 10 microM clarithromycin reduced the viral titer by 93% and 60% during the first and second days following viral infection, respectively, probably by down-regulating ICAM-1 expression.	Clarithromycin	57-71	intercellular adhesion molecule 1	Homo sapiens	213-219
30250474-3	2018	Recently, it was shown that macrolide antibiotic clarithromycin induces the release of LL-37-bearing NETs.	Clarithromycin	49-63	cathelicidin antimicrobial peptide	Homo sapiens	87-92
30276203-6	2018	By analyzing the sequence of human genomic CYP2C19*2 and CYP2C19*3 and mutations within the 23S rRNA and gyrA gene regions conferring clarithromycin and levofloxacin resistance, respectively, we developed a microarray for individual therapy detection of H. pylori infection.	Clarithromycin	134-148	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	43-50
30276203-6	2018	By analyzing the sequence of human genomic CYP2C19*2 and CYP2C19*3 and mutations within the 23S rRNA and gyrA gene regions conferring clarithromycin and levofloxacin resistance, respectively, we developed a microarray for individual therapy detection of H. pylori infection.	Clarithromycin	134-148	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	57-64
30250474-11	2018	Clarithromycin significantly increased the externalization of LL-37 on NETs generated from well-controlled T2D neutrophils, thus restoring NET antibacterial capacity and promoting the wound healing process via fibroblast activation and differentiation.	Clarithromycin	0-14	cathelicidin antimicrobial peptide	Homo sapiens	62-67
30250474-12	2018	Conclusion: This study suggests that clarithromycin may add further advantage to well-controlled T2D patients, by enhancing their antibacterial defense and improving wound healing capacity of fibroblasts, through upregulation of LL-37 on NET structures.	Clarithromycin	37-51	cathelicidin antimicrobial peptide	Homo sapiens	229-234
29575644-0	2018	HLA-A*02:07 Allele Associates with Clarithromycin-Induced Cutaneous Adverse Drug Reactions in Chinese Patients.	Clarithromycin	35-49	major histocompatibility complex, class I, A	Homo sapiens	0-5
30186615-4	2018	We have reported that clarithromycin (CAM), which is a representative macrolide antibiotic, could inhibit hydrogen peroxide (H2O2)-induced reduction of the glutathione (GSH)/glutathione disulfide (GSSG) ratio in human small airway epithelial cells (SAECs), via the maintenance of GSH levels through an effect on gamma-glutamylcysteine synthetase (gamma-GCS) expression.	Clarithromycin	22-36	glutamate-cysteine ligase catalytic subunit	Homo sapiens	312-345
30186615-4	2018	We have reported that clarithromycin (CAM), which is a representative macrolide antibiotic, could inhibit hydrogen peroxide (H2O2)-induced reduction of the glutathione (GSH)/glutathione disulfide (GSSG) ratio in human small airway epithelial cells (SAECs), via the maintenance of GSH levels through an effect on gamma-glutamylcysteine synthetase (gamma-GCS) expression.	Clarithromycin	22-36	glutamate-cysteine ligase catalytic subunit	Homo sapiens	347-356
30186615-4	2018	We have reported that clarithromycin (CAM), which is a representative macrolide antibiotic, could inhibit hydrogen peroxide (H2O2)-induced reduction of the glutathione (GSH)/glutathione disulfide (GSSG) ratio in human small airway epithelial cells (SAECs), via the maintenance of GSH levels through an effect on gamma-glutamylcysteine synthetase (gamma-GCS) expression.	Clarithromycin	38-41	glutamate-cysteine ligase catalytic subunit	Homo sapiens	312-345
30186615-4	2018	We have reported that clarithromycin (CAM), which is a representative macrolide antibiotic, could inhibit hydrogen peroxide (H2O2)-induced reduction of the glutathione (GSH)/glutathione disulfide (GSSG) ratio in human small airway epithelial cells (SAECs), via the maintenance of GSH levels through an effect on gamma-glutamylcysteine synthetase (gamma-GCS) expression.	Clarithromycin	38-41	glutamate-cysteine ligase catalytic subunit	Homo sapiens	347-356
30178440-5	2018	In addition, since zolpidem is metabolized at a high rate by CYP3A4, the effect of CYP2C9*3 allele on the pharmacokinetics of zolpidem was also observed in the condition where CYP3A4 was sufficiently inhibited by the steady-state concentration of clarithromycin, a potent CYP3A4 inhibitor.	Clarithromycin	247-261	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	61-67
30178440-5	2018	In addition, since zolpidem is metabolized at a high rate by CYP3A4, the effect of CYP2C9*3 allele on the pharmacokinetics of zolpidem was also observed in the condition where CYP3A4 was sufficiently inhibited by the steady-state concentration of clarithromycin, a potent CYP3A4 inhibitor.	Clarithromycin	247-261	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	83-89
30178440-5	2018	In addition, since zolpidem is metabolized at a high rate by CYP3A4, the effect of CYP2C9*3 allele on the pharmacokinetics of zolpidem was also observed in the condition where CYP3A4 was sufficiently inhibited by the steady-state concentration of clarithromycin, a potent CYP3A4 inhibitor.	Clarithromycin	247-261	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	176-182
30178440-5	2018	In addition, since zolpidem is metabolized at a high rate by CYP3A4, the effect of CYP2C9*3 allele on the pharmacokinetics of zolpidem was also observed in the condition where CYP3A4 was sufficiently inhibited by the steady-state concentration of clarithromycin, a potent CYP3A4 inhibitor.	Clarithromycin	247-261	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	176-182
30178440-9	2018	Even with the potent CYP3A4 inhibitor clarithromycin present at steady-state concentrations, there were no significant differences in the exposure of zolpidem, except for elimination half-life (t1/2).	Clarithromycin	38-52	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	21-27
30186615-10	2018	However, these alterations were not observed after pretreatment with high-dose (10 muM) CAM, which suppressed phosphorylation of cell proliferation-associated ERK to cause a significant (p < 0.01) decrease in cell viability.	Clarithromycin	88-91	latexin	Homo sapiens	83-86
30186615-10	2018	However, these alterations were not observed after pretreatment with high-dose (10 muM) CAM, which suppressed phosphorylation of cell proliferation-associated ERK to cause a significant (p < 0.01) decrease in cell viability.	Clarithromycin	88-91	mitogen-activated protein kinase 1	Homo sapiens	159-162
30186615-12	2018	On the other hand, pretreatment with high-dose CAM suppressed phosphorylation of cell proliferation-associated ERK and decreased cell viability.	Clarithromycin	47-50	mitogen-activated protein kinase 1	Homo sapiens	111-114
29575644-5	2018	A molecular docking analysis of HLA-A*02:07 protein and clarithromycin was conducted using glide module with Schrodinger Suite.	Clarithromycin	56-70	major histocompatibility complex, class I, A	Homo sapiens	32-37
29575644-8	2018	Furthermore, molecular docking data revealed that clarithromycin could bind to and interact with HLA-A*02:07 in two possible binding situations.	Clarithromycin	50-64	major histocompatibility complex, class I, A	Homo sapiens	97-102
29575644-9	2018	These data suggest that HLA-A*02:07 might be a genetic risk factor for developing clarithromycin-cADRs in Han Chinese and serve as a useful biomarker for personalized medicine to prevent clarithromycin-cADRs.	Clarithromycin	82-96	major histocompatibility complex, class I, A	Homo sapiens	24-29
29575644-9	2018	These data suggest that HLA-A*02:07 might be a genetic risk factor for developing clarithromycin-cADRs in Han Chinese and serve as a useful biomarker for personalized medicine to prevent clarithromycin-cADRs.	Clarithromycin	187-201	major histocompatibility complex, class I, A	Homo sapiens	24-29
29409357-9	2018	DISCUSSION: We expect to prove that: (i) clarithromycin allows identification of mutated APA before adrenalectomy and sequencing of tumour DNA; (ii) the acute changes of plasma aldosterone concentration, direct active renin concentration, and blood pressure in peripheral venous blood after roxithromycin can be a proxy for the presence of an APA with somatic mutations.	Clarithromycin	41-55	renin	Homo sapiens	218-223
29479714-4	2018	We have reported previously that ArabidopsisMAX1 converts CL to carlactonoic acid (CLA), whereas a rice MAX1 homolog has been shown to catalyze the conversion of CL to 4-deoxyorobanchol (4DO).	Clarithromycin	83-86	cytochrome P450, family 711, subfamily A, polypeptide 1	Arabidopsis thaliana	44-48
29479714-6	2018	The conversion of CL to CLA was found to be a common reaction catalyzed by MAX1 homologs, and MAX1s can be classified into three types: A1-type, converting CL to CLA; A2-type, converting CL to 4DO via CLA; and A3-type, converting CL to CLA and 4DO to orobanchol.	Clarithromycin	24-27	cytochrome P450, family 711, subfamily A, polypeptide 1	Arabidopsis thaliana	75-79
29621339-2	2018	In this study, we investigated the functional significance of the expansion of myeloid-derived suppressor cell (MDSC)-like CD11b+Gr-1+ cells in response to the macrolide antibiotic clarithromycin (CAM) in mouse models of shock and post-influenza pneumococcal pneumonia as well as in humans.	Clarithromycin	197-200	integrin subunit alpha M	Homo sapiens	123-128
29621339-6	2018	CAM also improved survival in post-influenza, CAM-resistant pneumococcal pneumonia, with improved lung pathology as well as decreased interferon (IFN)-gamma and increased IL-10 levels.	Clarithromycin	0-3	interferon gamma	Homo sapiens	134-156
29621339-0	2018	Clarithromycin expands CD11b+Gr-1+ cells via the STAT3/Bv8 axis to ameliorate lethal endotoxic shock and post-influenza bacterial pneumonia.	Clarithromycin	0-14	integrin subunit alpha M	Homo sapiens	23-28
29621339-6	2018	CAM also improved survival in post-influenza, CAM-resistant pneumococcal pneumonia, with improved lung pathology as well as decreased interferon (IFN)-gamma and increased IL-10 levels.	Clarithromycin	0-3	interleukin 10	Homo sapiens	171-176
29621339-0	2018	Clarithromycin expands CD11b+Gr-1+ cells via the STAT3/Bv8 axis to ameliorate lethal endotoxic shock and post-influenza bacterial pneumonia.	Clarithromycin	0-14	signal transducer and activator of transcription 3	Homo sapiens	49-54
28888990-4	2017	We have screened chemical libraries and found that two antibiotics, pentamidine and clarithromycin, can compensate two bcs1 point mutations in yeast, one of which is the equivalent of a mutation found in a human patient.	Clarithromycin	84-98	bifunctional AAA family ATPase chaperone/translocase BCS1	Saccharomyces cerevisiae S288C	119-123
29621339-0	2018	Clarithromycin expands CD11b+Gr-1+ cells via the STAT3/Bv8 axis to ameliorate lethal endotoxic shock and post-influenza bacterial pneumonia.	Clarithromycin	0-14	prokineticin 2	Homo sapiens	55-58
29621339-2	2018	In this study, we investigated the functional significance of the expansion of myeloid-derived suppressor cell (MDSC)-like CD11b+Gr-1+ cells in response to the macrolide antibiotic clarithromycin (CAM) in mouse models of shock and post-influenza pneumococcal pneumonia as well as in humans.	Clarithromycin	181-195	integrin subunit alpha M	Homo sapiens	123-128
29531461-10	2018	Primary clarithromycin resistance was significantly lower in cagA-positive strains than in cagA-negative strains [32% (n = 8/25) vs 56.3% (n = 45/80) P = 0.03].	Clarithromycin	8-22	S100 calcium binding protein A8	Homo sapiens	61-65
29531461-10	2018	Primary clarithromycin resistance was significantly lower in cagA-positive strains than in cagA-negative strains [32% (n = 8/25) vs 56.3% (n = 45/80) P = 0.03].	Clarithromycin	8-22	S100 calcium binding protein A8	Homo sapiens	91-95
29531461-14	2018	Less virulent (cagA-negative and vacA S2-containing) strains of H. pylori are associated with primary clarithromycin resistance.	Clarithromycin	102-116	S100 calcium binding protein A8	Homo sapiens	15-19
29406285-0	2018	Clarithromycin suppresses induction of monocyte chemoattractant protein-1 and matrix metalloproteinase-9 and improves pathological changes in the lungs and heart of mice infected with influenza A virus.	Clarithromycin	0-14	chemokine (C-C motif) ligand 2	Mus musculus	39-73
29406285-0	2018	Clarithromycin suppresses induction of monocyte chemoattractant protein-1 and matrix metalloproteinase-9 and improves pathological changes in the lungs and heart of mice infected with influenza A virus.	Clarithromycin	0-14	matrix metallopeptidase 9	Mus musculus	78-104
29406285-5	2018	Clarithromycin significantly suppressed the induction of serum MCP-1 and MMP-9 and vascular hyperpermeability in these organs in the early phase of infection, but did not suppress the induction of trypsin, IL-6 or IFN-gamma.	Clarithromycin	0-14	C-C motif chemokine ligand 2	Homo sapiens	63-68
29406285-5	2018	Clarithromycin significantly suppressed the induction of serum MCP-1 and MMP-9 and vascular hyperpermeability in these organs in the early phase of infection, but did not suppress the induction of trypsin, IL-6 or IFN-gamma.	Clarithromycin	0-14	matrix metallopeptidase 9	Homo sapiens	73-78
29406285-7	2018	These results suggest that clarithromycin suppresses infection-related inflammation and reduces vascular hyperpermeability by suppressing the induction of MCP-1 and MMP-9.	Clarithromycin	27-41	C-C motif chemokine ligand 2	Homo sapiens	155-160
29406285-7	2018	These results suggest that clarithromycin suppresses infection-related inflammation and reduces vascular hyperpermeability by suppressing the induction of MCP-1 and MMP-9.	Clarithromycin	27-41	matrix metallopeptidase 9	Homo sapiens	165-170
29093413-0	2018	Effects of the Concomitant Use of Low-dose Clarithromycin with an Anti-TNFalpha Antibody in a Patient with Intestinal Behcet Disease.	Clarithromycin	43-57	tumor necrosis factor	Homo sapiens	71-79
29332324-12	2018	More histone deacetylase 2 (HDAC2) activity was recovered in the DXM and CAM+DXM challenged groups than in the control group (p<0.05).	Clarithromycin	73-76	histone deacetylase 2	Mus musculus	5-26
29332324-12	2018	More histone deacetylase 2 (HDAC2) activity was recovered in the DXM and CAM+DXM challenged groups than in the control group (p<0.05).	Clarithromycin	73-76	histone deacetylase 2	Mus musculus	28-33
28806472-3	2017	Based on these findings, a clinical study was designed to investigate the pharmacokinetic (PK) interaction of evogliptin with a CYP inhibitor, clarithromycin.	Clarithromycin	143-157	peptidylprolyl isomerase G	Homo sapiens	128-131
28993452-2	2017	Because KCNJ5 mutated channels were reported to be specifically sensitive to inhibition by macrolide antibiotics, which concentration dependently blunts aldosterone production in HAC15 transfected with the G151R and L168R mutated channel, we herein tested the effect of clarithromycin on aldosterone synthesis and secretion in a pure population of aldosterone-secreting cells obtained by immunoseparation (CD56+ cells) from APA tissues with/without the 2 most common KCNJ5 mutations.	Clarithromycin	270-284	potassium inwardly rectifying channel subfamily J member 5	Homo sapiens	8-13
28993452-4	2017	We found that clarithromycin concentration dependently lowered CYP11B2 gene expression (by 60%) and aldosterone secretion (by 70%; P<0.001 for both) in CD56+ cells isolated ex vivo from KCNJ5 mutated APAs, although it was ineffective in CD56+ cells from wild-type APAs.	Clarithromycin	14-28	cytochrome P450 family 11 subfamily B member 2	Homo sapiens	63-70
28993452-4	2017	We found that clarithromycin concentration dependently lowered CYP11B2 gene expression (by 60%) and aldosterone secretion (by 70%; P<0.001 for both) in CD56+ cells isolated ex vivo from KCNJ5 mutated APAs, although it was ineffective in CD56+ cells from wild-type APAs.	Clarithromycin	14-28	potassium inwardly rectifying channel subfamily J member 5	Homo sapiens	189-194
28502905-11	2017	The resulted potent COX-2 inhibitor of the isolated constituents compound 5, designated as coumaroyl lupendioic acid (CLA), was investigated in carrageenan induced inflammation and its effect was also compared with betulinic acid (BA) at the doses of 10 and 20mgkg-1, p.o.	Clarithromycin	118-121	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	20-25
29079298-0	2017	Rapid detection of mutations in erm(41) and rrl associated with clarithromycin resistance in Mycobacterium abscessus complex by denaturing gradient gel electrophoresis.	Clarithromycin	64-78	rrl	Mycobacterium abscessus	44-47
29079298-10	2017	This is the first report to identify PCR-based DGGE as a practical, relatively inexpensive technique for rapidly detecting mutations in the erm(41) and rrl genes associated with clarithromycin resistance in M. abscessus complex.	Clarithromycin	178-192	rrl	Mycobacterium abscessus	152-155
27614743-0	2017	Clarithromycin attenuates the expression of monocyte chemoattractant protein-1 by activating toll-like receptor 4 in human mesangial cells.	Clarithromycin	0-14	C-C motif chemokine ligand 2	Homo sapiens	44-78
27614743-0	2017	Clarithromycin attenuates the expression of monocyte chemoattractant protein-1 by activating toll-like receptor 4 in human mesangial cells.	Clarithromycin	0-14	toll like receptor 4	Homo sapiens	93-113
28550735-0	2017	Clarithromycin inhibits TNF-alpha-induced MUC5AC mucin gene expression via the MKP-1-p38MAPK-dependent pathway.	Clarithromycin	0-14	tumor necrosis factor	Homo sapiens	24-33
28550735-0	2017	Clarithromycin inhibits TNF-alpha-induced MUC5AC mucin gene expression via the MKP-1-p38MAPK-dependent pathway.	Clarithromycin	0-14	LOC100508689	Homo sapiens	49-54
28550735-0	2017	Clarithromycin inhibits TNF-alpha-induced MUC5AC mucin gene expression via the MKP-1-p38MAPK-dependent pathway.	Clarithromycin	0-14	dual specificity phosphatase 1	Homo sapiens	79-84
28550735-6	2017	Here, we demonstrate that the MKP-1 protein is induced by clarithromycin and that clarithromycin suppresses TNF-alpha-induced MUC5AC mucin gene expression in a p38 MAPK-dependent manner in human airway epithelial (NCI-H292) cells.	Clarithromycin	58-72	dual specificity phosphatase 1	Homo sapiens	30-35
28711984-4	2017	Clarithromycin (CAM) is a strong CYP3A inhibitor often used to prevent rash associated with anti-EGFR therapy.	Clarithromycin	0-14	epidermal growth factor receptor	Homo sapiens	97-101
28711984-4	2017	Clarithromycin (CAM) is a strong CYP3A inhibitor often used to prevent rash associated with anti-EGFR therapy.	Clarithromycin	16-19	epidermal growth factor receptor	Homo sapiens	97-101
28500979-5	2017	The assay was successfully applied to assess the time course of plasma ET-1 concentrations in two human volunteers after co-administration of bosentan and clarithromycin.	Clarithromycin	155-169	endothelin 1	Homo sapiens	71-75
28550735-6	2017	Here, we demonstrate that the MKP-1 protein is induced by clarithromycin and that clarithromycin suppresses TNF-alpha-induced MUC5AC mucin gene expression in a p38 MAPK-dependent manner in human airway epithelial (NCI-H292) cells.	Clarithromycin	82-96	tumor necrosis factor	Homo sapiens	108-117
28550735-6	2017	Here, we demonstrate that the MKP-1 protein is induced by clarithromycin and that clarithromycin suppresses TNF-alpha-induced MUC5AC mucin gene expression in a p38 MAPK-dependent manner in human airway epithelial (NCI-H292) cells.	Clarithromycin	82-96	LOC100508689	Homo sapiens	133-138
28550735-6	2017	Here, we demonstrate that the MKP-1 protein is induced by clarithromycin and that clarithromycin suppresses TNF-alpha-induced MUC5AC mucin gene expression in a p38 MAPK-dependent manner in human airway epithelial (NCI-H292) cells.	Clarithromycin	82-96	mitogen-activated protein kinase 14	Homo sapiens	160-163
28502905-20	2017	Furthermore, immunohistochemical studies revealed that CLA significantly down regulated NF-kB, COX-2 and TNF-alpha protein expression.	Clarithromycin	55-58	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	95-100
28070612-8	2017	In vivo, chemically-induced HCC rat model proved that clarithromycin suppressed HCC via induction of apoptosis through up-regulation of both extrinsic/intrinsic apoptotic pathways" proteins (TNFR1, cleaved caspase-3, and Bax with an increased Bax/Bcl-2 ratio) along with MMP-9 normalization.	Clarithromycin	54-68	TNF receptor superfamily member 1A	Rattus norvegicus	191-196
28131578-8	2017	Expected CLA-induced downregulation of some genes, such as FASN or sterol regulatory element binding transcription factor 1 (SREBF1), could not be detected in our samples, which might be related, at least in part, to high inter-individual variation and relatively advanced lactation stage (on average 102-103 d in milk on d 38 and 39).	Clarithromycin	9-12	fatty acid synthase	Ovis aries	59-63
28070612-8	2017	In vivo, chemically-induced HCC rat model proved that clarithromycin suppressed HCC via induction of apoptosis through up-regulation of both extrinsic/intrinsic apoptotic pathways" proteins (TNFR1, cleaved caspase-3, and Bax with an increased Bax/Bcl-2 ratio) along with MMP-9 normalization.	Clarithromycin	54-68	BCL2 associated X, apoptosis regulator	Rattus norvegicus	221-224
28070612-8	2017	In vivo, chemically-induced HCC rat model proved that clarithromycin suppressed HCC via induction of apoptosis through up-regulation of both extrinsic/intrinsic apoptotic pathways" proteins (TNFR1, cleaved caspase-3, and Bax with an increased Bax/Bcl-2 ratio) along with MMP-9 normalization.	Clarithromycin	54-68	BCL2 associated X, apoptosis regulator	Rattus norvegicus	243-246
28070612-8	2017	In vivo, chemically-induced HCC rat model proved that clarithromycin suppressed HCC via induction of apoptosis through up-regulation of both extrinsic/intrinsic apoptotic pathways" proteins (TNFR1, cleaved caspase-3, and Bax with an increased Bax/Bcl-2 ratio) along with MMP-9 normalization.	Clarithromycin	54-68	BCL2, apoptosis regulator	Rattus norvegicus	247-252
28070612-8	2017	In vivo, chemically-induced HCC rat model proved that clarithromycin suppressed HCC via induction of apoptosis through up-regulation of both extrinsic/intrinsic apoptotic pathways" proteins (TNFR1, cleaved caspase-3, and Bax with an increased Bax/Bcl-2 ratio) along with MMP-9 normalization.	Clarithromycin	54-68	matrix metallopeptidase 9	Rattus norvegicus	271-276
28235416-0	2017	Long-term treatment of clarithromycin at a low concentration improves hydrogen peroxide-induced oxidant/antioxidant imbalance in human small airway epithelial cells by increasing Nrf2 mRNA expression.	Clarithromycin	23-37	NFE2 like bZIP transcription factor 2	Homo sapiens	179-183
27928738-0	2017	Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study.	Clarithromycin	61-75	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	44-50
27928738-11	2017	CONCLUSIONS: Modest increases in plasma concentrations of the potent CYP3A4 inhibitor clarithromycin and vonoprazan were observed during coadministration, however these differences were not considered clinically significant.	Clarithromycin	86-100	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-75
28235416-8	2017	RESULTS: Pretreatment with low-dose (1 or 5 muM), long-term (72 h) CAM inhibited H2O2-induced IL-8 levels, NF-kappaB activity, and IL-8 mRNA expression, and improved the GSH/GSSG ratio via the maintenance of gamma-GCS expression levels.	Clarithromycin	67-70	C-X-C motif chemokine ligand 8	Homo sapiens	94-98
28235416-8	2017	RESULTS: Pretreatment with low-dose (1 or 5 muM), long-term (72 h) CAM inhibited H2O2-induced IL-8 levels, NF-kappaB activity, and IL-8 mRNA expression, and improved the GSH/GSSG ratio via the maintenance of gamma-GCS expression levels.	Clarithromycin	67-70	C-X-C motif chemokine ligand 8	Homo sapiens	131-135
28235416-8	2017	RESULTS: Pretreatment with low-dose (1 or 5 muM), long-term (72 h) CAM inhibited H2O2-induced IL-8 levels, NF-kappaB activity, and IL-8 mRNA expression, and improved the GSH/GSSG ratio via the maintenance of gamma-GCS expression levels.	Clarithromycin	67-70	glutamate-cysteine ligase catalytic subunit	Homo sapiens	208-217
28235416-9	2017	Similar to its enhancing effect on the GSH/GSSG ratio, pretreatment with low-dose CAM for 72 h significantly increased Nrf2 mRNA expression (p < 0.01 and p < 0.05).	Clarithromycin	82-85	NFE2 like bZIP transcription factor 2	Homo sapiens	119-123
28219384-0	2017	Clarithromycin attenuates IL-13-induced periostin production in human lung fibroblasts.	Clarithromycin	0-14	interleukin 13	Homo sapiens	26-31
28219384-0	2017	Clarithromycin attenuates IL-13-induced periostin production in human lung fibroblasts.	Clarithromycin	0-14	periostin	Homo sapiens	40-49
28219384-4	2017	METHODS: Using quantitative PCR and ELISA, we measured periostin production in human lung fibroblasts stimulated by interleukin-13 (IL-13) in the presence of two 14-member-ring macrolides-clarithromycin or erythromycin-or a 16-member-ring macrolide, josamycin.	Clarithromycin	188-202	periostin	Homo sapiens	55-64
28219384-7	2017	RESULTS: Clarithromycin and erythromycin, but not josamycin, inhibited IL-13-stimulated periostin production.	Clarithromycin	9-23	interleukin 13	Homo sapiens	71-76
28219384-7	2017	RESULTS: Clarithromycin and erythromycin, but not josamycin, inhibited IL-13-stimulated periostin production.	Clarithromycin	9-23	periostin	Homo sapiens	88-97
28219384-9	2017	Clarithromycin significantly attenuated STAT6 phosphorylation induced by IL-13.	Clarithromycin	0-14	signal transducer and activator of transcription 6	Homo sapiens	40-45
28219384-9	2017	Clarithromycin significantly attenuated STAT6 phosphorylation induced by IL-13.	Clarithromycin	0-14	interleukin 13	Homo sapiens	73-78
28219384-12	2017	Clarithromycin primarily attenuated the gene expression of extracellular matrix protein, including periostin, especially after IL-13.	Clarithromycin	0-14	periostin	Homo sapiens	99-108
28219384-12	2017	Clarithromycin primarily attenuated the gene expression of extracellular matrix protein, including periostin, especially after IL-13.	Clarithromycin	0-14	interleukin 13	Homo sapiens	127-132
28219384-13	2017	CONCLUSIONS: Clarithromycin suppressed IL-13-induced periostin production in human lung fibroblasts, in part by inhibiting STAT6 phosphorylation.	Clarithromycin	13-27	interleukin 13	Homo sapiens	39-44
28219384-13	2017	CONCLUSIONS: Clarithromycin suppressed IL-13-induced periostin production in human lung fibroblasts, in part by inhibiting STAT6 phosphorylation.	Clarithromycin	13-27	periostin	Homo sapiens	53-62
28219384-13	2017	CONCLUSIONS: Clarithromycin suppressed IL-13-induced periostin production in human lung fibroblasts, in part by inhibiting STAT6 phosphorylation.	Clarithromycin	13-27	signal transducer and activator of transcription 6	Homo sapiens	123-128
27468646-4	2016	CAM treatment led to a significant reduction in poly I:C- and RSV-mediated IL-8, CCL5, IFN-beta and -lambda production.	Clarithromycin	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	75-79
27550358-0	2016	Clarithromycin Suppresses Chloride Channel Accessory 1 and Inhibits Interleukin-13-Induced Goblet Cell Hyperplasia in Human Bronchial Epithelial Cells.	Clarithromycin	0-14	chloride channel accessory 1	Homo sapiens	26-54
27550358-0	2016	Clarithromycin Suppresses Chloride Channel Accessory 1 and Inhibits Interleukin-13-Induced Goblet Cell Hyperplasia in Human Bronchial Epithelial Cells.	Clarithromycin	0-14	interleukin 13	Homo sapiens	68-82
27550358-3	2016	We examined the effect of clarithromycin IL-13 signaling leading to production.	Clarithromycin	26-40	interleukin 13	Homo sapiens	41-46
27550358-8	2016	Clarithromycin decreased IL-13-induced goblet cell hyperplasia and MUC5AC mRNA expression in a dose-dependent manner.	Clarithromycin	0-14	interleukin 13	Homo sapiens	25-30
27550358-8	2016	Clarithromycin decreased IL-13-induced goblet cell hyperplasia and MUC5AC mRNA expression in a dose-dependent manner.	Clarithromycin	0-14	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	67-73
27550358-9	2016	Clarithromycin decreased IL-13-stimulated SPDEF and CLCA1 mRNA expression in a dose-dependent manner, and at 32 mug/ml CLCA1 was profoundly decreased (P < 0.001).	Clarithromycin	0-14	interleukin 13	Homo sapiens	25-30
27550358-9	2016	Clarithromycin decreased IL-13-stimulated SPDEF and CLCA1 mRNA expression in a dose-dependent manner, and at 32 mug/ml CLCA1 was profoundly decreased (P < 0.001).	Clarithromycin	0-14	SAM pointed domain containing ETS transcription factor	Homo sapiens	42-47
27550358-9	2016	Clarithromycin decreased IL-13-stimulated SPDEF and CLCA1 mRNA expression in a dose-dependent manner, and at 32 mug/ml CLCA1 was profoundly decreased (P < 0.001).	Clarithromycin	0-14	chloride channel accessory 1	Homo sapiens	52-57
27550358-10	2016	Although clarithromycin had no effect on STAT6 phosphorylation induced by IL-13, it decreased constitutive phosphorylation of ERK1/2 (P < 0.05).	Clarithromycin	9-23	mitogen-activated protein kinase 3	Homo sapiens	126-132
27998764-0	2017	Mitochondrial proteins NIP-SNAP-1 and -2 are a target for the immunomodulatory activity of clarithromycin, which involves NF-kappaB-mediated cytokine production.	Clarithromycin	91-105	nipsnap homolog 1	Homo sapiens	23-40
27998764-5	2017	We identified mitochondrial proteins 4-nitrophenylphosphatase domain and non-neuronal synaptosomal associated protein 25-like protein homolog (NIP-SNAP)-1 and -2 and very long-chain acyl-CoA dehydrogenase (VLCAD) as CAM-binding proteins.	Clarithromycin	216-219	nipsnap homolog 1	Homo sapiens	86-161
27998764-8	2017	Thus, CAM suppresses NF-kappaB-mediated proinflammatory cytokine production by interacting with mitochondrial proteins, NIP-SNAP-1 and -2.	Clarithromycin	6-9	nipsnap homolog 1	Homo sapiens	120-137
27822600-1	2017	Clarithromycin is a substrate and mechanism-based inhibitor of cytochrome P450 (CYP) 3A4 as well as a substrate and competitive inhibitor of P-glycoprotein (P-gp) and organic anion-transporting polypeptides (OATP) 1B1 and 1B3.	Clarithromycin	0-14	ATP binding cassette subfamily B member 1	Homo sapiens	141-155
27822600-1	2017	Clarithromycin is a substrate and mechanism-based inhibitor of cytochrome P450 (CYP) 3A4 as well as a substrate and competitive inhibitor of P-glycoprotein (P-gp) and organic anion-transporting polypeptides (OATP) 1B1 and 1B3.	Clarithromycin	0-14	ATP binding cassette subfamily B member 1	Homo sapiens	157-161
27822600-1	2017	Clarithromycin is a substrate and mechanism-based inhibitor of cytochrome P450 (CYP) 3A4 as well as a substrate and competitive inhibitor of P-glycoprotein (P-gp) and organic anion-transporting polypeptides (OATP) 1B1 and 1B3.	Clarithromycin	0-14	solute carrier organic anion transporter family member 1B1	Homo sapiens	167-225
27822600-2	2017	Administered concomitantly, clarithromycin causes drug-drug interactions (DDI) with the victim drugs midazolam (CYP3A4 substrate) and digoxin (P-gp substrate).	Clarithromycin	28-42	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	112-118
27822600-2	2017	Administered concomitantly, clarithromycin causes drug-drug interactions (DDI) with the victim drugs midazolam (CYP3A4 substrate) and digoxin (P-gp substrate).	Clarithromycin	28-42	ATP binding cassette subfamily B member 1	Homo sapiens	143-147
27822600-8	2017	During co-treatment with 250 or 500 mg clarithromycin (bid), the midazolam and digoxin doses should be reduced by 74 to 88% and by 21 to 22%, respectively, to ensure constant midazolam and digoxin exposures (AUC).	Clarithromycin	39-53	BH3 interacting domain death agonist	Homo sapiens	55-58
28674358-0	2017	Acute Kidney Injury from Excessive Potentiation of Calcium-channel Blocker via Synergistic CYP3A4 Inhibition by Clarithromycin Plus Voriconazole.	Clarithromycin	112-126	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	91-97
28674358-6	2017	The combination of CYP3A4-inhibitors such as clarithromycin plus voriconazole can synergistically potentiate calcium-channel blockers.	Clarithromycin	45-59	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	19-25
27733592-0	2017	Clarithromycin increases neuronal excitability in CA3 pyramidal neurons through a reduction in GABAergic signaling.	Clarithromycin	0-14	carbonic anhydrase 3	Homo sapiens	50-53
27236320-9	2016	Higher bioavailability and non-linear pharmacokinetics are expected to be a common property of drugs that are substrates and inhibitors of CYP3A, e.g. clarithromycin.	Clarithromycin	151-165	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	139-144
28028949-0	2016	Clarithromycin Decreases IL-6 Concentration in Serum and BAL Fluid in Patients with Cryptogenic Organizing Pneumonia.	Clarithromycin	0-14	interleukin 6	Homo sapiens	25-29
28028949-9	2016	Clarithromycin treatment resulted in a significantly lower mean value of serum IL-6 responders than non-responders.	Clarithromycin	0-14	interleukin 6	Homo sapiens	79-83
28028949-10	2016	CONCLUSIONS: In COP patients, response to clarithromycin treatment was associated with decreases in serum concentrations of IL-6, IL-8 and TGF-beta, and of rations, and of the BAL-f concentration of IL-6.	Clarithromycin	42-56	interleukin 6	Homo sapiens	124-128
28028949-10	2016	CONCLUSIONS: In COP patients, response to clarithromycin treatment was associated with decreases in serum concentrations of IL-6, IL-8 and TGF-beta, and of rations, and of the BAL-f concentration of IL-6.	Clarithromycin	42-56	C-X-C motif chemokine ligand 8	Homo sapiens	130-134
28028949-10	2016	CONCLUSIONS: In COP patients, response to clarithromycin treatment was associated with decreases in serum concentrations of IL-6, IL-8 and TGF-beta, and of rations, and of the BAL-f concentration of IL-6.	Clarithromycin	42-56	transforming growth factor beta 1	Homo sapiens	139-147
28028949-10	2016	CONCLUSIONS: In COP patients, response to clarithromycin treatment was associated with decreases in serum concentrations of IL-6, IL-8 and TGF-beta, and of rations, and of the BAL-f concentration of IL-6.	Clarithromycin	42-56	interleukin 6	Homo sapiens	199-203
27489022-8	2016	These results suggest that CAM protects against SBP during influenza in elastase-induced emphysema mice by reducing IFN-gamma production, thus enhancing immunity to SBP, and by decreasing neutrophil infiltration into the lung to prevent injury.	Clarithromycin	27-30	interferon gamma	Mus musculus	116-125
27468646-4	2016	CAM treatment led to a significant reduction in poly I:C- and RSV-mediated IL-8, CCL5, IFN-beta and -lambda production.	Clarithromycin	0-3	C-C motif chemokine ligand 5	Homo sapiens	81-85
27468646-4	2016	CAM treatment led to a significant reduction in poly I:C- and RSV-mediated IL-8, CCL5, IFN-beta and -lambda production.	Clarithromycin	0-3	interferon beta 1	Homo sapiens	87-95
27468646-5	2016	Furthermore, IFN-beta promoter activity (activated by poly I:C and RSV infection) was significantly reduced after treatment with CAM.	Clarithromycin	129-132	interferon beta 1	Homo sapiens	13-21
27468646-6	2016	CAM also inhibited IRF-3 dimerization and subsequent translocation to the nucleus.	Clarithromycin	0-3	interferon regulatory factor 3	Homo sapiens	19-24
27227911-10	2016	By using PCR-RFLP, the consistency of human CYP2C19 gene polymorphism from blood samples and gastric juice was as high as 94.9% (149/157).The manipulated gastric juice is actually an effective diagnostic sample for evaluation of H pylori existence, clarithromycin resistance, and host CYP2C19 polymorphism.	Clarithromycin	249-263	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	44-51
27586548-7	2016	CONCLUSION: CLA improved insulin resistance, lipid disturbances, oxidative stress, and liver function in NAFLD.	Clarithromycin	12-15	insulin	Homo sapiens	25-32
26808255-11	2016	In vitro, CLA showed affinity to human and equine P-gp.	Clarithromycin	10-13	phosphoglycolate phosphatase	Equus caballus	50-54
26953210-2	2016	In all clarithromycin-resistant strains, the transcript level of acrB was significantly elevated, and these strains had a frameshift mutation in acrR Introduction of the acrR mutation into H. influenzae Rd generated a clarithromycin-resistant transformant with the same MIC as the donor strain.	Clarithromycin	7-21	efflux RND transporter permease subunit	Haemophilus influenzae Rd KW20	65-69
26953210-2	2016	In all clarithromycin-resistant strains, the transcript level of acrB was significantly elevated, and these strains had a frameshift mutation in acrR Introduction of the acrR mutation into H. influenzae Rd generated a clarithromycin-resistant transformant with the same MIC as the donor strain.	Clarithromycin	218-232	efflux RND transporter permease subunit	Haemophilus influenzae Rd KW20	65-69
26953210-3	2016	Our results indicate that the acrR mutation confers clarithromycin resistance by the increasing the transcription of acrB.	Clarithromycin	52-66	efflux RND transporter permease subunit	Haemophilus influenzae Rd KW20	117-121
26808255-13	2016	In conclusion, the major undesired influence of RIF on oral absorption and pulmonary distribution of CLA is associated with induction of intestinal P-gp.	Clarithromycin	101-104	phosphoglycolate phosphatase	Equus caballus	148-152
26987326-3	2016	The present study was performed to assess the correlation between concentrations of IL-1beta, IL-6, IL-8, and TGF-beta1 in the serum with response to clarithromycin (CAM) treatment in patients with COP.	Clarithromycin	150-164	interleukin 1 beta	Homo sapiens	84-92
26668209-8	2016	The results indicate that, like ketoconazole, the alternative clinical CYP3A4/5 inhibitors ritonavir, clarithromycin, and itraconazole each have unique transporter inhibition profiles.	Clarithromycin	102-116	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	71-77
26998073-0	2016	Remission of ALK-negative primary pulmonary inflammatory myofibroblastic tumor on treatment with clarithromycin: A case report and review of the literature.	Clarithromycin	97-111	ALK receptor tyrosine kinase	Homo sapiens	13-16
26987326-3	2016	The present study was performed to assess the correlation between concentrations of IL-1beta, IL-6, IL-8, and TGF-beta1 in the serum with response to clarithromycin (CAM) treatment in patients with COP.	Clarithromycin	150-164	interleukin 6	Homo sapiens	94-98
26987326-3	2016	The present study was performed to assess the correlation between concentrations of IL-1beta, IL-6, IL-8, and TGF-beta1 in the serum with response to clarithromycin (CAM) treatment in patients with COP.	Clarithromycin	150-164	C-X-C motif chemokine ligand 8	Homo sapiens	100-104
26987326-3	2016	The present study was performed to assess the correlation between concentrations of IL-1beta, IL-6, IL-8, and TGF-beta1 in the serum with response to clarithromycin (CAM) treatment in patients with COP.	Clarithromycin	150-164	transforming growth factor beta 1	Homo sapiens	110-119
26987326-3	2016	The present study was performed to assess the correlation between concentrations of IL-1beta, IL-6, IL-8, and TGF-beta1 in the serum with response to clarithromycin (CAM) treatment in patients with COP.	Clarithromycin	166-169	interleukin 1 beta	Homo sapiens	84-92
26987326-3	2016	The present study was performed to assess the correlation between concentrations of IL-1beta, IL-6, IL-8, and TGF-beta1 in the serum with response to clarithromycin (CAM) treatment in patients with COP.	Clarithromycin	166-169	transforming growth factor beta 1	Homo sapiens	110-119
26987326-9	2016	We conclude that IL-6, IL-8, and TGF-beta1 may play a role in the pathogenesis of COP, as their decreased concentrations were associated with a positive response to CAM treatment.	Clarithromycin	165-168	interleukin 6	Homo sapiens	17-21
26987326-9	2016	We conclude that IL-6, IL-8, and TGF-beta1 may play a role in the pathogenesis of COP, as their decreased concentrations were associated with a positive response to CAM treatment.	Clarithromycin	165-168	C-X-C motif chemokine ligand 8	Homo sapiens	23-27
26987326-9	2016	We conclude that IL-6, IL-8, and TGF-beta1 may play a role in the pathogenesis of COP, as their decreased concentrations were associated with a positive response to CAM treatment.	Clarithromycin	165-168	transforming growth factor beta 1	Homo sapiens	33-42
25749777-10	2015	In addition, clarithromycin significantly alleviated IL-6-induced FoxA2 suppression and decreased MUC5AC expression in vitro (P<0.05).	Clarithromycin	13-27	interleukin 6	Homo sapiens	53-57
26588710-2	2016	METHODS: A CLA-cholesteryl hemisuccinate (CHEMS) ion pair (CIP) was prepared by the solvent evaporation method and confirmed by fourier transform infrared spectroscopy, (1)H-nuclear magnetic resonance, differential scanning calorimetry and X-ray powder diffraction.	Clarithromycin	11-14	muscular LMNA interacting protein	Homo sapiens	59-62
26228509-6	2015	KEY RESULTS: The expression levels of 3beta-HSD, CYP21, 11beta-HSD1 and CYP11B1 increased in human epithelial cells treated with clarithromycin and azithromycin, whereas the expression levels of 11beta-HSD2 and CYP11A1 were not affected.	Clarithromycin	129-143	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	Homo sapiens	38-47
26228509-6	2015	KEY RESULTS: The expression levels of 3beta-HSD, CYP21, 11beta-HSD1 and CYP11B1 increased in human epithelial cells treated with clarithromycin and azithromycin, whereas the expression levels of 11beta-HSD2 and CYP11A1 were not affected.	Clarithromycin	129-143	cytochrome P450 family 21 subfamily A member 2	Homo sapiens	49-54
26228509-6	2015	KEY RESULTS: The expression levels of 3beta-HSD, CYP21, 11beta-HSD1 and CYP11B1 increased in human epithelial cells treated with clarithromycin and azithromycin, whereas the expression levels of 11beta-HSD2 and CYP11A1 were not affected.	Clarithromycin	129-143	hydroxysteroid 11-beta dehydrogenase 1	Homo sapiens	56-67
26228509-6	2015	KEY RESULTS: The expression levels of 3beta-HSD, CYP21, 11beta-HSD1 and CYP11B1 increased in human epithelial cells treated with clarithromycin and azithromycin, whereas the expression levels of 11beta-HSD2 and CYP11A1 were not affected.	Clarithromycin	129-143	cytochrome P450 family 11 subfamily B member 1	Homo sapiens	72-79
26228509-6	2015	KEY RESULTS: The expression levels of 3beta-HSD, CYP21, 11beta-HSD1 and CYP11B1 increased in human epithelial cells treated with clarithromycin and azithromycin, whereas the expression levels of 11beta-HSD2 and CYP11A1 were not affected.	Clarithromycin	129-143	hydroxysteroid 11-beta dehydrogenase 2	Homo sapiens	195-206
26228509-6	2015	KEY RESULTS: The expression levels of 3beta-HSD, CYP21, 11beta-HSD1 and CYP11B1 increased in human epithelial cells treated with clarithromycin and azithromycin, whereas the expression levels of 11beta-HSD2 and CYP11A1 were not affected.	Clarithromycin	129-143	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	211-218
26228509-9	2015	The expression of 3beta-HSD, CYP11A1, CYP21, CYP11B1 and 11beta-HSD1 was upregulated in nasal mucosa of mice treated with clarithromycin or azithromycin, but not in adrenalectomized mice.	Clarithromycin	122-136	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	Homo sapiens	18-27
26228509-9	2015	The expression of 3beta-HSD, CYP11A1, CYP21, CYP11B1 and 11beta-HSD1 was upregulated in nasal mucosa of mice treated with clarithromycin or azithromycin, but not in adrenalectomized mice.	Clarithromycin	122-136	cytochrome P450, family 11, subfamily a, polypeptide 1	Mus musculus	29-36
26228509-9	2015	The expression of 3beta-HSD, CYP11A1, CYP21, CYP11B1 and 11beta-HSD1 was upregulated in nasal mucosa of mice treated with clarithromycin or azithromycin, but not in adrenalectomized mice.	Clarithromycin	122-136	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	38-43
26228509-9	2015	The expression of 3beta-HSD, CYP11A1, CYP21, CYP11B1 and 11beta-HSD1 was upregulated in nasal mucosa of mice treated with clarithromycin or azithromycin, but not in adrenalectomized mice.	Clarithromycin	122-136	cytochrome P450, family 11, subfamily b, polypeptide 1	Mus musculus	45-52
26228509-9	2015	The expression of 3beta-HSD, CYP11A1, CYP21, CYP11B1 and 11beta-HSD1 was upregulated in nasal mucosa of mice treated with clarithromycin or azithromycin, but not in adrenalectomized mice.	Clarithromycin	122-136	hydroxysteroid 11-beta dehydrogenase 1	Mus musculus	57-68
26363279-12	2015	Studies by quantitative PCR demonstrated CAM treatment significantly reduced lung expression levels of IL-17A, keratinocyte-derived chemokine (KC), granulocyte-macrophage colony stimulating factor (GM-CSF) and MMP-9 induced by cigarette smoke.	Clarithromycin	41-44	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	148-196
26363279-12	2015	Studies by quantitative PCR demonstrated CAM treatment significantly reduced lung expression levels of IL-17A, keratinocyte-derived chemokine (KC), granulocyte-macrophage colony stimulating factor (GM-CSF) and MMP-9 induced by cigarette smoke.	Clarithromycin	41-44	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	198-204
26363279-12	2015	Studies by quantitative PCR demonstrated CAM treatment significantly reduced lung expression levels of IL-17A, keratinocyte-derived chemokine (KC), granulocyte-macrophage colony stimulating factor (GM-CSF) and MMP-9 induced by cigarette smoke.	Clarithromycin	41-44	matrix metallopeptidase 9	Mus musculus	210-215
26819743-1	2015	BACKGROUND: Concomitant use of clarithromycin (CAM) and rifampicin (RFP) for the treatment of pulmonary Mycobacterium avium complex (MAC) disease affects the systemic concentrations of both drugs due to CYP3A4-related interactions.	Clarithromycin	31-45	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	203-209
26819743-1	2015	BACKGROUND: Concomitant use of clarithromycin (CAM) and rifampicin (RFP) for the treatment of pulmonary Mycobacterium avium complex (MAC) disease affects the systemic concentrations of both drugs due to CYP3A4-related interactions.	Clarithromycin	47-50	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	203-209
26819743-11	2015	The explanation for the low levels of serum CAM in pulmonary MAC disease patients is that RFP-mediated CYP3A4 induction reached a maximum by day 15 and remained high thereafter.	Clarithromycin	44-47	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	103-109
26819743-13	2015	CONCLUSIONS: Our study demonstrated that serum CAM concentrations in pulmonary MAC disease patients were continuously low because of RFP-mediated CYP3A4 induction, which may be responsible for the unsatisfactory clinical outcomes.	Clarithromycin	47-50	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	146-152
26497728-1	2015	BACKGROUND: Clarithromycin, known as a potent inhibitor of the cytochrome P450 isoenzyme CYP3A, may increase the plasma concentration of statins metabolized by this pathway; therefore, increase the risk of interaction with statins in reference to pharmacokinetic studies.	Clarithromycin	12-26	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	89-94
25749777-10	2015	In addition, clarithromycin significantly alleviated IL-6-induced FoxA2 suppression and decreased MUC5AC expression in vitro (P<0.05).	Clarithromycin	13-27	forkhead box A2	Homo sapiens	66-71
25749777-10	2015	In addition, clarithromycin significantly alleviated IL-6-induced FoxA2 suppression and decreased MUC5AC expression in vitro (P<0.05).	Clarithromycin	13-27	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	98-104
25907295-0	2015	Itraconazole and clarithromycin inhibit P-glycoprotein activity in primary human sinonasal epithelial cells.	Clarithromycin	17-31	ATP binding cassette subfamily B member 1	Homo sapiens	40-54
25976224-10	2015	(3) When cells were perfused concomitantly with Berberine and Clarithromycin, they showed a stronger inhibitive effect on hERG currents by decreasing the time constant for the onset of inactivation.	Clarithromycin	62-76	ETS transcription factor ERG	Homo sapiens	122-126
25976224-11	2015	(4) The combined administration of Berberine with Clarithromycin had a powerful inhibitive effect on CYP3A activities than use of a single drug alone.	Clarithromycin	50-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	101-106
25769240-9	2015	EM900, CAM, or erythromycin significantly inhibited MUC5AC secretion induced by tumor necrosis factor-alpha from NCI-H292 cells.	Clarithromycin	7-10	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	52-58
25769240-9	2015	EM900, CAM, or erythromycin significantly inhibited MUC5AC secretion induced by tumor necrosis factor-alpha from NCI-H292 cells.	Clarithromycin	7-10	tumor necrosis factor	Homo sapiens	80-107
26068338-0	2015	Detection of clarithromycin-resistant Helicobacter pylori strains in a dyspeptic patient population in Sri Lanka by polymerase chain reaction-restriction fragment length polymorphism.	Clarithromycin	13-27	sorcin	Homo sapiens	103-106
26068338-1	2015	AIM: The aim of this study was to investigate the proportion of common clarithromycin-resistant mutation types present in the 23S ribosomal ribonucleic acid (rRNA) gene of H. pylori strains in Sri Lanka.	Clarithromycin	71-85	sorcin	Homo sapiens	193-196
26380735-0	2015	Clarithromycin might attenuate the airway inflammation of smoke-exposed asthmatic mice via affecting HDAC2.	Clarithromycin	0-14	histone deacetylase 2	Mus musculus	101-106
26380735-19	2015	CONCLUSIONS: Clarithromycin could improve AHR and attenuate airway inflammation in smoke exposed asthmatic mice which may involve HDAC2.	Clarithromycin	13-27	histone deacetylase 2	Mus musculus	130-135
26114656-8	2015	Radiation-induced expression of tumor necrosis factor (TNF)-alpha, TNF receptor 1, acetylated nuclear factor kappa B, cyclooxygenase 2, vascular cell adhesion molecule 1, and matrix metallopeptidase 9 were also attenuated by CLA.	Clarithromycin	225-228	tumor necrosis factor	Mus musculus	32-65
26114656-8	2015	Radiation-induced expression of tumor necrosis factor (TNF)-alpha, TNF receptor 1, acetylated nuclear factor kappa B, cyclooxygenase 2, vascular cell adhesion molecule 1, and matrix metallopeptidase 9 were also attenuated by CLA.	Clarithromycin	225-228	prostaglandin-endoperoxide synthase 2	Mus musculus	118-134
26114656-8	2015	Radiation-induced expression of tumor necrosis factor (TNF)-alpha, TNF receptor 1, acetylated nuclear factor kappa B, cyclooxygenase 2, vascular cell adhesion molecule 1, and matrix metallopeptidase 9 were also attenuated by CLA.	Clarithromycin	225-228	matrix metallopeptidase 9	Mus musculus	175-200
25915157-7	2015	Moreover, clarithromycin overcame stromal-mediated MM resistance to dexamethasone, suggesting that CYP3A4 inhibition plays a role in its ability to augment the activity of lenalidomide and dexamethasone as part of the BiRd regimen.	Clarithromycin	10-24	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	99-105
25925057-6	2015	Milk c9, t11-conjugated linoleic acid (CLA) proportion increased by 198.11% in the LSO-FO group relative to the control group (p<0.01).	Clarithromycin	39-42	Weaning weight-maternal milk	Bos taurus	0-4
25907295-7	2015	A dose-response curve was generated for itraconazole and clarithromycin (maximal concentration 100 muM) and compared to that of Zosuquidar, a highly specific known P-gp inhibitor.	Clarithromycin	57-71	latexin	Homo sapiens	99-102
25907295-9	2015	RESULTS: Both itraconazole and clarithromycin demonstrated a dose-response curve for P-gp inhibition similar to that of Zosuquidar.	Clarithromycin	31-45	ATP binding cassette subfamily B member 1	Homo sapiens	85-89
25907295-10	2015	The respective maximal inhibitory concentrations of Zosuquidar, itraconazole, and clarithromycin prior to induction of cytotoxicity were 0.31, 3.13, and 1.56 muM, respectively, as demonstrated by a statistically significant increase in total intracellular fluorescence (p < 0.05 in all groups).	Clarithromycin	82-96	latexin	Homo sapiens	158-161
25907295-11	2015	CONCLUSION: Both itraconazole and clarithromycin are capable of inhibiting sinonasal epithelial cell associated P-gp.	Clarithromycin	34-48	ATP binding cassette subfamily B member 1	Homo sapiens	112-116
25907295-3	2015	Both itraconazole and clarithromycin have also been shown to have P-gp inhibitory properties in other tissues, suggesting a novel explanation for their immunomodulatory effects in CRS.	Clarithromycin	22-36	ATP binding cassette subfamily B member 1	Homo sapiens	66-70
25858318-0	2015	EGFR-independent autophagy induction with gefitinib and enhancement of its cytotoxic effect by targeting autophagy with clarithromycin in non-small cell lung cancer cells.	Clarithromycin	120-134	epidermal growth factor receptor	Homo sapiens	0-4
25537341-6	2015	The concentration of interleukin-8 secreted from Calu-3 cells following stimulation with transforming growth factor-beta resulted in significantly lower level of interleukin-8 released from the cells pre-treated with clarithromycin (5.2 +- 0.5 ng.ml(-1) clarithromycin treated vs. 7.7 +- 0.8 ng.ml(-1) control, respectively).	Clarithromycin	217-231	C-X-C motif chemokine ligand 8	Homo sapiens	21-34
25537341-6	2015	The concentration of interleukin-8 secreted from Calu-3 cells following stimulation with transforming growth factor-beta resulted in significantly lower level of interleukin-8 released from the cells pre-treated with clarithromycin (5.2 +- 0.5 ng.ml(-1) clarithromycin treated vs. 7.7 +- 0.8 ng.ml(-1) control, respectively).	Clarithromycin	217-231	C-X-C motif chemokine ligand 8	Homo sapiens	162-175
25537341-6	2015	The concentration of interleukin-8 secreted from Calu-3 cells following stimulation with transforming growth factor-beta resulted in significantly lower level of interleukin-8 released from the cells pre-treated with clarithromycin (5.2 +- 0.5 ng.ml(-1) clarithromycin treated vs. 7.7 +- 0.8 ng.ml(-1) control, respectively).	Clarithromycin	254-268	C-X-C motif chemokine ligand 8	Homo sapiens	21-34
25537341-7	2015	CONCLUSIONS: Our data demonstrate that treatment with clarithromycin decreases the paracellular permeability of epithelial cells, mucus secretion and interleukin-8 release and therefore, inhaled clarithromycin holds potential as an anti-inflammatory therapy.	Clarithromycin	54-68	C-X-C motif chemokine ligand 8	Homo sapiens	150-163
25537341-7	2015	CONCLUSIONS: Our data demonstrate that treatment with clarithromycin decreases the paracellular permeability of epithelial cells, mucus secretion and interleukin-8 release and therefore, inhaled clarithromycin holds potential as an anti-inflammatory therapy.	Clarithromycin	195-209	C-X-C motif chemokine ligand 8	Homo sapiens	150-163
26190895-0	2015	Effect of Clarithromycin on the Expression of UL16-Binding Protein 2 in Human Cells.	Clarithromycin	10-24	UL16 binding protein 2	Homo sapiens	46-68
25583725-4	2015	We observed a moderate (1.5-fold) decrease in the MICs of amoxicillin and cefotaxime and a marked (4.7-fold) decrease in the MICs of clarithromycin for acrA, acrB, and oprM mutants in comparison with the wild-type O35E strain.	Clarithromycin	133-147	opioid receptor mu 1	Homo sapiens	168-172
25583725-5	2015	Exposure of the M. catarrhalis strains O35E and 300 to amoxicillin triggered an increased transcription of all AcrAB-OprM pump genes, and exposure of strains O35E, 300, and 415 to clarithromycin enhanced the expression of acrA and oprM mRNA.	Clarithromycin	180-194	opioid receptor mu 1	Homo sapiens	231-235
26190895-3	2015	In this study, we examined the effect of clarithromycin on a potent NKG2D ligand, UL16-binding protein 2 (ULBP2), in the lung and its shedding mechanism.	Clarithromycin	41-55	killer cell lectin like receptor K1	Rattus norvegicus	68-73
26190895-3	2015	In this study, we examined the effect of clarithromycin on a potent NKG2D ligand, UL16-binding protein 2 (ULBP2), in the lung and its shedding mechanism.	Clarithromycin	41-55	UL16 binding protein 2	Homo sapiens	82-104
26190895-8	2015	RESULTS: Clarithromycin significantly induced transcription of ULBP2 and ADAM17 in both A549 and LCSC #2 cells, which endogenously express minimal and abundant levels of ULBP2, respectively.	Clarithromycin	9-23	ADAM metallopeptidase domain 17	Rattus norvegicus	73-79
26190895-12	2015	Finally, clarithromycin significantly inhibited the activity of ADAM17 in LCSC #2 cells.	Clarithromycin	9-23	ADAM metallopeptidase domain 17	Rattus norvegicus	64-70
26190895-13	2015	CONCLUSION: These findings suggest that clarithromycin induces ULBP2 expression and reduces the amount of sULBP2, by possibly inhibiting the activity of the potent ULBP2-shedding enzyme ADAM17.	Clarithromycin	40-54	ADAM metallopeptidase domain 17	Rattus norvegicus	186-192
25429094-3	2015	Clarithromycin is an inhibitor of CYP3A4, whereas azithromycin is not.	Clarithromycin	0-14	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	34-40
25534598-1	2015	BACKGROUND: The cytochrome P450 3A4 (CYP3A4) inhibitor clarithromycin may also inhibit liver-specific organic anion-transporting polypeptides (OATP1B1 and OATP1B3).	Clarithromycin	55-69	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	16-35
25534598-1	2015	BACKGROUND: The cytochrome P450 3A4 (CYP3A4) inhibitor clarithromycin may also inhibit liver-specific organic anion-transporting polypeptides (OATP1B1 and OATP1B3).	Clarithromycin	55-69	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	37-43
25534598-1	2015	BACKGROUND: The cytochrome P450 3A4 (CYP3A4) inhibitor clarithromycin may also inhibit liver-specific organic anion-transporting polypeptides (OATP1B1 and OATP1B3).	Clarithromycin	55-69	solute carrier organic anion transporter family member 1B1	Homo sapiens	143-150
25534598-1	2015	BACKGROUND: The cytochrome P450 3A4 (CYP3A4) inhibitor clarithromycin may also inhibit liver-specific organic anion-transporting polypeptides (OATP1B1 and OATP1B3).	Clarithromycin	55-69	solute carrier organic anion transporter family member 1B3	Homo sapiens	155-162
25534598-9	2015	INTERPRETATION: Among older adults taking a statin not metabolized by CYP3A4, co-prescription of clarithromycin versus azithromycin was associated with a modest but statistically significant increase in the 30-day absolute risk of adverse outcomes.	Clarithromycin	97-111	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	70-76
26143935-7	2015	In the cytokine analysis, lower levels of interleukin (IL)-6 and IL-17A and higher IL-10 were found in the clarithromycin, prednisolone, and clarithromycin+prednisolone groups than in the experimental group (p < 0.05).	Clarithromycin	107-121	interleukin-6	Cavia porcellus	42-60
26143935-7	2015	In the cytokine analysis, lower levels of interleukin (IL)-6 and IL-17A and higher IL-10 were found in the clarithromycin, prednisolone, and clarithromycin+prednisolone groups than in the experimental group (p < 0.05).	Clarithromycin	107-121	interleukin-17A	Cavia porcellus	65-71
26143935-7	2015	In the cytokine analysis, lower levels of interleukin (IL)-6 and IL-17A and higher IL-10 were found in the clarithromycin, prednisolone, and clarithromycin+prednisolone groups than in the experimental group (p < 0.05).	Clarithromycin	107-121	interleukin-10	Cavia porcellus	83-88
26143935-7	2015	In the cytokine analysis, lower levels of interleukin (IL)-6 and IL-17A and higher IL-10 were found in the clarithromycin, prednisolone, and clarithromycin+prednisolone groups than in the experimental group (p < 0.05).	Clarithromycin	141-155	interleukin-6	Cavia porcellus	42-60
26143935-7	2015	In the cytokine analysis, lower levels of interleukin (IL)-6 and IL-17A and higher IL-10 were found in the clarithromycin, prednisolone, and clarithromycin+prednisolone groups than in the experimental group (p < 0.05).	Clarithromycin	141-155	interleukin-17A	Cavia porcellus	65-71
26143935-7	2015	In the cytokine analysis, lower levels of interleukin (IL)-6 and IL-17A and higher IL-10 were found in the clarithromycin, prednisolone, and clarithromycin+prednisolone groups than in the experimental group (p < 0.05).	Clarithromycin	141-155	interleukin-10	Cavia porcellus	83-88
26156575-1	2015	The aim of this study was to investigate the effect of clarithromycin in rat endometriosis and its association with matrix metalloproteinase-9 (MMP-9) expression.	Clarithromycin	55-69	matrix metallopeptidase 9	Rattus norvegicus	116-142
26156575-1	2015	The aim of this study was to investigate the effect of clarithromycin in rat endometriosis and its association with matrix metalloproteinase-9 (MMP-9) expression.	Clarithromycin	55-69	matrix metallopeptidase 9	Rattus norvegicus	144-149
24934663-8	2015	A combination of rifampin and clarithromycin released from the polymer film provided >99.9% kill of an MRSA inoculate for up to 72 h. CONCLUSION: Results showed that combining multiple drugs in copolymer films with unique surface properties, initial hydrophilicity and increase in roughness, can be an effective way to prevent biofilm formation.	Clarithromycin	30-44	solute carrier family 9 member A6	Homo sapiens	106-110
25958627-15	2015	CONCLUSION: Simple exercise and exercise combined with CLA conld significantly reduced adolescent obese rats weight, weight growth rate, percentage of body fat, blood glucose content and also reduced RBP4 mRNA expression in visceral adipose tissue, RBP4 protein expression in liver tissue, RBP4 level in plasma,but can increase sensitivity to insulin, in a word, the treatment of exercise and exercise combine with CLA is better than the simple complement of CLA to adolescent obese rats.	Clarithromycin	55-58	retinol binding protein 4	Rattus norvegicus	200-204
25958627-15	2015	CONCLUSION: Simple exercise and exercise combined with CLA conld significantly reduced adolescent obese rats weight, weight growth rate, percentage of body fat, blood glucose content and also reduced RBP4 mRNA expression in visceral adipose tissue, RBP4 protein expression in liver tissue, RBP4 level in plasma,but can increase sensitivity to insulin, in a word, the treatment of exercise and exercise combine with CLA is better than the simple complement of CLA to adolescent obese rats.	Clarithromycin	55-58	retinol binding protein 4	Rattus norvegicus	249-253
25958627-15	2015	CONCLUSION: Simple exercise and exercise combined with CLA conld significantly reduced adolescent obese rats weight, weight growth rate, percentage of body fat, blood glucose content and also reduced RBP4 mRNA expression in visceral adipose tissue, RBP4 protein expression in liver tissue, RBP4 level in plasma,but can increase sensitivity to insulin, in a word, the treatment of exercise and exercise combine with CLA is better than the simple complement of CLA to adolescent obese rats.	Clarithromycin	55-58	retinol binding protein 4	Rattus norvegicus	249-253
25425668-6	2014	MAX1 catalyzed consecutive oxidations at C-19 of CL to convert the C-19 methyl group into carboxylic acid, 9-desmethyl-9-carboxy-CL [designated as carlactonoic acid (CLA)].	Clarithromycin	166-169	cytochrome P450, family 711, subfamily A, polypeptide 1	Arabidopsis thaliana	0-4
25425668-8	2014	Although an exogenous application of either CLA or MeCLA suppressed the growth of lateral inflorescences of the max1 mutant, MeCLA, but not CLA, interacted with Arabidopsis thaliana DWARF14 (AtD14) protein, a putative SL receptor, as shown by differential scanning fluorimetry and hydrolysis activity tests.	Clarithromycin	44-47	cytochrome P450, family 711, subfamily A, polypeptide 1	Arabidopsis thaliana	112-116
25425668-8	2014	Although an exogenous application of either CLA or MeCLA suppressed the growth of lateral inflorescences of the max1 mutant, MeCLA, but not CLA, interacted with Arabidopsis thaliana DWARF14 (AtD14) protein, a putative SL receptor, as shown by differential scanning fluorimetry and hydrolysis activity tests.	Clarithromycin	53-56	cytochrome P450, family 711, subfamily A, polypeptide 1	Arabidopsis thaliana	112-116
25106415-0	2014	Clinical CYP3A inhibitor alternatives to ketoconazole, clarithromycin and itraconazole, are not transported into the liver by hepatic organic anion transporting polypeptides and organic cation transporter 1.	Clarithromycin	55-69	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	9-14
25500904-12	2014	We show for the first time that AZM and to a lesser extent CLM act as immunosuppressive agents on CD4(+) T-cells by inhibiting mTOR activity.	Clarithromycin	59-62	CD4 molecule	Homo sapiens	98-101
25500904-12	2014	We show for the first time that AZM and to a lesser extent CLM act as immunosuppressive agents on CD4(+) T-cells by inhibiting mTOR activity.	Clarithromycin	59-62	mechanistic target of rapamycin kinase	Homo sapiens	127-131
25106415-1	2014	Ketoconazole is no longer available for clinical determination of worst-case victim drug-drug interaction (DDI) potential for cytochrome P450 3A (CYP3A)-substrate drugs; clarithromycin and itraconazole are the proposed replacements.	Clarithromycin	170-184	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	146-151
25106415-3	2014	At present, transport of clarithromycin, itraconazole, and hydroxyitraconazole by hepatic organic anion transporting polypeptides (OATPs) and organic cation transporter 1 (OCT1) was examined in vitro and in vivo.	Clarithromycin	25-39	solute carrier family 22 member 1	Homo sapiens	142-170
25106415-3	2014	At present, transport of clarithromycin, itraconazole, and hydroxyitraconazole by hepatic organic anion transporting polypeptides (OATPs) and organic cation transporter 1 (OCT1) was examined in vitro and in vivo.	Clarithromycin	25-39	solute carrier family 22 member 1	Homo sapiens	172-176
25106415-4	2014	As for ketoconazole, uptake of clarithromycin, itraconazole, and hydroxyitraconazole into OATP1B1, OATP1B3, OATP2B1, and OCT1 expressing human embryonic kidney 293 (HEK293) cells was not greater than in vector controls.	Clarithromycin	31-45	solute carrier organic anion transporter family member 1B1	Homo sapiens	90-97
25106415-4	2014	As for ketoconazole, uptake of clarithromycin, itraconazole, and hydroxyitraconazole into OATP1B1, OATP1B3, OATP2B1, and OCT1 expressing human embryonic kidney 293 (HEK293) cells was not greater than in vector controls.	Clarithromycin	31-45	solute carrier organic anion transporter family member 1B3	Homo sapiens	99-106
25106415-4	2014	As for ketoconazole, uptake of clarithromycin, itraconazole, and hydroxyitraconazole into OATP1B1, OATP1B3, OATP2B1, and OCT1 expressing human embryonic kidney 293 (HEK293) cells was not greater than in vector controls.	Clarithromycin	31-45	solute carrier organic anion transporter family member 2B1	Homo sapiens	108-115
25106415-4	2014	As for ketoconazole, uptake of clarithromycin, itraconazole, and hydroxyitraconazole into OATP1B1, OATP1B3, OATP2B1, and OCT1 expressing human embryonic kidney 293 (HEK293) cells was not greater than in vector controls.	Clarithromycin	31-45	solute carrier family 22 member 1	Homo sapiens	121-125
24659566-7	2014	Concentration of ECP in the nasal secretions increased dramatically after surgery, then returned to baseline levels after 12 and 24 weeks of treatment with clarithromycin.	Clarithromycin	156-170	ribonuclease A family member 3	Homo sapiens	17-20
25201298-5	2014	The obtained clarithromycin nanocrystals were identified as cubic particles by SEM with a bulk population of approximately 400nm existed in crystalline and/or partial amorphous form as investigated by DSC and XRPD.	Clarithromycin	13-27	desmocollin 3	Homo sapiens	201-204
25169846-12	2014	CONCLUSIONS: Clarithromycin may have the additional clinical benefit of improving fever, the main symptom of influenza, in patients treated with neuraminidase inhibitors.	Clarithromycin	13-27	neuraminidase 1	Homo sapiens	145-158
25359648-7	2014	However, patients taking anticoagulants or cytochrome P450 3A4 substrates (such as clarithromycin, erythromycin, ketoconazole, itraconazole, midazolam and triazolam) in addition to specific vitamin or mineral supplements (vitamins D, E, K, calcium, fluoride, iron, magnesium, selenium or zinc) may face additional challenges.	Clarithromycin	83-97	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-62
25248908-0	2014	[Three cases of lenalidomide-resistant IgA myeloma for which a response was regained after the addition of clarithromycin].	Clarithromycin	107-121	CD79a molecule	Homo sapiens	39-42
24035278-1	2014	BACKGROUND: To investigate the correlation between CYP3A4/5 activity and clarithromycin metabolism, and between CYP3A activity and CYP3A genotype.	Clarithromycin	73-87	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	51-57
25041770-1	2014	Clarithromycin is the most documented cytochrome P450 3A4 (CYP3A4) inhibitor to cause an adverse interaction with simvastatin.	Clarithromycin	0-14	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-57
25041770-1	2014	Clarithromycin is the most documented cytochrome P450 3A4 (CYP3A4) inhibitor to cause an adverse interaction with simvastatin.	Clarithromycin	0-14	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	59-65
25028548-10	2014	The results of the cellular uptake experiment indicated that the increased cellular uptake of CLA-PTX in the iRGD-SSL-CLA-PTX-treated group was 1.9-, 2.4-, or 2.1-fold compared with that in the CLA-PTX group after a 2-, 4-, or 6-hour incubation, respectively.	Clarithromycin	94-97	interferon gamma inducible protein 47	Mus musculus	109-113
25028548-11	2014	In the biodistribution test, the CLA-PTX level in tumor tissues from iRGD-SSL-CLA-PTX-treated mice at 1 hour (1.84+-0.17 mug/g) and 4 hours (1.17+-0.28 mug/g) was 2.3- and 2.0-fold higher than that of CLA-PTX solution at 1 hour (0.79+-0.06 mug/g) and 4 hours (0.58+-0.04 mug/g).	Clarithromycin	33-36	interferon gamma inducible protein 47	Mus musculus	69-73
25028548-12	2014	The value of the area under the curve for the first 24 hours in the tumors of iRGD-SSL-CLA-PTX-treated mice was significantly higher than that in the SSL-CLA-PTX and CLA-PTX solution-treated groups (P<0.01).	Clarithromycin	87-90	interferon gamma inducible protein 47	Mus musculus	78-82
25028548-13	2014	The in vivo antitumor results indicated that iRGD-SSL-CLA-PTX significantly inhibited the growth of B16-F10 tumors compared with the SSL-CLA-PTX or CLA-PTX solution-treatment groups (P<0.01).	Clarithromycin	54-57	interferon gamma inducible protein 47	Mus musculus	45-49
25028548-14	2014	The results of tumor-cell apoptosis showed that tumors from the iRGD-SSL-CLA-PTX-treated group exhibited more advanced cell apoptosis compared with the control, CLA-PTX solution-, and SSL-CLA-PTX-treated groups.	Clarithromycin	73-76	interferon gamma inducible protein 47	Mus musculus	64-68
24636825-10	2014	Milk fat t10,c12-CLA concentration and secretion increased with the CLA dose, and its apparent transfer efficiency from diet to milk was 1.18%, 1.17% and 1.21% for CLA15, CLA30 and CLA45 treatments, respectively.	Clarithromycin	17-20	Weaning weight-maternal milk	Bos taurus	0-4
24035278-1	2014	BACKGROUND: To investigate the correlation between CYP3A4/5 activity and clarithromycin metabolism, and between CYP3A activity and CYP3A genotype.	Clarithromycin	73-87	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	51-56
24035278-9	2014	A linear correlation between the CYP3A4-activity and clarithromycin metabolism was demonstrated (P < 0.05).	Clarithromycin	53-67	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	33-39
24212378-4	2014	From a set of potential P-gp inhibitors, clarithromycin, cyclosporin A, itraconazole, ketoconazole, quinidine, and ritonavir inhibited P-gp-mediated transport of dabigatran etexilate over a concentration range that may hypothetically occur in the intestine.	Clarithromycin	41-55	ATP binding cassette subfamily B member 1	Homo sapiens	24-28
25185282-1	2014	OBJECTIVE: To investigate the expression of vascular endothelial growth factor in the nasal mucosa of chronic rhinosinusitis with nasal polys patients, and explored the regulation of clarithromycin on VEGF.	Clarithromycin	183-197	vascular endothelial growth factor A	Homo sapiens	201-205
25185282-3	2014	Nasal mucosal tissue explant culture measure and ELISA were used to explore the effect of clarithromycin on VEGF expression.	Clarithromycin	90-104	vascular endothelial growth factor A	Homo sapiens	108-112
25185282-5	2014	(2) There was a significant decrease in CRSwNP group undergo clarithromycin treatment on protein expression level of VEGF and showed a statistic difference (P < 0.05).	Clarithromycin	61-75	vascular endothelial growth factor A	Homo sapiens	117-121
25185282-7	2014	Clarithromycin may play a therapeutical role on chronic rhinosinusitis through down-regulated the expression of VEGF.	Clarithromycin	0-14	vascular endothelial growth factor A	Homo sapiens	112-116
24555753-6	2014	Significant differences in nasal cytokine levels (interleukin-5 and -8) were also observed between the low-dose and high-dose groups after short-term clarithromycin treatment (p < 0.025).	Clarithromycin	150-164	interleukin 5	Homo sapiens	50-70
24212378-4	2014	From a set of potential P-gp inhibitors, clarithromycin, cyclosporin A, itraconazole, ketoconazole, quinidine, and ritonavir inhibited P-gp-mediated transport of dabigatran etexilate over a concentration range that may hypothetically occur in the intestine.	Clarithromycin	41-55	ATP binding cassette subfamily B member 1	Homo sapiens	135-139
25571290-2	2014	Clarithromycin is a commonly used macrolide antibiotics and a potent inhibitor of CYP3A4.	Clarithromycin	0-14	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-88
24346990-3	2013	Clarithromycin is an inhibitor of CYP3A4 and azithromycin is not, which makes comparisons between these 2 macrolide antibiotics useful in assessing clinically important drug interactions.	Clarithromycin	0-14	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	34-40
23738582-6	2014	Clarithromycin also reduced CYP3A activity (midazolam clearance) in all participants; however, these changes were not correlated to the changes of bosentan clearance.	Clarithromycin	0-14	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	28-33
24070791-6	2013	Although there is no standard for complete conclusive identification, structural characterization strongly suggests that the Delta11,13-conjugated linoleic acid (CLA) produced by FADS3 from trans-vaccenate is the trans11,cis13-CLA isomer.	Clarithromycin	162-165	fatty acid desaturase 3	Rattus norvegicus	179-184
23847265-1	2013	OBJECTIVE: Clarithromycin strongly inhibits enzyme cytochrome P450 3A4, preventing the metabolism of some other drugs, while azithromycin is a weak inhibitor.	Clarithromycin	11-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	51-70
23792097-8	2013	The specific HDAC6 inhibitor tubacin also exhibited a pronounced cytocidal effect with a combination of CAM plus BZ.	Clarithromycin	104-107	histone deacetylase 6	Mus musculus	13-18
23875018-0	2013	Immunomodulator clarithromycin enhances mucosal and systemic immune responses and reduces re-infection rate in pediatric patients with influenza treated with antiviral neuraminidase inhibitors: a retrospective analysis.	Clarithromycin	16-30	neuraminidase 1	Homo sapiens	168-181
24400172-8	2013	However, the I hERG inhibitory potency of the antibiotic clarithromycin and of the prokinetic drug cisapride was altered by KCNE1 variants.	Clarithromycin	57-71	ETS transcription factor ERG	Homo sapiens	15-19
24400172-8	2013	However, the I hERG inhibitory potency of the antibiotic clarithromycin and of the prokinetic drug cisapride was altered by KCNE1 variants.	Clarithromycin	57-71	potassium voltage-gated channel subfamily E regulatory subunit 1	Homo sapiens	124-129
23643509-6	2013	The FPF increased from 35% and 31% for the physical blend for tobramycin and clarithromycin, respectively, to 65% and 63% for the spray-dried formulation.	Clarithromycin	77-91	TNF receptor superfamily member 1A	Homo sapiens	4-7
23527897-2	2013	Since macrolide antibiotics, such as clarithromycin and azithromycin, exert immunomodulatory effects, they would affect the Kv1.3-channel currents in lymphocytes.	Clarithromycin	37-51	potassium voltage-gated channel, shaker-related subfamily, member 3	Mus musculus	124-129
23401164-4	2013	The detection limits were 0.02, 0.01, 0.01, 0.06 and 0.003 ng/muL for erythromycin, clarithromycin, doxepin, amitriptyline and clomipramine, respectively.	Clarithromycin	84-98	tripartite motif containing 37	Homo sapiens	62-65
23778904-1	2013	BACKGROUND: Clarithromycin and erythromycin, but not azithromycin, inhibit cytochrome P450 isoenzyme 3A4 (CYP3A4), and inhibition increases blood concentrations of statins that are metabolized by CYP3A4.	Clarithromycin	12-26	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-104
23778904-1	2013	BACKGROUND: Clarithromycin and erythromycin, but not azithromycin, inhibit cytochrome P450 isoenzyme 3A4 (CYP3A4), and inhibition increases blood concentrations of statins that are metabolized by CYP3A4.	Clarithromycin	12-26	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-112
23778904-1	2013	BACKGROUND: Clarithromycin and erythromycin, but not azithromycin, inhibit cytochrome P450 isoenzyme 3A4 (CYP3A4), and inhibition increases blood concentrations of statins that are metabolized by CYP3A4.	Clarithromycin	12-26	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	196-202
23778904-11	2013	CONCLUSION: In older adults, coprescription of clarithromycin or erythromycin with a statin that is metabolized by CYP3A4 increases the risk for statin toxicity.	Clarithromycin	47-61	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	115-121
24252529-6	2013	The concomitant use of RPV with a CYP3A4 inhibitor (such as clarithromycin) can increase RPV concentrations.	Clarithromycin	60-74	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	34-40
23210726-1	2013	AIM: The aim of this study was to develop a PK/PD model to assess drug-drug interactions between dabigatran and P-gp modulators, using the example of clarithromycin, a strong inhibitor of P-gp.	Clarithromycin	150-164	phosphoglycolate phosphatase	Homo sapiens	112-116
23210726-1	2013	AIM: The aim of this study was to develop a PK/PD model to assess drug-drug interactions between dabigatran and P-gp modulators, using the example of clarithromycin, a strong inhibitor of P-gp.	Clarithromycin	150-164	phosphoglycolate phosphatase	Homo sapiens	188-192
23210726-10	2013	CONCLUSION: The model proposed effectively describes the complex PK of dabigatran and takes into account drug-drug interactions with P-gp activity modulators, such as clarithromycin.	Clarithromycin	167-181	phosphoglycolate phosphatase	Homo sapiens	133-137
23199585-7	2013	CAM and AZM induced a dose-dependent suppression of spontaneous TNF-alpha, sTNFR2, IL-6, IL-8 and CCL18 production (p<0.05).	Clarithromycin	0-3	tumor necrosis factor	Homo sapiens	64-73
23199585-7	2013	CAM and AZM induced a dose-dependent suppression of spontaneous TNF-alpha, sTNFR2, IL-6, IL-8 and CCL18 production (p<0.05).	Clarithromycin	0-3	interleukin 6	Homo sapiens	83-87
23199585-7	2013	CAM and AZM induced a dose-dependent suppression of spontaneous TNF-alpha, sTNFR2, IL-6, IL-8 and CCL18 production (p<0.05).	Clarithromycin	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	89-93
23199585-7	2013	CAM and AZM induced a dose-dependent suppression of spontaneous TNF-alpha, sTNFR2, IL-6, IL-8 and CCL18 production (p<0.05).	Clarithromycin	0-3	C-C motif chemokine ligand 18	Homo sapiens	98-103
23199585-8	2013	CAM also inhibited the IL-1beta production.	Clarithromycin	0-3	interleukin 1 beta	Homo sapiens	23-31
23199585-9	2013	CAM and AZM significantly and dose-dependently attenuated the LPS-stimulated production of sTNFR1, sTNFR2, IL-8 and CCL18 (p<0.05).	Clarithromycin	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	107-111
23199585-9	2013	CAM and AZM significantly and dose-dependently attenuated the LPS-stimulated production of sTNFR1, sTNFR2, IL-8 and CCL18 (p<0.05).	Clarithromycin	0-3	C-C motif chemokine ligand 18	Homo sapiens	116-121
23199585-10	2013	CAM also inhibited the LPS-stimulated TNF-alpha, IL-1beta, IL-6 and IL-10 production.	Clarithromycin	0-3	tumor necrosis factor	Homo sapiens	38-47
23199585-10	2013	CAM also inhibited the LPS-stimulated TNF-alpha, IL-1beta, IL-6 and IL-10 production.	Clarithromycin	0-3	interleukin 1 beta	Homo sapiens	49-57
23199585-10	2013	CAM also inhibited the LPS-stimulated TNF-alpha, IL-1beta, IL-6 and IL-10 production.	Clarithromycin	0-3	interleukin 6	Homo sapiens	59-63
23199585-10	2013	CAM also inhibited the LPS-stimulated TNF-alpha, IL-1beta, IL-6 and IL-10 production.	Clarithromycin	0-3	interleukin 10	Homo sapiens	68-73
23527897-8	2013	DISCUSSION AND CONCLUSION: This study demonstrated for the first time that clarithromycin exerts inhibitory effects on thymocyte Kv1.3-channel currents, while azithromycin decreases the membrane capacitance without affecting the channel currents.	Clarithromycin	75-89	potassium voltage-gated channel, shaker-related subfamily, member 3	Mus musculus	129-134
23546223-2	2013	The macrolide antibiotics including concanamycin A, erythromycin (EM), clarithromycin (CAM) and azithromycin (AZM) all blocked autophagy flux, as assessed by intracellular accumulation of LC3B-II and p62.	Clarithromycin	71-85	nucleoporin 62	Mus musculus	200-203
23606690-0	2013	Enhancement of thioredoxin production from nasal epithelial cells by the macrolide antibiotic, clarithromycin in vitro.	Clarithromycin	95-109	thioredoxin	Homo sapiens	15-26
23606690-6	2013	The addition of clarithromycin (CAM) to cell cultures caused an increase in the ability of cells to produce TRX in response to H2O2 stimulation, and the minimum concentration that caused a significant increase was 0.5 mug/ml.	Clarithromycin	16-30	thioredoxin	Homo sapiens	108-111
23606690-6	2013	The addition of clarithromycin (CAM) to cell cultures caused an increase in the ability of cells to produce TRX in response to H2O2 stimulation, and the minimum concentration that caused a significant increase was 0.5 mug/ml.	Clarithromycin	32-35	thioredoxin	Homo sapiens	108-111
23546223-5	2013	Expression levels of the proapoptotic genes transcriptionally regulated by CHOP (BIM, BAX, DR5 and TRB3) were all enhanced by combined treatment with BZ plus CAM, compared with treatment with each reagent alone.	Clarithromycin	158-161	BCL2-associated X protein	Mus musculus	86-89
23546223-2	2013	The macrolide antibiotics including concanamycin A, erythromycin (EM), clarithromycin (CAM) and azithromycin (AZM) all blocked autophagy flux, as assessed by intracellular accumulation of LC3B-II and p62.	Clarithromycin	87-90	nucleoporin 62	Mus musculus	200-203
23546223-5	2013	Expression levels of the proapoptotic genes transcriptionally regulated by CHOP (BIM, BAX, DR5 and TRB3) were all enhanced by combined treatment with BZ plus CAM, compared with treatment with each reagent alone.	Clarithromycin	158-161	DNA-damage inducible transcript 3	Mus musculus	75-79
23546223-5	2013	Expression levels of the proapoptotic genes transcriptionally regulated by CHOP (BIM, BAX, DR5 and TRB3) were all enhanced by combined treatment with BZ plus CAM, compared with treatment with each reagent alone.	Clarithromycin	158-161	tumor necrosis factor receptor superfamily, member 10b	Mus musculus	91-94
22777148-5	2013	RESULTS: Intestinal CYP3A activity decreased by 64 % (p = 0.0029) following the first dose of clarithromycin, but hepatic CYP3A activity did not significantly decrease.	Clarithromycin	94-108	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	20-25
23546223-5	2013	Expression levels of the proapoptotic genes transcriptionally regulated by CHOP (BIM, BAX, DR5 and TRB3) were all enhanced by combined treatment with BZ plus CAM, compared with treatment with each reagent alone.	Clarithromycin	158-161	tribbles pseudokinase 3	Mus musculus	99-103
23462027-9	2013	Coadministration of CYP3A4 inhibitors (particularly clarithromycin) and colchicine has resulted in acute colchicine toxicity manifested by severe gastrointestional toxicity, bone marrow suppression, multiorgan failure, and death.	Clarithromycin	52-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	20-26
22777148-0	2013	Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin.	Clarithromycin	61-75	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	52-57
22777148-1	2013	AIMS: To determine the extent and time-course of hepatic and intestinal cytochrome P450 3A (CYP3A) inactivation due to the mechanism-based inhibitor clarithromycin.	Clarithromycin	149-163	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	72-90
22777148-1	2013	AIMS: To determine the extent and time-course of hepatic and intestinal cytochrome P450 3A (CYP3A) inactivation due to the mechanism-based inhibitor clarithromycin.	Clarithromycin	149-163	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	92-97
22777148-6	2013	Repeated dosing of clarithromycin caused a significant decrease in hepatic CYP3A activity (p = 0.005), while intestinal activity showed little further decline.	Clarithromycin	19-33	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-80
22777148-8	2013	CONCLUSIONS: Following the administration of clarithromycin, the onset of hepatic CYP3A inactivation is delayed compared to that of intestinal CYP3A.	Clarithromycin	45-59	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-87
22777148-9	2013	The time-course of drug-drug interactions due to clarithromycin will vary with the relative contribution of intestinal and hepatic CYP3A to the clearance and bioavailability of a victim substrate.	Clarithromycin	49-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	131-136
22181324-1	2012	BACKGROUND AND OBJECTIVE: Although clarithromycin (CAM) has many biological functions, including regulation of MMPs, little is known about its effect on abdominal aortic aneurysms.	Clarithromycin	35-49	matrix metallopeptidase 2	Mus musculus	111-115
23264678-2	2013	Based on our published data showing that trans-10, cis-12 conjugated linoleic acid (t10,c12 CLA)-mediated intracellular calcium accumulation is linked to inflammation and insulin resistance, we hypothesized that inhibiting DGKs with R59022 would prevent t10,c12 CLA-mediated inflammatory signaling and insulin resistance in human adipocytes.	Clarithromycin	92-95	insulin	Homo sapiens	171-178
23264678-2	2013	Based on our published data showing that trans-10, cis-12 conjugated linoleic acid (t10,c12 CLA)-mediated intracellular calcium accumulation is linked to inflammation and insulin resistance, we hypothesized that inhibiting DGKs with R59022 would prevent t10,c12 CLA-mediated inflammatory signaling and insulin resistance in human adipocytes.	Clarithromycin	92-95	insulin	Homo sapiens	302-309
23253473-2	2013	OBJECTIVE: This study was aimed to assess whether the efficacy of one-week triple therapy comprising of proton pump inhibitor, amoxicillin and clarithromycin (PPI/A/C) on Helicobacter pylori (H. pylori) infection in Singapore has decreased over the duration from 2005 to 2010.	Clarithromycin	143-157	peptidylprolyl isomerase C	Homo sapiens	159-166
25011542-3	2013	Clarithromycin, a potent inhibitor of CYP3A4, is occasionally used in combination with docetaxel.	Clarithromycin	0-14	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-44
23514827-5	2013	In this study, we quantitatively investigated the inhibition kinetics of MBI inhibitors, erythromycin and clarithromycin, on the CYP3A4 variants CYP3A4.1, 4.2, 4.7, 4.16, and 4.18.	Clarithromycin	106-120	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	129-135
23514827-5	2013	In this study, we quantitatively investigated the inhibition kinetics of MBI inhibitors, erythromycin and clarithromycin, on the CYP3A4 variants CYP3A4.1, 4.2, 4.7, 4.16, and 4.18.	Clarithromycin	106-120	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	145-151
23514827-7	2013	Both erythromycin and clarithromycin decreased the activity of CYP3A4 in a time-dependent manner.	Clarithromycin	22-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	63-69
22896605-0	2012	Oral clarithromycin enhances airway immunoglobulin A (IgA) immunity through induction of IgA class switching recombination and B-cell-activating factor of the tumor necrosis factor family molecule on mucosal dendritic cells in mice infected with influenza A virus.	Clarithromycin	5-19	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	36-52
22896605-0	2012	Oral clarithromycin enhances airway immunoglobulin A (IgA) immunity through induction of IgA class switching recombination and B-cell-activating factor of the tumor necrosis factor family molecule on mucosal dendritic cells in mice infected with influenza A virus.	Clarithromycin	5-19	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	54-57
22896605-0	2012	Oral clarithromycin enhances airway immunoglobulin A (IgA) immunity through induction of IgA class switching recombination and B-cell-activating factor of the tumor necrosis factor family molecule on mucosal dendritic cells in mice infected with influenza A virus.	Clarithromycin	5-19	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	89-92
23054570-2	2013	METHODS: The study adopted a 14-day clarithromycin-based triple therapy in first-line treatment as proposed by the Maastricht III consensus-proton pump inhibitor bid, clarithromycin 500 mg bid and amoxicillin 1,000 mg bid-and a 14-day second-line levofloxacin-based empirical regimen-proton pump inhibitor bid, amoxicillin 1,000 mg bid and levofloxacin 500 mg od.	Clarithromycin	36-50	BH3 interacting domain death agonist	Homo sapiens	162-165
22896605-1	2012	We previously reported that the macrolide antibiotic clarithromycin (CAM) enhanced the mucosal immune response in pediatric influenza, particularly in children treated with the antiviral neuraminidase inhibitor oseltamivir (OSV) with low production of mucosal antiviral secretory IgA (S-IgA).	Clarithromycin	53-67	neuraminidase 1	Homo sapiens	187-200
22896605-1	2012	We previously reported that the macrolide antibiotic clarithromycin (CAM) enhanced the mucosal immune response in pediatric influenza, particularly in children treated with the antiviral neuraminidase inhibitor oseltamivir (OSV) with low production of mucosal antiviral secretory IgA (S-IgA).	Clarithromycin	53-67	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	280-283
22896605-1	2012	We previously reported that the macrolide antibiotic clarithromycin (CAM) enhanced the mucosal immune response in pediatric influenza, particularly in children treated with the antiviral neuraminidase inhibitor oseltamivir (OSV) with low production of mucosal antiviral secretory IgA (S-IgA).	Clarithromycin	53-67	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	287-290
22896605-1	2012	We previously reported that the macrolide antibiotic clarithromycin (CAM) enhanced the mucosal immune response in pediatric influenza, particularly in children treated with the antiviral neuraminidase inhibitor oseltamivir (OSV) with low production of mucosal antiviral secretory IgA (S-IgA).	Clarithromycin	69-72	neuraminidase 1	Homo sapiens	187-200
22896605-1	2012	We previously reported that the macrolide antibiotic clarithromycin (CAM) enhanced the mucosal immune response in pediatric influenza, particularly in children treated with the antiviral neuraminidase inhibitor oseltamivir (OSV) with low production of mucosal antiviral secretory IgA (S-IgA).	Clarithromycin	69-72	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	280-283
22896605-1	2012	We previously reported that the macrolide antibiotic clarithromycin (CAM) enhanced the mucosal immune response in pediatric influenza, particularly in children treated with the antiviral neuraminidase inhibitor oseltamivir (OSV) with low production of mucosal antiviral secretory IgA (S-IgA).	Clarithromycin	69-72	CD79A antigen (immunoglobulin-associated alpha)	Mus musculus	287-290
22896605-6	2012	The expression levels of B-cell-activating factor of the tumor necrosis factor family (BAFF) molecule on mucosal dendritic cells as well as those of activation-induced cytidine deaminase and Imu-Calpha transcripts on B cells were enhanced by CAM, compared with the levels without CAM treatment, but CAM had no effect on the expression of the BAFF receptor on B cells.	Clarithromycin	242-245	activation induced cytidine deaminase	Homo sapiens	149-186
22181324-1	2012	BACKGROUND AND OBJECTIVE: Although clarithromycin (CAM) has many biological functions, including regulation of MMPs, little is known about its effect on abdominal aortic aneurysms.	Clarithromycin	51-54	matrix metallopeptidase 2	Mus musculus	111-115
22181324-10	2012	CONCLUSION: These findings suggest that CAM administration is useful to suppress periodontal bacteria-accelerated abdominal aortic aneurysms via MMP regulation.	Clarithromycin	40-43	matrix metallopeptidase 2	Mus musculus	145-148
22677362-4	2012	The tested macrolides, clarithromycin and azithromycin, administered orally (2 x 150 mg/kg) 0.5 h before and 5 h after cantharidin challenge, reduced MIP-2, MCP-1, KC, and MPO concentrations and thereby decreased ear swelling.	Clarithromycin	23-37	chemokine (C-X-C motif) ligand 2	Mus musculus	150-155
22677362-4	2012	The tested macrolides, clarithromycin and azithromycin, administered orally (2 x 150 mg/kg) 0.5 h before and 5 h after cantharidin challenge, reduced MIP-2, MCP-1, KC, and MPO concentrations and thereby decreased ear swelling.	Clarithromycin	23-37	chemokine (C-C motif) ligand 2	Mus musculus	157-162
22677362-4	2012	The tested macrolides, clarithromycin and azithromycin, administered orally (2 x 150 mg/kg) 0.5 h before and 5 h after cantharidin challenge, reduced MIP-2, MCP-1, KC, and MPO concentrations and thereby decreased ear swelling.	Clarithromycin	23-37	myeloperoxidase	Mus musculus	172-175
22564837-6	2012	The ratio of serum interleukin-10 (IL-10) to serum tumor necrosis factor alpha (TNF-alpha) was decreased in the clarithromycin group compared with the results in the placebo group.	Clarithromycin	112-126	interleukin 10	Homo sapiens	19-33
22564837-6	2012	The ratio of serum interleukin-10 (IL-10) to serum tumor necrosis factor alpha (TNF-alpha) was decreased in the clarithromycin group compared with the results in the placebo group.	Clarithromycin	112-126	interleukin 10	Homo sapiens	35-40
22564837-6	2012	The ratio of serum interleukin-10 (IL-10) to serum tumor necrosis factor alpha (TNF-alpha) was decreased in the clarithromycin group compared with the results in the placebo group.	Clarithromycin	112-126	tumor necrosis factor	Homo sapiens	51-78
22564837-6	2012	The ratio of serum interleukin-10 (IL-10) to serum tumor necrosis factor alpha (TNF-alpha) was decreased in the clarithromycin group compared with the results in the placebo group.	Clarithromycin	112-126	tumor necrosis factor	Homo sapiens	80-89
22564837-9	2012	The release of TNF-alpha, IL-6, and soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) by circulating monocytes after stimulation was greater in the clarithromycin group than in the placebo group.	Clarithromycin	165-179	tumor necrosis factor	Homo sapiens	15-24
22564837-9	2012	The release of TNF-alpha, IL-6, and soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) by circulating monocytes after stimulation was greater in the clarithromycin group than in the placebo group.	Clarithromycin	165-179	interleukin 6	Homo sapiens	26-30
22644980-6	2012	Both erythromycin and clarithromycin have been shown to prolong the Q-T interval, an effect that appears to increase when these drugs are given with CYP3A4 inhibitors.	Clarithromycin	22-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	149-155
22490230-5	2012	The apparent K(I) estimates derived from the various systems displayed a range of variability from 3-fold for clarithromycin (5.4-17.7 muM) to 6-fold for verapamil (1.9-12.6 muM).	Clarithromycin	110-124	latexin	Homo sapiens	135-138
22200786-0	2012	Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic             reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer             cells.	Clarithromycin	0-14	DNA damage inducible transcript 3	Homo sapiens	110-114
22559798-5	2012	Clarithromycin treatment decreased the levels of eosinophilic cationic protein only in non-allergic patients (p < 0.05), and decreased the level of interleukin 6 only in allergic patients (p < 0.05).	Clarithromycin	0-14	interleukin 6	Homo sapiens	151-164
22404374-0	2012	Low-dose clarithromycin therapy modulates CD4(+)  T-cell responses in a mouse model of chronic Pseudomonas aeruginosa lung infection.	Clarithromycin	9-23	CD4 antigen	Mus musculus	42-45
22404374-3	2012	As CD4(+) T cells play an important role in the initiation of immune responses to infectious microorganisms, we aimed to investigate the effects of low-dose CAM on CD4(+) T-cell responses.	Clarithromycin	157-160	CD4 antigen	Mus musculus	164-167
22404374-10	2012	CONCLUSIONS: This study demonstrated a downregulation of Th1/Th17/naturally occurring Treg responses after treatment with low-dose CAM in mice with chronic P. aeruginosa lung infection.	Clarithromycin	131-134	negative elongation factor complex member C/D, Th1l	Mus musculus	57-60
22200786-0	2012	Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic             reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer             cells.	Clarithromycin	0-14	DNA damage inducible transcript 3	Homo sapiens	116-123
22372724-3	2012	Clarithromycin is a potent inhibitor of CYP3A4, and patients taking both of these drugs may be at increased risk of cardiac adverse events.	Clarithromycin	0-14	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-46
22577246-5	2012	AZM or CAM significantly inhibited tumor necrosis factor-alpha (TNF-alpha) (20 ng/mL)-induced MUC5AC secretion from NCI-H292 cells at 10-6-10-7 M, whereas JM or ABPC showed no effect.	Clarithromycin	7-10	tumor necrosis factor	Homo sapiens	35-62
22170330-1	2012	Pulmonary penetration of clarithromycin (CLR) in epithelial lining fluid (ELF) and bronchoalveolar lavage cells (BALCs) can be influenced by CYP3A4, by P-glycoprotein, and, according to our hypothesis, by a member of the organic anion-transporting protein (OATP) family, for which rifampicin (RIF) is inhibiting in single doses but inducing after long-term coadministration.	Clarithromycin	25-39	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	141-147
22170330-1	2012	Pulmonary penetration of clarithromycin (CLR) in epithelial lining fluid (ELF) and bronchoalveolar lavage cells (BALCs) can be influenced by CYP3A4, by P-glycoprotein, and, according to our hypothesis, by a member of the organic anion-transporting protein (OATP) family, for which rifampicin (RIF) is inhibiting in single doses but inducing after long-term coadministration.	Clarithromycin	41-44	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	141-147
21336676-8	2012	In conclusion, azithromycin and clarithromycin attenuate pro-inflammatory cytokine production and leukocyte infiltration during innate immune reactions, while selectively affecting Th2 rather than Th1 immunity in DTH reactions.	Clarithromycin	32-46	heart and neural crest derivatives expressed 2	Mus musculus	181-184
21336676-8	2012	In conclusion, azithromycin and clarithromycin attenuate pro-inflammatory cytokine production and leukocyte infiltration during innate immune reactions, while selectively affecting Th2 rather than Th1 immunity in DTH reactions.	Clarithromycin	32-46	negative elongation factor complex member C/D, Th1l	Mus musculus	197-200
22687800-2	2012	Subsequently she received four weeks of oral levofloxacin and eight weeks of oral clarithromycin due to persistent elevation of C-reactive protein.	Clarithromycin	82-96	C-reactive protein	Homo sapiens	128-146
22761540-3	2012	Clarithromycin (CAM), which is an antimicrobial agent and is also known as an immunomodulator, significantly suppressed RSV-induced production of interleukin-6, interleukin-8, and regulated on activation, normal T-cell expressed and secreted (RANTES).	Clarithromycin	0-14	interleukin 6	Homo sapiens	146-159
22761540-3	2012	Clarithromycin (CAM), which is an antimicrobial agent and is also known as an immunomodulator, significantly suppressed RSV-induced production of interleukin-6, interleukin-8, and regulated on activation, normal T-cell expressed and secreted (RANTES).	Clarithromycin	0-14	C-X-C motif chemokine ligand 8	Homo sapiens	161-174
21336676-3	2012	Dexamethasone (50 mug/ear), azithromycin, and clarithromycin (500 mug/ear) reduced TNF-alpha and interleukin (IL)-1beta concentration in ear tissue by inhibiting inflammatory cell accumulation in PMA-induced inflammation.	Clarithromycin	46-60	tumor necrosis factor	Mus musculus	83-92
21336676-3	2012	Dexamethasone (50 mug/ear), azithromycin, and clarithromycin (500 mug/ear) reduced TNF-alpha and interleukin (IL)-1beta concentration in ear tissue by inhibiting inflammatory cell accumulation in PMA-induced inflammation.	Clarithromycin	46-60	interleukin 1 beta	Mus musculus	97-119
22761540-3	2012	Clarithromycin (CAM), which is an antimicrobial agent and is also known as an immunomodulator, significantly suppressed RSV-induced production of interleukin-6, interleukin-8, and regulated on activation, normal T-cell expressed and secreted (RANTES).	Clarithromycin	0-14	C-C motif chemokine ligand 5	Homo sapiens	243-249
22577246-5	2012	AZM or CAM significantly inhibited tumor necrosis factor-alpha (TNF-alpha) (20 ng/mL)-induced MUC5AC secretion from NCI-H292 cells at 10-6-10-7 M, whereas JM or ABPC showed no effect.	Clarithromycin	7-10	tumor necrosis factor	Homo sapiens	64-73
22761540-3	2012	Clarithromycin (CAM), which is an antimicrobial agent and is also known as an immunomodulator, significantly suppressed RSV-induced production of interleukin-6, interleukin-8, and regulated on activation, normal T-cell expressed and secreted (RANTES).	Clarithromycin	16-19	interleukin 6	Homo sapiens	146-159
22761540-3	2012	Clarithromycin (CAM), which is an antimicrobial agent and is also known as an immunomodulator, significantly suppressed RSV-induced production of interleukin-6, interleukin-8, and regulated on activation, normal T-cell expressed and secreted (RANTES).	Clarithromycin	16-19	C-X-C motif chemokine ligand 8	Homo sapiens	161-174
22577246-5	2012	AZM or CAM significantly inhibited tumor necrosis factor-alpha (TNF-alpha) (20 ng/mL)-induced MUC5AC secretion from NCI-H292 cells at 10-6-10-7 M, whereas JM or ABPC showed no effect.	Clarithromycin	7-10	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	94-100
22761540-3	2012	Clarithromycin (CAM), which is an antimicrobial agent and is also known as an immunomodulator, significantly suppressed RSV-induced production of interleukin-6, interleukin-8, and regulated on activation, normal T-cell expressed and secreted (RANTES).	Clarithromycin	16-19	C-C motif chemokine ligand 5	Homo sapiens	243-249
22009620-11	2011	CYP3A is probably one of the most important isoenzymes since it contributes to at least the partial transformation of 60% of drugs that undergo oxidation: erythromycin and clarithromycin are CYP3A4 substrates.	Clarithromycin	172-186	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-5
21642590-0	2011	Clarithromycin inhibits interleukin-13-induced goblet cell hyperplasia in human airway cells.	Clarithromycin	0-14	interleukin 13	Homo sapiens	24-38
21642590-2	2011	Because macrolide antibiotics are known to have immunomodulatory and mucoregulatory properties, the aim of this study was to examine the effect of clarithromycin on IL-13-induced goblet cell hyperplasia and mucin hypersecretion in normal human bronchial epithelial (NHBE) cells.	Clarithromycin	147-161	interleukin 13	Homo sapiens	165-170
21642590-7	2011	IL-13 significantly increased the number of PAS-positive, MUC5AC-positive goblet cells, and this was significantly attenuated by clarithromycin at concentrations greater than 8 mug/ml (P < 0.01).	Clarithromycin	129-143	interleukin 13	Homo sapiens	0-5
21642590-8	2011	Clarithromycin also dose-dependently decreased MUC5AC mRNA expression induced by IL-13 (P < 0.001), and, at 24 mug/ml, clarithromycin significantly attenuated the amount of MUC5AC protein in cell supernatants (P < 0.01).	Clarithromycin	0-14	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	47-53
21642590-8	2011	Clarithromycin also dose-dependently decreased MUC5AC mRNA expression induced by IL-13 (P < 0.001), and, at 24 mug/ml, clarithromycin significantly attenuated the amount of MUC5AC protein in cell supernatants (P < 0.01).	Clarithromycin	0-14	interleukin 13	Homo sapiens	81-86
21642590-8	2011	Clarithromycin also dose-dependently decreased MUC5AC mRNA expression induced by IL-13 (P < 0.001), and, at 24 mug/ml, clarithromycin significantly attenuated the amount of MUC5AC protein in cell supernatants (P < 0.01).	Clarithromycin	0-14	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	176-182
21642590-8	2011	Clarithromycin also dose-dependently decreased MUC5AC mRNA expression induced by IL-13 (P < 0.001), and, at 24 mug/ml, clarithromycin significantly attenuated the amount of MUC5AC protein in cell supernatants (P < 0.01).	Clarithromycin	122-136	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	176-182
21642590-9	2011	Western blotting showed that clarithromycin affected IL-13 receptor janus kinase signal transducers, activators of transcription6 (STAT6), and epidermal growth factor receptor mitogen-activated protein kinase signaling and that inhibition of these pathways by clarithromycin decreased goblet cell hyperplasia via nuclear factor-kappaB inactivation.	Clarithromycin	29-43	interleukin 13	Homo sapiens	53-58
21642590-9	2011	Western blotting showed that clarithromycin affected IL-13 receptor janus kinase signal transducers, activators of transcription6 (STAT6), and epidermal growth factor receptor mitogen-activated protein kinase signaling and that inhibition of these pathways by clarithromycin decreased goblet cell hyperplasia via nuclear factor-kappaB inactivation.	Clarithromycin	29-43	signal transducer and activator of transcription 6	Homo sapiens	131-136
21642590-10	2011	We conclude that clarithromycin inhibits goblet cell hyperplasia and may directly regulate mucus secretion by IL-13 in NHBE cells.	Clarithromycin	17-31	interleukin 13	Homo sapiens	110-115
21812004-4	2011	MDR1 substrates reduced the basolateral-to-apical transport of CAM and AZM.	Clarithromycin	63-66	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	0-4
21812004-7	2011	These data suggest that the high distribution of CAM and AZM to AMs is due to the sustained distribution to ELF via MDR1 as well as the high uptake by the AMs themselves via active transport mechanisms.	Clarithromycin	49-52	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	116-120
22009620-11	2011	CYP3A is probably one of the most important isoenzymes since it contributes to at least the partial transformation of 60% of drugs that undergo oxidation: erythromycin and clarithromycin are CYP3A4 substrates.	Clarithromycin	172-186	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	191-197
21315154-4	2011	Three of the four tested macrolides, azithromycin, clarithromycin and roxithromycin, exhibited pronounced, concentration-related reduction of IL-1beta, IL-6, IL-10, TNF-alpha, CCL3, CCL5, CCL20, CCL22, CXCL1, CXCL5, and G-CSF release.	Clarithromycin	51-65	interleukin 1 beta	Homo sapiens	142-150
21665488-0	2011	Clarithromycin and telithromycin increases interleukin-10 expression in the rat endometriosis model.	Clarithromycin	0-14	interleukin 10	Rattus norvegicus	43-57
21665488-5	2011	The aim of this study is to investigate the effect of clarithromycin, one of the major macrolides, and telithromycin, one of the antibiotics belonging to a macrolide group (ketolide), on IL6, IL10 and Ccl2 expression in a rat endometriosis model induced by the surgical transplantation of endometrium onto the peritoneum in 8-week-old female Sprague-Dawley rats.	Clarithromycin	54-68	interleukin 10	Rattus norvegicus	192-196
21665488-5	2011	The aim of this study is to investigate the effect of clarithromycin, one of the major macrolides, and telithromycin, one of the antibiotics belonging to a macrolide group (ketolide), on IL6, IL10 and Ccl2 expression in a rat endometriosis model induced by the surgical transplantation of endometrium onto the peritoneum in 8-week-old female Sprague-Dawley rats.	Clarithromycin	54-68	C-C motif chemokine ligand 2	Rattus norvegicus	201-205
21665488-8	2011	After treatment, IL10 expression in the lesions was increased in rats treated with clarithromycin (1.70-fold) and telithromycin (2.88-fold).	Clarithromycin	83-97	interleukin 10	Rattus norvegicus	17-21
21480191-2	2011	Seven separate drug-drug interaction (DDI) studies were performed to elucidate the in vivo effects of concomitant treatment with colchicine and known inhibitors of cytochrome P450 3A4 (CYP3A4)/P-glycoprotein (cyclosporine, ketoconazole, ritonavir, clarithromycin, azithromycin, verapamil ER [extended release]), and diltiazem ER) on the pharmacokinetics of colchicine.	Clarithromycin	248-262	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	185-191
21315154-4	2011	Three of the four tested macrolides, azithromycin, clarithromycin and roxithromycin, exhibited pronounced, concentration-related reduction of IL-1beta, IL-6, IL-10, TNF-alpha, CCL3, CCL5, CCL20, CCL22, CXCL1, CXCL5, and G-CSF release.	Clarithromycin	51-65	interleukin 6	Homo sapiens	152-156
21315154-4	2011	Three of the four tested macrolides, azithromycin, clarithromycin and roxithromycin, exhibited pronounced, concentration-related reduction of IL-1beta, IL-6, IL-10, TNF-alpha, CCL3, CCL5, CCL20, CCL22, CXCL1, CXCL5, and G-CSF release.	Clarithromycin	51-65	interleukin 10	Homo sapiens	158-163
21315154-4	2011	Three of the four tested macrolides, azithromycin, clarithromycin and roxithromycin, exhibited pronounced, concentration-related reduction of IL-1beta, IL-6, IL-10, TNF-alpha, CCL3, CCL5, CCL20, CCL22, CXCL1, CXCL5, and G-CSF release.	Clarithromycin	51-65	tumor necrosis factor	Homo sapiens	165-174
21315154-4	2011	Three of the four tested macrolides, azithromycin, clarithromycin and roxithromycin, exhibited pronounced, concentration-related reduction of IL-1beta, IL-6, IL-10, TNF-alpha, CCL3, CCL5, CCL20, CCL22, CXCL1, CXCL5, and G-CSF release.	Clarithromycin	51-65	C-C motif chemokine ligand 3	Homo sapiens	176-180
21315154-4	2011	Three of the four tested macrolides, azithromycin, clarithromycin and roxithromycin, exhibited pronounced, concentration-related reduction of IL-1beta, IL-6, IL-10, TNF-alpha, CCL3, CCL5, CCL20, CCL22, CXCL1, CXCL5, and G-CSF release.	Clarithromycin	51-65	C-C motif chemokine ligand 5	Homo sapiens	182-186
21315154-4	2011	Three of the four tested macrolides, azithromycin, clarithromycin and roxithromycin, exhibited pronounced, concentration-related reduction of IL-1beta, IL-6, IL-10, TNF-alpha, CCL3, CCL5, CCL20, CCL22, CXCL1, CXCL5, and G-CSF release.	Clarithromycin	51-65	C-C motif chemokine ligand 20	Homo sapiens	188-193
21315154-4	2011	Three of the four tested macrolides, azithromycin, clarithromycin and roxithromycin, exhibited pronounced, concentration-related reduction of IL-1beta, IL-6, IL-10, TNF-alpha, CCL3, CCL5, CCL20, CCL22, CXCL1, CXCL5, and G-CSF release.	Clarithromycin	51-65	C-C motif chemokine ligand 22	Homo sapiens	195-200
21315154-4	2011	Three of the four tested macrolides, azithromycin, clarithromycin and roxithromycin, exhibited pronounced, concentration-related reduction of IL-1beta, IL-6, IL-10, TNF-alpha, CCL3, CCL5, CCL20, CCL22, CXCL1, CXCL5, and G-CSF release.	Clarithromycin	51-65	C-X-C motif chemokine ligand 1	Homo sapiens	202-207
21315154-4	2011	Three of the four tested macrolides, azithromycin, clarithromycin and roxithromycin, exhibited pronounced, concentration-related reduction of IL-1beta, IL-6, IL-10, TNF-alpha, CCL3, CCL5, CCL20, CCL22, CXCL1, CXCL5, and G-CSF release.	Clarithromycin	51-65	C-X-C motif chemokine ligand 5	Homo sapiens	209-214
21315154-4	2011	Three of the four tested macrolides, azithromycin, clarithromycin and roxithromycin, exhibited pronounced, concentration-related reduction of IL-1beta, IL-6, IL-10, TNF-alpha, CCL3, CCL5, CCL20, CCL22, CXCL1, CXCL5, and G-CSF release.	Clarithromycin	51-65	colony stimulating factor 3	Homo sapiens	220-225
19922478-0	2011	Borderline CD30+ cutaneous lymphoproliferative disorder: report of a case with expression of cytotoxic markers and response to clarithromycin.	Clarithromycin	127-141	TNF receptor superfamily member 8	Homo sapiens	11-15
21353492-12	2011	It is concluded that clarithromycin modulates the function of the immune response in experimental peritonitis by decreasing the rate of early apoptosis of lymphocytes and monocytes and by decreasing the ex vivo release of TNFalpha by blood monocytes.	Clarithromycin	21-35	tumor necrosis factor	Oryctolagus cuniculus	222-230
21242274-10	2011	Erythromycin (the strongest inhibitor of cytochrome P450 3A4) was most strongly associated with hypotension (odds ratio [OR] 5.8, 95% confidence interval [CI] 2.3-15.0), followed by clarithromycin (OR 3.7, 95% CI 2.3-6.1).	Clarithromycin	182-196	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-60
21398439-6	2011	Leukocytes from sheep with CLA chronic abscesses produced higher IFN-gamma levels when compared with seropositive sheep without CLA clinical signs, but this difference was not significant in goats.	Clarithromycin	27-30	interferon gamma	Ovis aries	65-74
21757966-6	2011	CAM treatment was more effective for IL-8(high) CRSnNP patients than for IL-8(low) CRSnNP patients (p < 0.05).	Clarithromycin	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	37-41
21042828-0	2011	Renoprotective effects of clarithromycin via reduction of urinary MCP-1 levels in type 2 diabetic patients.	Clarithromycin	26-40	C-C motif chemokine ligand 2	Homo sapiens	66-71
21042828-7	2011	Urinary MCP-1 levels were significantly reduced in the clarithromycin-administrated group (P = 0.009).	Clarithromycin	55-69	C-C motif chemokine ligand 2	Homo sapiens	8-13
21042828-11	2011	CONCLUSION: The results from our study suggest that clarithromycin may attenuate the production of renal MCP-1 in type 2 diabetic patients, resulting in amelioration of urinary ACR via anti-inflammatory effects.	Clarithromycin	52-66	C-C motif chemokine ligand 2	Homo sapiens	105-110
21757966-6	2011	CAM treatment was more effective for IL-8(high) CRSnNP patients than for IL-8(low) CRSnNP patients (p < 0.05).	Clarithromycin	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	73-77
20622181-6	2010	Addition of EPA or 18:0 for 48 h did not change the ACE2 mRNA abundance, whereas the treatments of arachidonic acid, CLA, and DHA significantly decreased ACE2 mRNA abundance after 48 h (P <= 0.05).	Clarithromycin	117-120	angiotensin converting enzyme 2	Sus scrofa	154-158
21092318-3	2010	The present study was designed to examine the influence of clarithromycin (CAM) and its metabolized materials, M-1, M-4 and M-5, on free radical generation from nasal polyp fibroblasts (NPFs) through the choice of nitric oxide (NO), which is one of important effector molecule in the development of airway inflammatory disease in vitro.	Clarithromycin	59-73	myoregulin	Homo sapiens	111-114
21092318-7	2010	RESULTS: The addition of CAM (> 0.4 mug/ml) and M-4 (> 0.04 mug/ml) could suppress NO production from NPFs after LPS stimulation through the suppression of iNOS mRNA expression and NF-kappaB activation.	Clarithromycin	25-28	nitric oxide synthase 2	Homo sapiens	162-166
20837591-4	2010	Coadministration of clarithromycin (a potent cytochrome P450 3A4 inhibitor) for an ear infection and valproic acid for seizures since birth further prevented drug elimination from the body.	Clarithromycin	20-34	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-64
20811702-6	2010	CAM induced an accumulation of LC3-II without affecting the mTOR or AKT pathways, eventually leading to cell death.	Clarithromycin	0-3	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	31-34
20621639-6	2010	In conclusion, out of seven applied methods and assessed parameters, four of them gave similar rough evaluation on the strength of interaction of five macrolides with MDR1, with clarithromycin, roxithromycin and telithromycin showing stronger interaction than azithromycin and erythromycin.	Clarithromycin	178-192	ATP binding cassette subfamily B member 1	Homo sapiens	167-171
20735423-6	2010	Clarithromycin, another CYP3A4 inhibitor, impaired clopidogrel biotransformation and antiplatelet activity almost as effectively as ketoconazole.	Clarithromycin	0-14	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-30
20621639-1	2010	In this study five macrolide antibiotics (azithromycin, erythromycin, clarithromycin, roxithromycin and telithromycin) were compared based on their ability to interact with human MDR1 (ABCB1, P-glycoprotein), studied from two main aspects: by determining the influence of macrolide antibiotics on MDR1 function, as well as the influence of MDR1 on macrolide accumulation in MES-SA/Dx5 cells overexpressing human MDR1.	Clarithromycin	70-84	ATP binding cassette subfamily B member 1	Homo sapiens	179-183
20621639-1	2010	In this study five macrolide antibiotics (azithromycin, erythromycin, clarithromycin, roxithromycin and telithromycin) were compared based on their ability to interact with human MDR1 (ABCB1, P-glycoprotein), studied from two main aspects: by determining the influence of macrolide antibiotics on MDR1 function, as well as the influence of MDR1 on macrolide accumulation in MES-SA/Dx5 cells overexpressing human MDR1.	Clarithromycin	70-84	ATP binding cassette subfamily B member 1	Homo sapiens	185-190
20803980-7	2010	Anti-NTM chemotherapy consisting of rifampicin, ethambutol and clarithromycin was started in addition to anticancer chemotherapy, without severe side effects.	Clarithromycin	63-77	neurotrimin	Homo sapiens	5-8
20380772-8	2010	Performance of an association analysis with a variety of milk traits revealed that goat LIPE genotype has highly suggestive effects on milk yield (P=0.0032) as well as on C18:3 n-6g (P=0.0051), trans-10 cis-12 CLA (P=0.007) and C12:0 (P=0.0084) milk contents.	Clarithromycin	210-213	hormone-sensitive lipase	Capra hircus	88-92
20427390-8	2010	The eradication rate was significantly lower in the presence of levofloxacin resistance in the LAL group (50% vs 84.4%, p=0.018) and clarithromycin resistance in the CAL group (44.4% vs 90.7%, p=0.002).	Clarithromycin	133-147	filamin binding LIM protein 1	Homo sapiens	166-169
19897389-0	2010	Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine.	Clarithromycin	0-14	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-43
19897389-9	2010	The relative amount of the CYP3A dependent metabolite norketamine was decreased by 54% by clarithromycin (p=0.004).	Clarithromycin	90-104	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-32
19897389-11	2010	CONCLUSIONS: Clarithromycin strongly increases plasma concentrations of oral S-ketamine probably by inhibiting its CYP3A-mediated N-demethylation.	Clarithromycin	13-27	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	115-120
20305307-6	2010	The reason of this effect is that tramadol is the substrate and clarithromycin is the inhibitor of the CYP 3A4 enzyme.	Clarithromycin	64-78	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	103-110
20446912-5	2010	At high concentrations (100 microM), clarithromycin had weak competitive inhibition potency towards CYP3A4 and CYP3A5.	Clarithromycin	37-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	100-106
20446912-5	2010	At high concentrations (100 microM), clarithromycin had weak competitive inhibition potency towards CYP3A4 and CYP3A5.	Clarithromycin	37-51	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	111-117
20446912-9	2010	Drug interactions between clarithromycin and several CYP3A substrates are predicted to be insidious; the risk of severe adverse events should increase over time and persist for a few days after cessation of the drug.	Clarithromycin	26-40	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	53-58
20350988-3	2010	However, little is known about the effect of CAM in myocarditis via MMPs.	Clarithromycin	45-48	matrix metallopeptidase 9	Rattus norvegicus	68-72
20350988-10	2010	CONCLUSIONS: Early CAM treatment is effective to attenuate myocarditis by suppressing MMP-9.	Clarithromycin	19-22	matrix metallopeptidase 9	Rattus norvegicus	86-91
19833228-8	2010	Adding CLA or DHA to the osteoblast media resulted in a reduced PGE(2) production and increased expression of osteocalcin.	Clarithromycin	7-10	LOC100286409	Salmo salar	110-121
20069466-1	2010	OBJECTIVE: To investigate the effects of the clinical dose of clarithromycin, a substrate of P-glycoprotein (P-gp), on P-gp function using positron emission tomography (PET) with [11C]verapamil.	Clarithromycin	62-76	ATP binding cassette subfamily B member 1	Homo sapiens	93-107
20069466-1	2010	OBJECTIVE: To investigate the effects of the clinical dose of clarithromycin, a substrate of P-glycoprotein (P-gp), on P-gp function using positron emission tomography (PET) with [11C]verapamil.	Clarithromycin	62-76	ATP binding cassette subfamily B member 1	Homo sapiens	109-113
20069466-1	2010	OBJECTIVE: To investigate the effects of the clinical dose of clarithromycin, a substrate of P-glycoprotein (P-gp), on P-gp function using positron emission tomography (PET) with [11C]verapamil.	Clarithromycin	62-76	ATP binding cassette subfamily B member 1	Homo sapiens	119-123
19884323-0	2010	Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin.	Clarithromycin	86-100	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	77-82
19884323-7	2010	The incorporation of CYP3A-dependent metabolism of clarithromycin enabled prediction of its nonlinear pharmacokinetics.	Clarithromycin	51-65	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	21-26
19884323-1	2010	The prediction of clinical drug-drug interactions (DDIs) due to mechanism-based inhibitors of CYP3A is complicated when the inhibitor itself is metabolized by CYP3Aas in the case of clarithromycin.	Clarithromycin	182-196	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	94-99
19884323-1	2010	The prediction of clinical drug-drug interactions (DDIs) due to mechanism-based inhibitors of CYP3A is complicated when the inhibitor itself is metabolized by CYP3Aas in the case of clarithromycin.	Clarithromycin	182-196	peptidylprolyl isomerase F	Homo sapiens	94-98
19884323-11	2010	This semiphysiologically based pharmacokinetic model incorporating CYP3A inactivation in the intestine and liver accurately predicts the nonlinear pharmacokinetics of clarithromycin and the DDI observed between clarithromycin and midazolam.	Clarithromycin	167-181	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	67-72
19884323-11	2010	This semiphysiologically based pharmacokinetic model incorporating CYP3A inactivation in the intestine and liver accurately predicts the nonlinear pharmacokinetics of clarithromycin and the DDI observed between clarithromycin and midazolam.	Clarithromycin	211-225	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	67-72
19884323-2	2010	Previous attempts to predict the effects of clarithromycin on CYP3A substrates, e.g., midazolam, failed to account for nonlinear metabolism of clarithromycin.	Clarithromycin	44-58	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-67
19884323-3	2010	A semiphysiologically based pharmacokinetic model was developed for clarithromycin and midazolam metabolism, incorporating hepatic and intestinal metabolism by CYP3A and non-CYP3A mechanisms.	Clarithromycin	68-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	160-165
19884323-3	2010	A semiphysiologically based pharmacokinetic model was developed for clarithromycin and midazolam metabolism, incorporating hepatic and intestinal metabolism by CYP3A and non-CYP3A mechanisms.	Clarithromycin	68-82	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	174-179
19884323-4	2010	CYP3A inactivation by clarithromycin occurred at both sites.	Clarithromycin	22-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-5
21294447-9	2010	Clarithromycin resistance (CLR-R) was present in the 16-39 age group in 21 (47%) (P = 0.007) compared to nine (19%) in the 40-79 age group.	Clarithromycin	0-14	doublecortin like kinase 3	Homo sapiens	27-30
19943026-3	2010	All protease inhibitors are inhibitors of CYP3A, which is important in the metabolism of approximately 50% of all drugs, e.g. simvastatin, atorvastatin, sildenafil, and clarithromycin.	Clarithromycin	169-183	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	42-47
20208392-3	2010	Among the inhibitors studied, erythromycin and clarithromycin exhibited markedly weaker MBI effects on CYP3A activity in rat and mouse liver microsomes compared to human liver microsomes.	Clarithromycin	47-61	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	103-108
20724802-9	2010	In contrast, clarithromycin and roxithromycin were 10-fold greater P-gp inhibitors.	Clarithromycin	13-27	ATP binding cassette subfamily B member 1	Homo sapiens	67-71
19741038-6	2009	cis-Inhibition and direct uptake studies further showed that azithromycin and clarithromycin were only very weak inhibitors and not substrates for human OATP1A2 and human/rat OATP2B1/Oatp2b1.	Clarithromycin	78-92	solute carrier organic anion transporter family member 1A2	Homo sapiens	153-160
20046053-8	2010	Pretreatment with clarithromycin ex vivo decreased CD40 expression on DCs obtained from P. aeruginosa-infected mice and also decreased the production of IL-6, IL-12p40 and TNF-alpha by DCs.	Clarithromycin	18-32	interleukin 6	Mus musculus	153-157
20046053-8	2010	Pretreatment with clarithromycin ex vivo decreased CD40 expression on DCs obtained from P. aeruginosa-infected mice and also decreased the production of IL-6, IL-12p40 and TNF-alpha by DCs.	Clarithromycin	18-32	interleukin 12b	Mus musculus	159-167
20046053-8	2010	Pretreatment with clarithromycin ex vivo decreased CD40 expression on DCs obtained from P. aeruginosa-infected mice and also decreased the production of IL-6, IL-12p40 and TNF-alpha by DCs.	Clarithromycin	18-32	tumor necrosis factor	Mus musculus	172-181
19762835-8	2009	Infusion of the CLA treatment reduced the mRNA expression of acetyl-coenzyme A carboxylase and fatty acid synthetase by 46 and 57%, respectively, and tended to reduce the expression of SCD1 and lipoprotein lipase.	Clarithromycin	16-19	stearoyl-CoA desaturase	Bos taurus	185-189
19606089-2	2009	Clarithromycin was associated with the highest risk of digoxin toxicity (adjusted odds ratio (OR) 14.8; 95% confidence interval (CI) 7.9-27.9), whereas erythromycin and azithromycin were associated with much lower risk (adjusted OR 3.7; 95% CI 1.7-7.9; and adjusted OR 3.7; 95% CI 1.1-12.5, respectively).	Clarithromycin	0-14	olfactory receptor family 4 subfamily N member 2	Homo sapiens	82-102
19762835-8	2009	Infusion of the CLA treatment reduced the mRNA expression of acetyl-coenzyme A carboxylase and fatty acid synthetase by 46 and 57%, respectively, and tended to reduce the expression of SCD1 and lipoprotein lipase.	Clarithromycin	16-19	lipoprotein lipase	Bos taurus	194-212
19762835-9	2009	Abundance of mRNA for sterol regulatory element-binding protein-1 was reduced by 59% in the CLA treatment group.	Clarithromycin	92-95	sterol regulatory element binding transcription factor 1	Bos taurus	22-65
19261952-3	2009	In theory, clarithromycin has the potential to alter vinorelbine"s pharmacokinetics by inhibiting CYP3A and/or P-glycoprotein; this may result in massive exposure to vinorelbine and severe toxicity.	Clarithromycin	11-25	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-103
19633061-0	2009	Azithromycin and clarithromycin inhibit lipopolysaccharide-induced murine pulmonary neutrophilia mainly through effects on macrophage-derived granulocyte-macrophage colony-stimulating factor and interleukin-1beta.	Clarithromycin	17-31	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	142-190
19633061-0	2009	Azithromycin and clarithromycin inhibit lipopolysaccharide-induced murine pulmonary neutrophilia mainly through effects on macrophage-derived granulocyte-macrophage colony-stimulating factor and interleukin-1beta.	Clarithromycin	17-31	interleukin 1 beta	Mus musculus	195-212
19633061-5	2009	Azithromycin and clarithromycin pretreatment reduced total cell and neutrophil numbers in bronchoalveolar lavage fluid and myeloperoxidase concentration in lung tissue.	Clarithromycin	17-31	myeloperoxidase	Mus musculus	123-138
19701237-11	2009	After 4 d of clarithromycin administration, CYP3A activity (MR) decreased by 75% (P=0.000), whereas AUC(F) increased by 19% (P=0.040), and Cl(m(6beta)) and 6beta-OHF/F decreased by 54.2% (P=0.000) and 50% (P=0.003), respectively.	Clarithromycin	13-27	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	44-49
19560456-6	2009	Clarithromycin treatment (200 mg/kg intraperitoneally) decreased IL-4, IL-5, IL-13, CXCL2 and CCL2 concentrations in bronchoalveolar lavage fluid and markedly reduced inflammatory cell accumulation in bronchoalveolar lavage fluid and into the lungs, as revealed by histopathological examination.	Clarithromycin	0-14	chemokine (C-X-C motif) ligand 2	Mus musculus	84-89
19560456-6	2009	Clarithromycin treatment (200 mg/kg intraperitoneally) decreased IL-4, IL-5, IL-13, CXCL2 and CCL2 concentrations in bronchoalveolar lavage fluid and markedly reduced inflammatory cell accumulation in bronchoalveolar lavage fluid and into the lungs, as revealed by histopathological examination.	Clarithromycin	0-14	chemokine (C-C motif) ligand 2	Mus musculus	94-98
19560456-8	2009	In summary, in ovalbumin-induced mouse models, clarithromycin efficiently inhibited two important pathological characteristics of asthma, airway hyperresponsiveness and inflammation.	Clarithromycin	47-61	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	15-24
19463856-5	2009	Bafilomycin A(1) and clarithromycin inhibited RhoA activation induced by lysophosphatidic acid in the cells.	Clarithromycin	21-35	ras homolog family member A	Homo sapiens	46-50
19457725-2	2009	Rifampicin is a CYP3A4 inducer while clarithromycin is known to inhibit CYP3A4.	Clarithromycin	37-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	72-78
20030038-0	2009	[Effect of clarithromycin on the expressions of cyclooxygenase-2 and nuclear factor-kappa B in nasal polyps in vitro].	Clarithromycin	11-25	prostaglandin-endoperoxide synthase 2	Homo sapiens	48-91
20030038-1	2009	OBJECTIVE: To detect the expression and correlation of cyclooxygenase-2 (COX-2) and nuclear factor-kappa B (NF-kappaB) in nasal polyps co-cultured with clarithromycin, and to investigate their roles in CRS pathogenesis.	Clarithromycin	152-166	prostaglandin-endoperoxide synthase 2	Homo sapiens	55-71
20030038-1	2009	OBJECTIVE: To detect the expression and correlation of cyclooxygenase-2 (COX-2) and nuclear factor-kappa B (NF-kappaB) in nasal polyps co-cultured with clarithromycin, and to investigate their roles in CRS pathogenesis.	Clarithromycin	152-166	prostaglandin-endoperoxide synthase 2	Homo sapiens	73-78
20030038-1	2009	OBJECTIVE: To detect the expression and correlation of cyclooxygenase-2 (COX-2) and nuclear factor-kappa B (NF-kappaB) in nasal polyps co-cultured with clarithromycin, and to investigate their roles in CRS pathogenesis.	Clarithromycin	152-166	nuclear factor kappa B subunit 1	Homo sapiens	84-106
20030038-1	2009	OBJECTIVE: To detect the expression and correlation of cyclooxygenase-2 (COX-2) and nuclear factor-kappa B (NF-kappaB) in nasal polyps co-cultured with clarithromycin, and to investigate their roles in CRS pathogenesis.	Clarithromycin	152-166	nuclear factor kappa B subunit 1	Homo sapiens	108-117
20030038-4	2009	RESULT: The expression levels of COX-2, NF-kappaBp50 and NF-kappaBp65 were most high in control groups (0 mol/L clarithromycin).	Clarithromycin	112-126	prostaglandin-endoperoxide synthase 2	Homo sapiens	33-38
20030038-4	2009	RESULT: The expression levels of COX-2, NF-kappaBp50 and NF-kappaBp65 were most high in control groups (0 mol/L clarithromycin).	Clarithromycin	112-126	RELA proto-oncogene, NF-kB subunit	Homo sapiens	57-69
20030038-5	2009	The expressions of COX-2, NF-kappaBp50 and NF-kappaBp65 were dose-dependently attenuated as the concentrations of clarithromycin increased.	Clarithromycin	114-128	prostaglandin-endoperoxide synthase 2	Homo sapiens	19-24
20030038-5	2009	The expressions of COX-2, NF-kappaBp50 and NF-kappaBp65 were dose-dependently attenuated as the concentrations of clarithromycin increased.	Clarithromycin	114-128	nuclear factor kappa B subunit 1	Homo sapiens	26-38
20030038-5	2009	The expressions of COX-2, NF-kappaBp50 and NF-kappaBp65 were dose-dependently attenuated as the concentrations of clarithromycin increased.	Clarithromycin	114-128	RELA proto-oncogene, NF-kB subunit	Homo sapiens	43-55
20030038-8	2009	It indicate that clarithromycin may play an anti-inflammatory effect on CRS by decreasing the synthesis of COX-2 through blocking NF-kappaB pathway.	Clarithromycin	17-31	prostaglandin-endoperoxide synthase 2	Homo sapiens	107-112
20030038-8	2009	It indicate that clarithromycin may play an anti-inflammatory effect on CRS by decreasing the synthesis of COX-2 through blocking NF-kappaB pathway.	Clarithromycin	17-31	nuclear factor kappa B subunit 1	Homo sapiens	130-139
19560456-5	2009	In order to investigate whether efficacy of macrolide antibiotics in asthma results from their immunomodulatory/anti-inflammatory activity, the influence of clarithromycin pretreatment (2 h before challenge) was examined on ovalbumin-induced airway hyperresponsiveness and airway inflammation in the mouse.	Clarithromycin	157-171	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	224-233
19560456-6	2009	Clarithromycin treatment (200 mg/kg intraperitoneally) decreased IL-4, IL-5, IL-13, CXCL2 and CCL2 concentrations in bronchoalveolar lavage fluid and markedly reduced inflammatory cell accumulation in bronchoalveolar lavage fluid and into the lungs, as revealed by histopathological examination.	Clarithromycin	0-14	interleukin 4	Mus musculus	65-69
19560456-6	2009	Clarithromycin treatment (200 mg/kg intraperitoneally) decreased IL-4, IL-5, IL-13, CXCL2 and CCL2 concentrations in bronchoalveolar lavage fluid and markedly reduced inflammatory cell accumulation in bronchoalveolar lavage fluid and into the lungs, as revealed by histopathological examination.	Clarithromycin	0-14	interleukin 5	Mus musculus	71-75
19560456-6	2009	Clarithromycin treatment (200 mg/kg intraperitoneally) decreased IL-4, IL-5, IL-13, CXCL2 and CCL2 concentrations in bronchoalveolar lavage fluid and markedly reduced inflammatory cell accumulation in bronchoalveolar lavage fluid and into the lungs, as revealed by histopathological examination.	Clarithromycin	0-14	interleukin 13	Mus musculus	77-82
19414584-1	2009	Clarithromycin decreases CYP3A4 activity and thus gradually inhibits its own metabolism as well as that of coadministered drugs.	Clarithromycin	0-14	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	25-31
19414584-9	2009	The proposed semimechanistic population pharmacokinetic model successfully described the autoinhibition of clarithromycin metabolism and may be used to adjust the doses of other drugs that are metabolized by CYP3A4 and that are coadministered with clarithromycin.	Clarithromycin	107-121	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	208-214
19414584-9	2009	The proposed semimechanistic population pharmacokinetic model successfully described the autoinhibition of clarithromycin metabolism and may be used to adjust the doses of other drugs that are metabolized by CYP3A4 and that are coadministered with clarithromycin.	Clarithromycin	248-262	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	208-214
19052724-18	2009	At a concentration of 400 mg/L medium clarithromycin induced a similar effect as erythromycin at twice this concentration: CD34 (+5%), E-selectin (+7%), ICAM-1 (+23%) and VCAM-1 (+4%).	Clarithromycin	38-52	CD34 molecule	Homo sapiens	123-127
19052724-18	2009	At a concentration of 400 mg/L medium clarithromycin induced a similar effect as erythromycin at twice this concentration: CD34 (+5%), E-selectin (+7%), ICAM-1 (+23%) and VCAM-1 (+4%).	Clarithromycin	38-52	selectin E	Homo sapiens	135-145
19052724-18	2009	At a concentration of 400 mg/L medium clarithromycin induced a similar effect as erythromycin at twice this concentration: CD34 (+5%), E-selectin (+7%), ICAM-1 (+23%) and VCAM-1 (+4%).	Clarithromycin	38-52	intercellular adhesion molecule 1	Homo sapiens	153-159
19052724-18	2009	At a concentration of 400 mg/L medium clarithromycin induced a similar effect as erythromycin at twice this concentration: CD34 (+5%), E-selectin (+7%), ICAM-1 (+23%) and VCAM-1 (+4%).	Clarithromycin	38-52	vascular cell adhesion molecule 1	Homo sapiens	171-177
19076731-7	2009	Clarithromycin reduced the lavage fluid levels of IL-8 at the low-dose histamine observation (P<0.001).	Clarithromycin	0-14	C-X-C motif chemokine ligand 8	Homo sapiens	50-54
19076731-9	2009	alpha(2)-Macroglobulin was reduced by clarithromycin (saline lavages) (P = 0.05), whereas fucose was unaffected.	Clarithromycin	38-52	alpha-2-macroglobulin	Homo sapiens	0-22
19957722-2	2009	It is established, that among components of antiulcerous therapy such as omeprazole, clarithromycin and metronidazole inhibit content and activity of MOS enzymes.	Clarithromycin	85-99	MOS proto-oncogene, serine/threonine kinase	Rattus norvegicus	150-153
19957722-5	2009	In triple therapy with omeprazole, clarithromycin and metronidazole the inhibit effect of preparations to system of MOS is exponentiated and it leads to suppression of mucous cytoprotaction of gastro duodenal zone.	Clarithromycin	35-49	MOS proto-oncogene, serine/threonine kinase	Rattus norvegicus	116-119
19261952-3	2009	In theory, clarithromycin has the potential to alter vinorelbine"s pharmacokinetics by inhibiting CYP3A and/or P-glycoprotein; this may result in massive exposure to vinorelbine and severe toxicity.	Clarithromycin	11-25	ATP binding cassette subfamily B member 1	Homo sapiens	111-125
19249565-1	2009	Although clarithromycin (CAM) has many biological functions, including regulation of matrix metalloproteinases (MMPs), little is known about its effects on heart transplantation.	Clarithromycin	9-23	matrix metallopeptidase 9	Mus musculus	112-116
18791145-11	2009	Simultaneous enhancement of tissue concentrations of CLA and n-3 PUFA concentrations in bovine muscle may be hindered by negative interactions between n-3 PUFA and Delta(9)-desaturase gene expression, possibly mediated through reduced expression of SREBP-1c.	Clarithromycin	53-56	PUFA	Bos taurus	155-159
18791145-11	2009	Simultaneous enhancement of tissue concentrations of CLA and n-3 PUFA concentrations in bovine muscle may be hindered by negative interactions between n-3 PUFA and Delta(9)-desaturase gene expression, possibly mediated through reduced expression of SREBP-1c.	Clarithromycin	53-56	stearoyl-CoA desaturase	Bos taurus	164-183
18931390-7	2009	Azithromycin and clarithromycin had inhibitory effects on overproduction of MUC5AC induced by HNP-1 or LPS stimulation.	Clarithromycin	17-31	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	76-82
18931390-9	2009	Phosphorylation of ERK1/2 was induced by HNP-1 or LPS stimulation, and azithromycin, clarithromycin and telithromycin had inhibitory effects on ERK1/2 phosphorylation induced by LPS, but not by HNP-1.	Clarithromycin	85-99	mitogen-activated protein kinase 3	Homo sapiens	19-25
18931390-9	2009	Phosphorylation of ERK1/2 was induced by HNP-1 or LPS stimulation, and azithromycin, clarithromycin and telithromycin had inhibitory effects on ERK1/2 phosphorylation induced by LPS, but not by HNP-1.	Clarithromycin	85-99	mitogen-activated protein kinase 3	Homo sapiens	144-150
19249565-1	2009	Although clarithromycin (CAM) has many biological functions, including regulation of matrix metalloproteinases (MMPs), little is known about its effects on heart transplantation.	Clarithromycin	25-28	matrix metallopeptidase 9	Mus musculus	112-116
19249565-3	2009	CAM suppressed MMP-9 expression in the allografts, resulting in a myocardial inflammatory cell infiltration.	Clarithromycin	0-3	matrix metallopeptidase 9	Mus musculus	15-20
18779356-7	2008	Clarithromycin exhibited no antimicrobial activity but had a good impact on endotoxin and TNF-alpha plasma concentrations.	Clarithromycin	0-14	tumor necrosis factor	Rattus norvegicus	90-99
18950461-3	2008	In a study of the immunomodulatory combination BiRD, (lenalidomide and dexamethasone with clarithromycin), we frequently detected the emergence of mono- and oligo-clonal immunoglobulins unrelated to the baseline diagnostic M-protein.	Clarithromycin	90-104	myomesin 2	Homo sapiens	223-232
17635500-1	2008	AIM: To assess the relative contribution of intestinal and hepatic CYP3A inhibition to the interaction between the prototypic CYP3A substrate midazolam and clarithromycin in the elderly.	Clarithromycin	156-170	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	67-72
18701271-1	2008	UNLABELLED: The aim of the current study was to investigate the effect of 14-membered ring macrolide clarithromycin (CAM) on migration induced by human plasma fibronectin (HFn) or on contraction of human fetal lung fibroblasts (HFL-1).	Clarithromycin	101-115	fibronectin 1	Homo sapiens	159-170
18701271-1	2008	UNLABELLED: The aim of the current study was to investigate the effect of 14-membered ring macrolide clarithromycin (CAM) on migration induced by human plasma fibronectin (HFn) or on contraction of human fetal lung fibroblasts (HFL-1).	Clarithromycin	101-115	complement factor H related 1	Homo sapiens	228-233
18701271-1	2008	UNLABELLED: The aim of the current study was to investigate the effect of 14-membered ring macrolide clarithromycin (CAM) on migration induced by human plasma fibronectin (HFn) or on contraction of human fetal lung fibroblasts (HFL-1).	Clarithromycin	117-120	fibronectin 1	Homo sapiens	159-170
18701271-1	2008	UNLABELLED: The aim of the current study was to investigate the effect of 14-membered ring macrolide clarithromycin (CAM) on migration induced by human plasma fibronectin (HFn) or on contraction of human fetal lung fibroblasts (HFL-1).	Clarithromycin	117-120	complement factor H related 1	Homo sapiens	228-233
22063598-4	2008	The pork fed CLA supplements contained higher (P<0.05) moisture, less fat, and lower MUFA:SFA, PUFA:SFA and n-6:n-3 ratios.	Clarithromycin	13-16	Polyunsaturated fatty acid percentage	Sus scrofa	98-102
22063598-6	2008	The CLA contents of meats increased (P<0.05) with increasing amounts of CLA in the diets, with the c9,t11 CLA isomer was the highest concentration.	Clarithromycin	4-7	complement C9	Sus scrofa	102-112
18717637-7	2008	Concentrations of interleukin (IL)-12 p40, RANTES, macrophage chemotactic protein-1, and cytokine-induced neutrophil chemoattractant were significantly lower in mice treated with clarithromycin alone and/or combination therapy compared with dexamethasone alone and/or placebo; combination therapy resulted in a significantly greater reduction than clarithromycin alone for IL-12 p40 and RANTES.	Clarithromycin	179-193	chemokine (C-C motif) ligand 5	Mus musculus	43-49
18717637-7	2008	Concentrations of interleukin (IL)-12 p40, RANTES, macrophage chemotactic protein-1, and cytokine-induced neutrophil chemoattractant were significantly lower in mice treated with clarithromycin alone and/or combination therapy compared with dexamethasone alone and/or placebo; combination therapy resulted in a significantly greater reduction than clarithromycin alone for IL-12 p40 and RANTES.	Clarithromycin	179-193	interleukin 12b	Mus musculus	373-382
18717637-7	2008	Concentrations of interleukin (IL)-12 p40, RANTES, macrophage chemotactic protein-1, and cytokine-induced neutrophil chemoattractant were significantly lower in mice treated with clarithromycin alone and/or combination therapy compared with dexamethasone alone and/or placebo; combination therapy resulted in a significantly greater reduction than clarithromycin alone for IL-12 p40 and RANTES.	Clarithromycin	179-193	chemokine (C-C motif) ligand 5	Mus musculus	387-393
18781017-0	2008	Electrochemical studies of the interaction of clarithromycin with bovine serum albumin.	Clarithromycin	46-60	albumin	Homo sapiens	73-86
18781017-1	2008	The interaction of clarithromycin (CAM) with bovine serum albumin (BSA) was investigated in pH 4.5-8.0 phosphate buffer solutions in which three irreversible reduction waves P(1), P(2) and P(3) of CAM appeared on linear-sweep voltammetry on a static dropping mercury working electrode.	Clarithromycin	19-33	albumin	Homo sapiens	52-65
18781017-1	2008	The interaction of clarithromycin (CAM) with bovine serum albumin (BSA) was investigated in pH 4.5-8.0 phosphate buffer solutions in which three irreversible reduction waves P(1), P(2) and P(3) of CAM appeared on linear-sweep voltammetry on a static dropping mercury working electrode.	Clarithromycin	35-38	albumin	Homo sapiens	52-65
18487355-14	2008	Whereas clarithromycin, azithromycin, and moxifloxacin individually were able to inhibit TNF-alpha-induction of IL-8, each failed to inhibit MMF-induction of IL-8.	Clarithromycin	8-22	C-X-C motif chemokine ligand 8	Homo sapiens	112-116
18212111-1	2008	The production of interleukin-8 induced by the activation of protease-activated receptor 2 and its synergism with interleukin-1beta were modulated by 14-membered-ring macrolides, namely, roxithromycin, erythromycin, and clarithromycin, in cultured normal human epidermal keratinocytes.	Clarithromycin	220-234	C-X-C motif chemokine ligand 8	Homo sapiens	18-31
18212111-1	2008	The production of interleukin-8 induced by the activation of protease-activated receptor 2 and its synergism with interleukin-1beta were modulated by 14-membered-ring macrolides, namely, roxithromycin, erythromycin, and clarithromycin, in cultured normal human epidermal keratinocytes.	Clarithromycin	220-234	F2R like trypsin receptor 1	Homo sapiens	61-90
18212111-1	2008	The production of interleukin-8 induced by the activation of protease-activated receptor 2 and its synergism with interleukin-1beta were modulated by 14-membered-ring macrolides, namely, roxithromycin, erythromycin, and clarithromycin, in cultured normal human epidermal keratinocytes.	Clarithromycin	220-234	interleukin 1 beta	Homo sapiens	114-131
19028625-7	2008	The clarithromycin treatment also significantly ( p<0.05) decreased the neutrophil infiltration into the lungs and decreased myeloperoxidase (MPO) activity.	Clarithromycin	4-18	myeloperoxidase	Mus musculus	128-143
19028625-7	2008	The clarithromycin treatment also significantly ( p<0.05) decreased the neutrophil infiltration into the lungs and decreased myeloperoxidase (MPO) activity.	Clarithromycin	4-18	myeloperoxidase	Mus musculus	145-148
18765615-10	2008	The temporal pattern of milk fat content showed a linear decrease during the infusion period for ALA + CLA and CD18:3 + CLA treatment groups.	Clarithromycin	120-123	integrin subunit beta 2	Bos taurus	111-115
18571382-0	2008	The anti-inflammatory activity of clarithromycin inhibits TNFalpha production and prolongs survival following lipopolysaccharide administration in mice.	Clarithromycin	34-48	tumor necrosis factor	Mus musculus	58-66
18628222-2	2008	We report the first case of desquamative interstitial pneumonia (DIP) showing a favorable response to treatment with clarithromycin.	Clarithromycin	117-131	DIP	Homo sapiens	65-68
18482668-1	2008	OBJECTIVES: Clarithromycin (CAM), a major macrolide antibiotic, has many biological functions, including matrix metalloproteinases (MMPs) regulation.	Clarithromycin	12-26	matrix metallopeptidase 2	Mus musculus	132-136
18482668-1	2008	OBJECTIVES: Clarithromycin (CAM), a major macrolide antibiotic, has many biological functions, including matrix metalloproteinases (MMPs) regulation.	Clarithromycin	28-31	matrix metallopeptidase 2	Mus musculus	132-136
18482668-12	2008	Clarithromycin inhibited the expression of MMP-9, whereas the treatment did not alter the expression of MMP-2 and tissue inhibitor metalloproteinase-1 in macrophages and smooth muscle cells.	Clarithromycin	0-14	matrix metallopeptidase 9	Mus musculus	43-48
18482668-14	2008	CONCLUSIONS: Clarithromycin is useful to suppress allograft remodeling, because it is critically involved in the prevention of cardiac rejection through the suppression of MMP-9.	Clarithromycin	13-27	matrix metallopeptidase 9	Mus musculus	172-177
17947611-3	2008	Macrolide antibiotics, such as clarithromycin, have in vitro efficacy against IL-8 and neutrophils, key inflammatory mediators in noneosinophilic asthma.	Clarithromycin	31-45	C-X-C motif chemokine ligand 8	Homo sapiens	78-82
17947611-9	2008	Clarithromycin therapy significantly reduced airway concentrations of IL-8 and neutrophil numbers and improved quality-of-life scores compared with placebo.	Clarithromycin	0-14	C-X-C motif chemokine ligand 8	Homo sapiens	70-74
17947611-12	2008	CONCLUSIONS: Clarithromycin therapy can modulate IL-8 levels and neutrophil accumulation and activation in the airways of patients with refractory asthma.	Clarithromycin	13-27	C-X-C motif chemokine ligand 8	Homo sapiens	49-53
17635500-20	2008	CONCLUSIONS: Intestinal and hepatic CYP3A inhibition by clarithromycin significantly reduces the clearance of midazolam in the elderly.	Clarithromycin	56-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	36-41
19122337-3	2008	Thus, the effect of clarithromycin, a potent CYP3A4 inhibitor, on the pharmacokinetics of pranlukast was examined in an open-label, randomized, two-way crossover study in 16 healthy male volunteers.	Clarithromycin	20-34	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-51
18558792-8	2008	Diltiazem (86 events), verapamil (72), erythromycin (48) and clarithromycin (29) were the most commonly co-prescribed CYP3A4 inhibitors.	Clarithromycin	61-75	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	118-124
18033049-8	2007	As clarithromycin is also metabolized by CYP3A4, this drug has the propensity to inhibit the metabolism of carbamazepine.	Clarithromycin	3-17	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-47
18086868-7	2008	However, betaine + CLA increased ADG (601 vs. 558 g, P = 0.03) and gain relative to ME intake (25.4 vs. 22.2 g/MJ, P = 0.03) compared with control pigs.	Clarithromycin	19-22	ADG	Sus scrofa	33-36
18086868-16	2008	Overall, dietary supplementation of betaine + CLA increased ADG, protein, water, and lean deposition in growing Iberian gilts.	Clarithromycin	46-49	ADG	Sus scrofa	60-63
17412724-0	2007	Clarithromycin has an immunomodulatory effect on ERK-mediated inflammation induced by Pseudomonas aeruginosa flagellin.	Clarithromycin	0-14	mitogen-activated protein kinase 1	Homo sapiens	49-52
17822662-7	2007	Clarithromycin resistance was found to be 44.1% (15/34) in the PAC-1 group and 58.8% (20/34) in the PAC-2 group (p>0.05).	Clarithromycin	0-14	dual specificity phosphatase 2	Homo sapiens	63-68
17822662-7	2007	Clarithromycin resistance was found to be 44.1% (15/34) in the PAC-1 group and 58.8% (20/34) in the PAC-2 group (p>0.05).	Clarithromycin	0-14	proteasome assembly chaperone 2	Homo sapiens	100-105
17822662-9	2007	H. pylori was eradicated in 4 of 15 (PP: 26.7%, ITT: 26.7%) clarithromycin-resistant patients in the PAC-1 group and in 12 of 20 (PP: 60%, ITT: 60%) clarithromycin-resistant patients in the PAC-2 group (p>0.05).	Clarithromycin	60-74	dual specificity phosphatase 2	Homo sapiens	101-106
17822662-10	2007	Among the clarithromycin-sensitive ones, eradication was achieved in 12 of 19 (PP: 63.2%, ITT: 57.1%) patients in the PAC-1 group and in 13 of 14 (PP: 92.8%, ITT: 76.5%) patients in the PAC-2 group (p>0.05).	Clarithromycin	10-24	dual specificity phosphatase 2	Homo sapiens	118-123
17822662-10	2007	Among the clarithromycin-sensitive ones, eradication was achieved in 12 of 19 (PP: 63.2%, ITT: 57.1%) patients in the PAC-1 group and in 13 of 14 (PP: 92.8%, ITT: 76.5%) patients in the PAC-2 group (p>0.05).	Clarithromycin	10-24	proteasome assembly chaperone 2	Homo sapiens	186-191
17695796-2	2007	Clarithromycin (CAM) metabolism is reportedly enhanced by induction of hepatic drug-metabolizing enzymes (CYP3A4) by RFP, so that the blood lend of CAM decreases when RFP is administered concurrently.	Clarithromycin	0-14	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-112
17695796-2	2007	Clarithromycin (CAM) metabolism is reportedly enhanced by induction of hepatic drug-metabolizing enzymes (CYP3A4) by RFP, so that the blood lend of CAM decreases when RFP is administered concurrently.	Clarithromycin	16-19	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-112
17695796-2	2007	Clarithromycin (CAM) metabolism is reportedly enhanced by induction of hepatic drug-metabolizing enzymes (CYP3A4) by RFP, so that the blood lend of CAM decreases when RFP is administered concurrently.	Clarithromycin	148-151	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-112
17697203-2	2007	AIM: To investigate whether MDR1 polymorphism is associated with eradication rates of Helicobacter pylori by a triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP2C19 genotype status and bacterial susceptibility to clarithromycin.	Clarithromycin	161-175	ATP binding cassette subfamily B member 1	Homo sapiens	28-32
17697203-9	2007	CONCLUSIONS: Polymorphism of MDR1 is one of the determinants of successful eradication of H. pylori by the triple therapy with lansoprazole, amoxicillin and clarithromycin, together with CYP2C19 genotype and bacterial susceptibility to clarithromycin.	Clarithromycin	157-171	ATP binding cassette subfamily B member 1	Homo sapiens	29-33
17697203-9	2007	CONCLUSIONS: Polymorphism of MDR1 is one of the determinants of successful eradication of H. pylori by the triple therapy with lansoprazole, amoxicillin and clarithromycin, together with CYP2C19 genotype and bacterial susceptibility to clarithromycin.	Clarithromycin	236-250	ATP binding cassette subfamily B member 1	Homo sapiens	29-33
17412724-2	2007	Clarithromycin initially decreases, then increases and finally produces a sustained suppression of interleukin (IL)-8 secretion from normal human bronchial epithelial (NHBE) cells through inhibition and activation of extracellular signal-regulated kinase (ERK).	Clarithromycin	0-14	C-X-C motif chemokine ligand 8	Homo sapiens	99-117
17412724-2	2007	Clarithromycin initially decreases, then increases and finally produces a sustained suppression of interleukin (IL)-8 secretion from normal human bronchial epithelial (NHBE) cells through inhibition and activation of extracellular signal-regulated kinase (ERK).	Clarithromycin	0-14	mitogen-activated protein kinase 1	Homo sapiens	217-254
17412724-2	2007	Clarithromycin initially decreases, then increases and finally produces a sustained suppression of interleukin (IL)-8 secretion from normal human bronchial epithelial (NHBE) cells through inhibition and activation of extracellular signal-regulated kinase (ERK).	Clarithromycin	0-14	mitogen-activated protein kinase 1	Homo sapiens	256-259
17412724-8	2007	Clarithromycin significantly decreased flagellin-induced IL-8 over the first 9 h but not at 24 h. A 60 min exposure to clarithromycin decreased flagellin-induced ERK phosphorylation, but at 24 h, clarithromycin increased phospho-ERK1/2 beyond the effect of flagellin alone.	Clarithromycin	0-14	mitogen-activated protein kinase 1	Homo sapiens	162-165
17412724-8	2007	Clarithromycin significantly decreased flagellin-induced IL-8 over the first 9 h but not at 24 h. A 60 min exposure to clarithromycin decreased flagellin-induced ERK phosphorylation, but at 24 h, clarithromycin increased phospho-ERK1/2 beyond the effect of flagellin alone.	Clarithromycin	119-133	mitogen-activated protein kinase 1	Homo sapiens	162-165
17384007-7	2007	CONCLUSION: Usefulness of the L:P ratio for differentiating non-PDH and PDH-D types of CLA increases at higher lactate concentrations.	Clarithromycin	87-90	pyruvate dehydrogenase phosphatase catalytic subunit 1	Homo sapiens	72-75
17453815-8	2007	At CLA dietary levels greater than 0.5%, lipoprotein lipase activity in plasma was significantly decreased.	Clarithromycin	3-6	lipoprotein lipase	Gallus gallus	41-59
17384007-1	2007	BACKGROUND: Although the blood lactate-to-pyruvate (L:P) molar ratio is used to distinguish between pyruvate dehydrogenase deficiency (PDH-D) and other causes of congenital lactic acidosis (CLA), its diagnostic accuracy for differentiating between these 2 types of CLA has not been evaluated formally.	Clarithromycin	190-193	pyruvate dehydrogenase phosphatase catalytic subunit 1	Homo sapiens	135-138
17296622-8	2007	The IC50 values for the inhibition of OATP1B3-mediated BSP uptake were 11 microM for telithromycin, 32 microM for clarithromycin, 34 microM for erythromycin, and 37 microM for roxithromycin.	Clarithromycin	114-128	solute carrier organic anion transporter family member 1B3	Homo sapiens	38-45
17295362-5	2007	Therefore, phenytoin, torasemide and clarithromycin (mainly metabolized via CYP2B1/2, 2C11 and 3A2 in rats, respectively) were administered intravenously to male rats with or without oral oxolamine.	Clarithromycin	37-51	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	76-82
17381388-9	2007	Previous reports of simvastatin-clarithromycin-related events involved additional drugs that inhibited CYP3A4 and P-glycoprotein.	Clarithromycin	32-46	ATP binding cassette subfamily B member 1	Homo sapiens	114-128
17381388-9	2007	Previous reports of simvastatin-clarithromycin-related events involved additional drugs that inhibited CYP3A4 and P-glycoprotein.	Clarithromycin	32-46	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	103-109
18027988-4	2007	RESULTS: All macrolides inhibited P-glycoprotein-mediated digoxin transport, with concentrations producing 50% inhibition (IC(50)) values of 1.8, 4.1, 15.4, 21.8 and 22.7 micromol/L for telithromycin, clarithromycin, roxithromycin, azithromycin and erythromycin, respectively.	Clarithromycin	201-215	ATP binding cassette subfamily B member 1	Homo sapiens	34-48
17302905-3	2007	A 15-membered macrolide, AZM, and a 14-membered macrolide, CAM, significantly enhanced the intensity of a co-stimulatory molecule, CD80, on DCs but not CD86 and CD40.	Clarithromycin	59-62	CD80 antigen	Mus musculus	131-135
17324565-1	2007	We studied the influence of the inhibitory effect of clarithromycin (CAM) and erythromycin (EM) on the production of macrophage inflammatory protein (MIP)-2, interleukin-6 (IL-6), and prostaglandin E(2) (PGE(2)), as well as PGE(2) receptor (EP(2)) expression, by LPS-stimulated RAW264.7 cells.	Clarithromycin	53-67	chemokine (C-X-C motif) ligand 2	Mus musculus	117-156
17324565-1	2007	We studied the influence of the inhibitory effect of clarithromycin (CAM) and erythromycin (EM) on the production of macrophage inflammatory protein (MIP)-2, interleukin-6 (IL-6), and prostaglandin E(2) (PGE(2)), as well as PGE(2) receptor (EP(2)) expression, by LPS-stimulated RAW264.7 cells.	Clarithromycin	53-67	interleukin 6	Mus musculus	158-171
17324565-1	2007	We studied the influence of the inhibitory effect of clarithromycin (CAM) and erythromycin (EM) on the production of macrophage inflammatory protein (MIP)-2, interleukin-6 (IL-6), and prostaglandin E(2) (PGE(2)), as well as PGE(2) receptor (EP(2)) expression, by LPS-stimulated RAW264.7 cells.	Clarithromycin	69-72	chemokine (C-X-C motif) ligand 2	Mus musculus	117-156
17324565-1	2007	We studied the influence of the inhibitory effect of clarithromycin (CAM) and erythromycin (EM) on the production of macrophage inflammatory protein (MIP)-2, interleukin-6 (IL-6), and prostaglandin E(2) (PGE(2)), as well as PGE(2) receptor (EP(2)) expression, by LPS-stimulated RAW264.7 cells.	Clarithromycin	69-72	interleukin 6	Mus musculus	158-171
17324565-2	2007	Production of IL-6 was significantly decreased by treatment with CAM or EM in a dose-dependent manner, but the inhibitory effect of CAM was significantly weaker than that of EM.	Clarithromycin	65-68	interleukin 6	Mus musculus	14-18
17324565-3	2007	In contrast, the production of MIP-2 and PGE(2) was inhibited to the same extent by CAM and EM.	Clarithromycin	84-87	chemokine (C-X-C motif) ligand 2	Mus musculus	31-36
17055675-0	2007	Application of ascorbic acid 2-glucoside as a solubilizing agent for clarithromycin: solubilization and nanoparticle formation.	Clarithromycin	69-83	PTOV1 extended AT-hook containing adaptor protein	Homo sapiens	24-30
17055675-1	2007	Clarithromycin (CAM) was co-ground with l-ascorbic acid 2-glucoside (AA-2G), a newly developed food additive, to improve the solubility characteristics.	Clarithromycin	0-14	PTOV1 extended AT-hook containing adaptor protein	Homo sapiens	51-57
17311557-10	2007	The combination of neuraminidase inhibitors and protease inhibitors, clarithromycin or ambroxol, could be potentially used as a potent anti-influenza therapy to minimize the emergence of drug-resistant mutant viruses.	Clarithromycin	69-83	neuraminidase 1	Homo sapiens	19-32
17484517-5	2007	Clinically established CYP3A4 inhibitors including itraconazole, ketoconazole, erythromycin and clarithromycin inhibited the elimination of IM in HLM.	Clarithromycin	96-110	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	23-29
17050564-7	2007	Treatment with clarithromycin was associated with a statistically significant reduction in the length of hospital stay, the duration of need for supplemental oxygen and the need for beta(2)-agonist treatment.	Clarithromycin	15-29	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	182-188
17050564-8	2007	There were significant decreases in plasma IL-4, IL-8 and eotaxin levels after 3 weeks of treatment with clarithromycin.	Clarithromycin	105-119	interleukin 4	Homo sapiens	43-47
17050564-8	2007	There were significant decreases in plasma IL-4, IL-8 and eotaxin levels after 3 weeks of treatment with clarithromycin.	Clarithromycin	105-119	C-X-C motif chemokine ligand 8	Homo sapiens	49-53
17050564-8	2007	There were significant decreases in plasma IL-4, IL-8 and eotaxin levels after 3 weeks of treatment with clarithromycin.	Clarithromycin	105-119	C-C motif chemokine ligand 11	Homo sapiens	58-65
17180882-10	2006	The results demonstrated that the inhibitory effects of CLA on differentiation, GPDH activity, and FA accumulation of 3T3-L1 cells are dependent on the isomer type, treatment period, and dose.	Clarithromycin	56-59	glycerol phosphate dehydrogenase 2, mitochondrial	Mus musculus	80-84
17069099-6	2006	RESULTS: Nasopharyngeal concentrations of TNF-alpha, IL-1beta, and IL-10 were significantly and persistently lower in children treated with clarithromycin compared with placebo.	Clarithromycin	140-154	tumor necrosis factor	Homo sapiens	42-51
17069099-6	2006	RESULTS: Nasopharyngeal concentrations of TNF-alpha, IL-1beta, and IL-10 were significantly and persistently lower in children treated with clarithromycin compared with placebo.	Clarithromycin	140-154	interleukin 1 beta	Homo sapiens	53-61
17069099-6	2006	RESULTS: Nasopharyngeal concentrations of TNF-alpha, IL-1beta, and IL-10 were significantly and persistently lower in children treated with clarithromycin compared with placebo.	Clarithromycin	140-154	interleukin 10	Homo sapiens	67-72
17069099-9	2006	CONCLUSION: Clarithromycin therapy reduces mucosal TNF-alpha, IL-1beta, and IL-10 concentrations in children with an acute exacerbation of recurrent wheezing.	Clarithromycin	12-26	tumor necrosis factor	Homo sapiens	51-60
17069099-9	2006	CONCLUSION: Clarithromycin therapy reduces mucosal TNF-alpha, IL-1beta, and IL-10 concentrations in children with an acute exacerbation of recurrent wheezing.	Clarithromycin	12-26	interleukin 1 beta	Homo sapiens	62-70
17069099-9	2006	CONCLUSION: Clarithromycin therapy reduces mucosal TNF-alpha, IL-1beta, and IL-10 concentrations in children with an acute exacerbation of recurrent wheezing.	Clarithromycin	12-26	interleukin 10	Homo sapiens	76-81
16416302-3	2006	METHODS: The in vitro kinetic constants of CYP3A inactivation (K (I) and k (inact)) were estimated by varying the time of pre-incubation and the concentration of troleandomycin, erythromycin, clarithromycin, roxithromycin or azithromycin.	Clarithromycin	192-206	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-48
16641444-4	2006	Therefore, we studied normal human bronchial epithelial (NHBE) cells to determine whether clarithromycin (CAM) suppresses ERK, delays bronchial epithelial cells from progressing to S phase, and delays cell growth.	Clarithromycin	90-104	mitogen-activated protein kinase 1	Homo sapiens	122-125
16641444-4	2006	Therefore, we studied normal human bronchial epithelial (NHBE) cells to determine whether clarithromycin (CAM) suppresses ERK, delays bronchial epithelial cells from progressing to S phase, and delays cell growth.	Clarithromycin	106-109	mitogen-activated protein kinase 1	Homo sapiens	122-125
16641444-6	2006	CAM also inhibited ERK1/2 phosphorylation over the first 90 min of exposure (P < 0.05 for 30 min, P < 0.0001 for 60 min, and P < 0.01 for 90 min) and decreased the ratio of phosphorylated ERK1/2 (pERK1/2) to total ERK1/2 (tERK1/2) (P < 0.0001).	Clarithromycin	0-3	mitogen-activated protein kinase 3	Homo sapiens	19-25
16641444-6	2006	CAM also inhibited ERK1/2 phosphorylation over the first 90 min of exposure (P < 0.05 for 30 min, P < 0.0001 for 60 min, and P < 0.01 for 90 min) and decreased the ratio of phosphorylated ERK1/2 (pERK1/2) to total ERK1/2 (tERK1/2) (P < 0.0001).	Clarithromycin	0-3	mitogen-activated protein kinase 3	Homo sapiens	197-203
16641444-6	2006	CAM also inhibited ERK1/2 phosphorylation over the first 90 min of exposure (P < 0.05 for 30 min, P < 0.0001 for 60 min, and P < 0.01 for 90 min) and decreased the ratio of phosphorylated ERK1/2 (pERK1/2) to total ERK1/2 (tERK1/2) (P < 0.0001).	Clarithromycin	0-3	mitogen-activated protein kinase 3	Homo sapiens	197-203
16921753-4	2006	CONCLUSION: CLA can improve insulin resistance of obese rat and increase the expression of ap2 mRNA,possibly acting through activing PPARgamma.	Clarithromycin	12-15	fatty acid binding protein 4	Rattus norvegicus	91-94
16921753-4	2006	CONCLUSION: CLA can improve insulin resistance of obese rat and increase the expression of ap2 mRNA,possibly acting through activing PPARgamma.	Clarithromycin	12-15	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	133-142
16815316-10	2006	CONCLUSIONS: IL1B -511 polymorphism, but not IL1RN, TNFA, or IL10 polymorphism, is one of the determinants of triple therapy for clarithromycin-sensitive strains of H pylori in CYP2C19 homozygous EMs.	Clarithromycin	129-143	interleukin 1 beta	Homo sapiens	13-17
16372380-3	2006	This study examined the effect of coadministration of ciprofloxacin or clarithromycin, which inhibit CYP3A4, on the bioavailability and pharmacokinetics of sildenafil.	Clarithromycin	71-85	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	101-107
16372380-8	2006	These results indicate that coadministration of ciprofloxacin and clarithromycin significantly increased sildenafil bioavailability which can be attributed to the inhibitory effect of ciprofloxacin and clarithromycin on CYP3A4.	Clarithromycin	66-80	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	220-226
16372380-8	2006	These results indicate that coadministration of ciprofloxacin and clarithromycin significantly increased sildenafil bioavailability which can be attributed to the inhibitory effect of ciprofloxacin and clarithromycin on CYP3A4.	Clarithromycin	202-216	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	220-226
16387930-1	2006	Clarithromycin (CM) has been found to inhibit the production of the intercellular adhesion molecule (ICAM)-1 and the secretion of interleukin (IL)-6 and IL-8, which may have beneficial effects on the pathophysiological changes related to rhinovirus (RV) infection.	Clarithromycin	0-14	intercellular adhesion molecule 1	Homo sapiens	68-108
16085674-4	2006	CAM decreased IL-8 over the first 6 h and then significantly increased interleukin (IL)-8 at 12-72 h after exposure (P < 0.0001).	Clarithromycin	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	14-18
16085674-4	2006	CAM decreased IL-8 over the first 6 h and then significantly increased interleukin (IL)-8 at 12-72 h after exposure (P < 0.0001).	Clarithromycin	0-3	C-X-C motif chemokine ligand 8	Homo sapiens	71-89
16085674-5	2006	AZM also increased IL-8 at 24 and 48 h, and CAM increased granulocyte-macrophage colony-stimulating factor at 48 h. In the presence of LPS, both CAM and AZM dose-dependently increased IL-8 secretion over 24 h, but after 5 days of exposure to 10 microg/ml CAM there is suppression of IL-8 (P < 0.001).	Clarithromycin	44-47	C-X-C motif chemokine ligand 8	Homo sapiens	184-188
16085674-5	2006	AZM also increased IL-8 at 24 and 48 h, and CAM increased granulocyte-macrophage colony-stimulating factor at 48 h. In the presence of LPS, both CAM and AZM dose-dependently increased IL-8 secretion over 24 h, but after 5 days of exposure to 10 microg/ml CAM there is suppression of IL-8 (P < 0.001).	Clarithromycin	44-47	C-X-C motif chemokine ligand 8	Homo sapiens	184-188
16085674-5	2006	AZM also increased IL-8 at 24 and 48 h, and CAM increased granulocyte-macrophage colony-stimulating factor at 48 h. In the presence of LPS, both CAM and AZM dose-dependently increased IL-8 secretion over 24 h, but after 5 days of exposure to 10 microg/ml CAM there is suppression of IL-8 (P < 0.001).	Clarithromycin	145-148	C-X-C motif chemokine ligand 8	Homo sapiens	19-23
16085674-5	2006	AZM also increased IL-8 at 24 and 48 h, and CAM increased granulocyte-macrophage colony-stimulating factor at 48 h. In the presence of LPS, both CAM and AZM dose-dependently increased IL-8 secretion over 24 h, but after 5 days of exposure to 10 microg/ml CAM there is suppression of IL-8 (P < 0.001).	Clarithromycin	145-148	C-X-C motif chemokine ligand 8	Homo sapiens	184-188
16085674-5	2006	AZM also increased IL-8 at 24 and 48 h, and CAM increased granulocyte-macrophage colony-stimulating factor at 48 h. In the presence of LPS, both CAM and AZM dose-dependently increased IL-8 secretion over 24 h, but after 5 days of exposure to 10 microg/ml CAM there is suppression of IL-8 (P < 0.001).	Clarithromycin	145-148	C-X-C motif chemokine ligand 8	Homo sapiens	184-188
16085674-7	2006	The p38 MAP kinase inhibitor SB-203580 increased CAM-induced IL-8 release (P < 0.001), and the c-jun NH2-terminal kinase inhibitor SP-600125 had no effect on IL-8.	Clarithromycin	49-52	mitogen-activated protein kinase 14	Homo sapiens	4-7
16085674-7	2006	The p38 MAP kinase inhibitor SB-203580 increased CAM-induced IL-8 release (P < 0.001), and the c-jun NH2-terminal kinase inhibitor SP-600125 had no effect on IL-8.	Clarithromycin	49-52	C-X-C motif chemokine ligand 8	Homo sapiens	61-65
16457617-4	2006	We determined that chloramphenicol and clarithromycin were effective inhibitors of serum hPON1.	Clarithromycin	39-53	paraoxonase 1	Homo sapiens	89-94
16387930-1	2006	Clarithromycin (CM) has been found to inhibit the production of the intercellular adhesion molecule (ICAM)-1 and the secretion of interleukin (IL)-6 and IL-8, which may have beneficial effects on the pathophysiological changes related to rhinovirus (RV) infection.	Clarithromycin	0-14	interleukin 6	Homo sapiens	130-148
16387930-1	2006	Clarithromycin (CM) has been found to inhibit the production of the intercellular adhesion molecule (ICAM)-1 and the secretion of interleukin (IL)-6 and IL-8, which may have beneficial effects on the pathophysiological changes related to rhinovirus (RV) infection.	Clarithromycin	0-14	C-X-C motif chemokine ligand 8	Homo sapiens	153-157
16387930-1	2006	Clarithromycin (CM) has been found to inhibit the production of the intercellular adhesion molecule (ICAM)-1 and the secretion of interleukin (IL)-6 and IL-8, which may have beneficial effects on the pathophysiological changes related to rhinovirus (RV) infection.	Clarithromycin	16-18	intercellular adhesion molecule 1	Homo sapiens	68-108
16387930-1	2006	Clarithromycin (CM) has been found to inhibit the production of the intercellular adhesion molecule (ICAM)-1 and the secretion of interleukin (IL)-6 and IL-8, which may have beneficial effects on the pathophysiological changes related to rhinovirus (RV) infection.	Clarithromycin	16-18	interleukin 6	Homo sapiens	130-148
16387930-1	2006	Clarithromycin (CM) has been found to inhibit the production of the intercellular adhesion molecule (ICAM)-1 and the secretion of interleukin (IL)-6 and IL-8, which may have beneficial effects on the pathophysiological changes related to rhinovirus (RV) infection.	Clarithromycin	16-18	C-X-C motif chemokine ligand 8	Homo sapiens	153-157
16387930-8	2006	The findings of this study suggest that, in A549 cells, clarithromycin inhibits the induction of intercellular adhesion molecule-1 expression, cytokine elaboration, and viral infection.	Clarithromycin	56-70	intercellular adhesion molecule 1	Homo sapiens	97-130
16388032-8	2006	Post-treatment resistance to metronidazole was common (81.6%) and that to clarithromycin was considerable (36%).	Clarithromycin	74-88	solute carrier family 35 member G1	Homo sapiens	0-4
16898513-12	2006	We conclude that an empirical combination treatment of clarithromycine and ceftazidime is appropriate and effective in children with UTI caused by PA.	Clarithromycin	55-70	alpha-1-microglobulin/bikunin precursor	Homo sapiens	133-136
16410677-2	2006	Clarithromycin is a potent inhibitor of CYP3A4 and P-glycoprotein and is often co-administered with cabergoline in usual clinical practice.	Clarithromycin	0-14	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	40-46
16410677-2	2006	Clarithromycin is a potent inhibitor of CYP3A4 and P-glycoprotein and is often co-administered with cabergoline in usual clinical practice.	Clarithromycin	0-14	ATP binding cassette subfamily B member 1	Homo sapiens	51-65
16319604-3	2005	RESULTS: Dose-dependent inhibitory effects on vascular endothelisal growth factor production stimulated by hypoxia or tumor necrosis factor-alpha were noted in the groups treated with Clarithromycin and Roxisthromycin, including inhibition of vascular endothelisal growth factor mRNA levels.	Clarithromycin	184-198	tumor necrosis factor	Homo sapiens	118-145
16429828-5	2005	The results indicate that dietary CLA inhibited the production of TNF-alpha by pig PBMC both at the protein and mRNA expression level.	Clarithromycin	34-37	tumor necrosis factor	Sus scrofa	66-75
16429828-7	2005	Both CLA isomers inhibited LPS-stimulated TNF-alpha production and expression, which may be partially due to inhibition of the binding activity of nuclear factor-kappaB.	Clarithromycin	5-8	tumor necrosis factor	Sus scrofa	42-51
16052483-1	2005	Synthetic Conjugated Linoleic Acid mixture (CLA; c9,t11; t10,c12-18:2) has been previously shown to inhibit growth, and enhance apoptosis and IL-2 mRNA synthesis in human lymphoblastic Jurkat T-cells.	Clarithromycin	44-47	interleukin 2	Homo sapiens	142-146
16000071-0	2005	Posttranslational control of a cardiac ion channel transgene in vivo: clarithromycin-hMiRP1-Q9E interactions.	Clarithromycin	70-84	potassium voltage-gated channel subfamily E regulatory subunit 2	Homo sapiens	85-91
16006447-1	2005	OBJECTIVES: To test whether ciprofloxacin, moxifloxacin and clarithromycin affect the expression of the T helper (Th) cell cytokines, interferon-gamma and interleukin-4.	Clarithromycin	60-74	interferon gamma	Homo sapiens	134-150
16006447-1	2005	OBJECTIVES: To test whether ciprofloxacin, moxifloxacin and clarithromycin affect the expression of the T helper (Th) cell cytokines, interferon-gamma and interleukin-4.	Clarithromycin	60-74	interleukin 4	Homo sapiens	155-168
16006447-9	2005	Only interleukin-4 expression however, was affected by clarithromycin (P=0.04).	Clarithromycin	55-69	interleukin 4	Homo sapiens	5-18
16006447-10	2005	There was no change in the Th1/Th2 ratio for moxifloxacin or ciprofloxacin, but the Th1/Th2 ratio increased with increasing concentrations of clarithromycin, from a median [range] of 5.3 [1.3--16.0] without antibiotic to 9.1 [1.8--18.8] at 125 mg/L (P=0.017).	Clarithromycin	142-156	negative elongation factor complex member C/D	Homo sapiens	84-87
16006447-12	2005	However, clarithromycin decreased only interleukin-4 expression such that the Th1/Th2 ratio increased.	Clarithromycin	9-23	interleukin 4	Homo sapiens	39-52
16006447-12	2005	However, clarithromycin decreased only interleukin-4 expression such that the Th1/Th2 ratio increased.	Clarithromycin	9-23	negative elongation factor complex member C/D	Homo sapiens	78-81
16000071-1	2005	The present study investigates a novel gene therapy approach for atrial arrhythmias, using a clarithromycin-responsive ion channel subunit mutation, hMiRP1-Q9E, cloned into an expression plasmid; wild-type expression plasmids encoding human minK-related protein 1 (hMiRP1) were also used as controls.	Clarithromycin	93-107	potassium voltage-gated channel subfamily E regulatory subunit 2	Homo sapiens	149-155
16000071-1	2005	The present study investigates a novel gene therapy approach for atrial arrhythmias, using a clarithromycin-responsive ion channel subunit mutation, hMiRP1-Q9E, cloned into an expression plasmid; wild-type expression plasmids encoding human minK-related protein 1 (hMiRP1) were also used as controls.	Clarithromycin	93-107	potassium voltage-gated channel subfamily E regulatory subunit 2	Homo sapiens	265-271
16159721-12	2005	Systemic clarithromycin treatment decreased the conjunctival flora of HIV patients, including those who had a CD4 count that was less than 50/microl.	Clarithromycin	9-23	CD4 molecule	Homo sapiens	110-113
15856433-1	2005	The aim of this study was to examine the effect of clarithromycin, a CYP3A4 inhibitor, on the enantioselective disposition of lansoprazole among three different CYP2C19 genotype groups in healthy Japanese subjects.	Clarithromycin	51-65	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-75
15917564-0	2005	Effect of CYP3A1(23) induction on clarithromycin pharmacokinetics in rats with diabetes mellitus.	Clarithromycin	34-48	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	10-16
15917564-3	2005	The above data suggested that metabolism of clarithromycin increased in both types of diabetic rat due to an increase in the expression and mRNA level of CYP3A1(23) in the rats.	Clarithromycin	44-58	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	154-160
15856433-0	2005	Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes.	Clarithromycin	10-24	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	92-99
15856433-3	2005	In the EMs of CYP2C19, clarithromycin markedly increased Cmax and the AUC0-infinity of (S)-lansoprazole and (S)-hydroxylansoprazole compared with those of the corresponding (R)-enantiomers.	Clarithromycin	23-37	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	14-21
15856433-6	2005	In the of PMs CYP2C19, clarithromycin significantly increased Cmax and the AUC0-infinity and significantly prolonged the elimination half-lives of (R)- and (S)-lansoprazole by 51% and 49%, respectively.	Clarithromycin	23-37	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	14-21
15856433-7	2005	The present study suggests that there are significant drug interactions between (R)- or (S)-lansoprazole and clarithromycin in EMs by inhibiting the CYP3A4-catalyzed sulfoxidation primarily during the first pass, whereas in PMs, the overall metabolism of lansoprazole is inhibited.	Clarithromycin	109-123	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	149-155
15735612-0	2005	Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression.	Clarithromycin	83-97	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	101-120
15752376-2	2005	The aim of this study was to compare the inhibitory effects of clarithromycin, an inhibitor of CYP3A on the metabolism of lansoprazole between CYP2C19 genotypes.	Clarithromycin	63-77	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-100
15752376-2	2005	The aim of this study was to compare the inhibitory effects of clarithromycin, an inhibitor of CYP3A on the metabolism of lansoprazole between CYP2C19 genotypes.	Clarithromycin	63-77	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	143-150
15752376-9	2005	CONCLUSIONS: The present study indicates that there are significant drug interactions between lansoprazole and clarithromycin in all CYP2C19 genotype groups probably through CYP3A inhibition.	Clarithromycin	111-125	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	133-140
15752376-9	2005	CONCLUSIONS: The present study indicates that there are significant drug interactions between lansoprazole and clarithromycin in all CYP2C19 genotype groups probably through CYP3A inhibition.	Clarithromycin	111-125	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	174-179
15735612-2	2005	This study was designed to identify determinants of variability in the extent of intestinal wall CYP3A inhibition by clarithromycin, such as CYP3A5 genotype, and the mechanism of inhibition.	Clarithromycin	117-131	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-102
15735612-2	2005	This study was designed to identify determinants of variability in the extent of intestinal wall CYP3A inhibition by clarithromycin, such as CYP3A5 genotype, and the mechanism of inhibition.	Clarithromycin	117-131	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	141-147
15735612-22	2005	Compared with CYP3A5 nonexpressers, subjects with at least 1 CYP3A5*1 allele (CYP3A5 expressers) had greater inhibition of intestinal CYP3A activity after treatment with clarithromycin.	Clarithromycin	170-184	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	14-20
15735612-22	2005	Compared with CYP3A5 nonexpressers, subjects with at least 1 CYP3A5*1 allele (CYP3A5 expressers) had greater inhibition of intestinal CYP3A activity after treatment with clarithromycin.	Clarithromycin	170-184	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	61-67
15735612-22	2005	Compared with CYP3A5 nonexpressers, subjects with at least 1 CYP3A5*1 allele (CYP3A5 expressers) had greater inhibition of intestinal CYP3A activity after treatment with clarithromycin.	Clarithromycin	170-184	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	61-67
15735612-24	2005	CONCLUSION: Baseline intestinal activity of CYP3A4 was a key determinant of variability of the inhibitory effect of clarithromycin among individuals.	Clarithromycin	116-130	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	44-50
15576322-8	2004	Another agent, clarithromycin, is a macrolide antibiotic that increases IgA levels through augmentation of interleukin-12 levels and mucosal immunization in the airway.	Clarithromycin	15-29	CD79a molecule	Homo sapiens	72-75
15736403-10	2004	Bcl-2 expression was seen only in the control group and FasL was never seen, while the expression of TNFR1, Fas and caspase-3, -8 and -9 was seen in the amoxicillin-treated group, clarithromycin-treated group, amoxicillin and clarithromycin-treated group and the positive control group.	Clarithromycin	226-240	tumor necrosis factor receptor superfamily, member 1b	Mus musculus	101-106
15251115-0	2004	Clarithromycin and azithromycin induce apoptosis of activated lymphocytes via down-regulation of Bcl-xL.	Clarithromycin	0-14	BCL2 like 1	Homo sapiens	97-103
15252191-3	2004	OBJECTIVE: To evaluate the antiinflammatory effect of clarithromycin on serum and sputum interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-alpha), and leukotriene B4 levels in patients with COPD.	Clarithromycin	54-68	C-X-C motif chemokine ligand 8	Homo sapiens	89-102
15252191-3	2004	OBJECTIVE: To evaluate the antiinflammatory effect of clarithromycin on serum and sputum interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-alpha), and leukotriene B4 levels in patients with COPD.	Clarithromycin	54-68	C-X-C motif chemokine ligand 8	Homo sapiens	104-108
15252191-3	2004	OBJECTIVE: To evaluate the antiinflammatory effect of clarithromycin on serum and sputum interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-alpha), and leukotriene B4 levels in patients with COPD.	Clarithromycin	54-68	tumor necrosis factor	Homo sapiens	111-138
15252191-9	2004	After the treatment, the induced sputum total cell counts, and IL-8 and TNF-alpha levels decreased significantly in the clarithromycin group compared with pretreatment levels (mean +/- SD IL-8 1606 +/- 367.3 vs 882 +/- 143.6 pg/mL, p = 0.001; TNF-alpha 638.2 +/- 287.5 vs 390 +/- 235 pg/mL, p = 0.001).	Clarithromycin	120-134	C-X-C motif chemokine ligand 8	Homo sapiens	63-67
15252191-9	2004	After the treatment, the induced sputum total cell counts, and IL-8 and TNF-alpha levels decreased significantly in the clarithromycin group compared with pretreatment levels (mean +/- SD IL-8 1606 +/- 367.3 vs 882 +/- 143.6 pg/mL, p = 0.001; TNF-alpha 638.2 +/- 287.5 vs 390 +/- 235 pg/mL, p = 0.001).	Clarithromycin	120-134	tumor necrosis factor	Homo sapiens	72-81
15252191-9	2004	After the treatment, the induced sputum total cell counts, and IL-8 and TNF-alpha levels decreased significantly in the clarithromycin group compared with pretreatment levels (mean +/- SD IL-8 1606 +/- 367.3 vs 882 +/- 143.6 pg/mL, p = 0.001; TNF-alpha 638.2 +/- 287.5 vs 390 +/- 235 pg/mL, p = 0.001).	Clarithromycin	120-134	C-X-C motif chemokine ligand 8	Homo sapiens	188-192
15252191-9	2004	After the treatment, the induced sputum total cell counts, and IL-8 and TNF-alpha levels decreased significantly in the clarithromycin group compared with pretreatment levels (mean +/- SD IL-8 1606 +/- 367.3 vs 882 +/- 143.6 pg/mL, p = 0.001; TNF-alpha 638.2 +/- 287.5 vs 390 +/- 235 pg/mL, p = 0.001).	Clarithromycin	120-134	tumor necrosis factor	Homo sapiens	243-252
15252191-11	2004	CONCLUSIONS: This study demonstrated that the decrease in IL-8 and TNF-alpha levels might be related to the antiinflammatory effect of clarithromycin.	Clarithromycin	135-149	C-X-C motif chemokine ligand 8	Homo sapiens	58-62
15252191-11	2004	CONCLUSIONS: This study demonstrated that the decrease in IL-8 and TNF-alpha levels might be related to the antiinflammatory effect of clarithromycin.	Clarithromycin	135-149	tumor necrosis factor	Homo sapiens	67-76
15334627-2	2004	This indicated that clarithromycin was metabolized via CYP3A1/2 in rats.	Clarithromycin	20-34	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	55-61
15334627-6	2004	The 9000 x g supernatant fraction of liver homogenates in rats with U-ARF had comparable metabolic activities for clarithromycin compared with those in control rats, suggesting that the CYP3A isozyme responsible for metabolism of clarithromycin seemed not to be expressed considerably in the rats.	Clarithromycin	230-244	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	186-191
15325428-3	2004	Lymphocytes treated with clarithromycin, azithromycin and josamycin at a final concentration of 200 microg/ml showed positive staining for Annexin V, Fas and Fas ligand using flow cytometry with time at 12-72 h, while other antibiotics did not.	Clarithromycin	25-39	annexin A5	Homo sapiens	139-148
15325428-3	2004	Lymphocytes treated with clarithromycin, azithromycin and josamycin at a final concentration of 200 microg/ml showed positive staining for Annexin V, Fas and Fas ligand using flow cytometry with time at 12-72 h, while other antibiotics did not.	Clarithromycin	25-39	Fas ligand	Homo sapiens	158-168
15058617-4	2004	RESULTS: The antibiotics erythromycin and clarithromycin are potent inhibitors of CYP3A4 and can increase blood levels and toxicity of CYP3A4 substrates.	Clarithromycin	42-56	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-88
15336223-5	2004	Prophylaxis with azithromycin or clarithromycin is recommended for all patients with CD4 counts less than 50 cells/mL.	Clarithromycin	33-47	CD4 molecule	Homo sapiens	85-88
15211799-5	2004	RESULTS: It was shown that the supplement of CLA could decrease decreased blood glucose, serum triglyceride, cholesterol and leptin levels, and increased the expression of PPAR gamma in white adipose tissue of obese rat.	Clarithromycin	45-48	leptin	Rattus norvegicus	125-131
15211799-5	2004	RESULTS: It was shown that the supplement of CLA could decrease decreased blood glucose, serum triglyceride, cholesterol and leptin levels, and increased the expression of PPAR gamma in white adipose tissue of obese rat.	Clarithromycin	45-48	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	172-182
15211799-6	2004	CONCLUSION: CLA could decrease blood glucose, serum lipids, and decrease the levels of leptin possibly via activating peroxisome proliferator--activated receptor gamma (PPAR gamma), resulting in the improvement of leptin resistance of obese rat.	Clarithromycin	12-15	leptin	Rattus norvegicus	87-93
15211799-6	2004	CONCLUSION: CLA could decrease blood glucose, serum lipids, and decrease the levels of leptin possibly via activating peroxisome proliferator--activated receptor gamma (PPAR gamma), resulting in the improvement of leptin resistance of obese rat.	Clarithromycin	12-15	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	118-167
15211799-6	2004	CONCLUSION: CLA could decrease blood glucose, serum lipids, and decrease the levels of leptin possibly via activating peroxisome proliferator--activated receptor gamma (PPAR gamma), resulting in the improvement of leptin resistance of obese rat.	Clarithromycin	12-15	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	169-179
15211799-6	2004	CONCLUSION: CLA could decrease blood glucose, serum lipids, and decrease the levels of leptin possibly via activating peroxisome proliferator--activated receptor gamma (PPAR gamma), resulting in the improvement of leptin resistance of obese rat.	Clarithromycin	12-15	leptin	Rattus norvegicus	214-220
14551160-7	2004	On the other hand, pretreatment of TNF-alpha-stimulated A549 cells by erythromycin, clarithromycin, azithromycin, or dexamethasone, but not josamycin, decreased the neutrophil survival-enhancing effects in a dose-dependent manner.	Clarithromycin	84-98	tumor necrosis factor	Homo sapiens	35-44
14551160-9	2004	Erythromycin, clarithromycin, azithromycin, and dexamethasone inhibited TNF-alpha-induced GM-CSF expression in A549 cells at both the protein and messenger RNA levels.	Clarithromycin	14-28	tumor necrosis factor	Homo sapiens	72-81
14551160-9	2004	Erythromycin, clarithromycin, azithromycin, and dexamethasone inhibited TNF-alpha-induced GM-CSF expression in A549 cells at both the protein and messenger RNA levels.	Clarithromycin	14-28	colony stimulating factor 2	Homo sapiens	90-96
15203552-14	2004	CONCLUSIONS: The beneficial effect of the prolonged treatment of CF patients with a 14-membered ring macrolide antibiotic clarithromycin seems to be associated not only with down-regulation of the inflammatory response, but also with immunological changes including the switch from Th2 to Th1 type response.	Clarithromycin	122-136	negative elongation factor complex member C/D	Homo sapiens	289-292
15058617-4	2004	RESULTS: The antibiotics erythromycin and clarithromycin are potent inhibitors of CYP3A4 and can increase blood levels and toxicity of CYP3A4 substrates.	Clarithromycin	42-56	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	135-141
15038091-2	2004	Two proton pump inhibitor(PPI)-based triple therapy, combining with clarithromycin(CAM), amoxicillin(AMPC) or metronidazole have been established as standard regimens worldwide.	Clarithromycin	68-82	calmodulin 3	Homo sapiens	83-86
14755204-0	2004	Effect of clarithromycin on nuclear factor-kappa B and transforming growth factor-beta in chronic rhinosinusitis.	Clarithromycin	10-24	transforming growth factor beta 1	Homo sapiens	55-86
15078004-0	2004	Effect of multiple doses of clarithromycin and amoxicillin on IL-6, IFNgamma and IL-10 plasma levels in patients with community acquired pneumonia.	Clarithromycin	28-42	interleukin 6	Homo sapiens	62-66
15078004-0	2004	Effect of multiple doses of clarithromycin and amoxicillin on IL-6, IFNgamma and IL-10 plasma levels in patients with community acquired pneumonia.	Clarithromycin	28-42	interferon gamma	Homo sapiens	68-76
15078004-0	2004	Effect of multiple doses of clarithromycin and amoxicillin on IL-6, IFNgamma and IL-10 plasma levels in patients with community acquired pneumonia.	Clarithromycin	28-42	interleukin 10	Homo sapiens	81-86
15078004-7	2004	Clarithromycin significantly decreased plasma levels of IL-6 and significantly increased those of IFNgamma and IL-10 at the 3rd and 7th day in comparison to basal levels.	Clarithromycin	0-14	interleukin 6	Homo sapiens	56-60
15078004-7	2004	Clarithromycin significantly decreased plasma levels of IL-6 and significantly increased those of IFNgamma and IL-10 at the 3rd and 7th day in comparison to basal levels.	Clarithromycin	0-14	interferon gamma	Homo sapiens	98-106
15078004-7	2004	Clarithromycin significantly decreased plasma levels of IL-6 and significantly increased those of IFNgamma and IL-10 at the 3rd and 7th day in comparison to basal levels.	Clarithromycin	0-14	interleukin 10	Homo sapiens	111-116
14687228-14	2004	Clarithromycin and ofloxacin slightly decreased the protein expression of integrin beta4.	Clarithromycin	0-14	integrin subunit beta 4	Homo sapiens	74-88
14755204-3	2004	In this study, the effect of clarithromycin treatment on the expression of transforming growth factor (TGF)-beta and the key pro-inflammatory nuclear transcription factor, NF-kappa B, was examined in vitro and in vivo.	Clarithromycin	29-43	transforming growth factor beta 1	Homo sapiens	75-112
14755204-3	2004	In this study, the effect of clarithromycin treatment on the expression of transforming growth factor (TGF)-beta and the key pro-inflammatory nuclear transcription factor, NF-kappa B, was examined in vitro and in vivo.	Clarithromycin	29-43	nuclear factor kappa B subunit 1	Homo sapiens	172-182
14755204-9	2004	RESULTS: Clarithromycin, when applied to nasal biopsies in vitro, reduced cellular expression of TGF-beta and NF-kappa B.	Clarithromycin	9-23	transforming growth factor beta 1	Homo sapiens	97-105
14755204-9	2004	RESULTS: Clarithromycin, when applied to nasal biopsies in vitro, reduced cellular expression of TGF-beta and NF-kappa B.	Clarithromycin	9-23	nuclear factor kappa B subunit 1	Homo sapiens	110-120
14755204-11	2004	CONCLUSION: Clarithromycin can reduce cellular expression of TGF-beta and NF-kappa B when applied in vitro, but its action during clinical therapy is less clear.	Clarithromycin	12-26	transforming growth factor beta 1	Homo sapiens	61-69
14755204-11	2004	CONCLUSION: Clarithromycin can reduce cellular expression of TGF-beta and NF-kappa B when applied in vitro, but its action during clinical therapy is less clear.	Clarithromycin	12-26	nuclear factor kappa B subunit 1	Homo sapiens	74-84
14674677-0	2003	Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel.	Clarithromycin	63-77	potassium voltage-gated channel subfamily H member 2	Homo sapiens	85-89
15017629-3	2004	The aim of this study was to investigate whether IL-1beta polymorphism is associated with eradication rates of H. pylori by triple therapy with a proton pump inhibitor (PPI), amoxicillin, and clarithromycin.	Clarithromycin	192-206	interleukin 1 beta	Homo sapiens	49-57
15017629-8	2004	CONCLUSIONS: IL-1beta-511 polymorphism is one of the determinants of successful eradication of H. pylori using triple therapy with a PPI, amoxicillin, and clarithromycin, together with CYP2C19 genotype and bacterial resistance to clarithromycin.	Clarithromycin	155-169	interleukin 1 beta	Homo sapiens	13-21
15017629-8	2004	CONCLUSIONS: IL-1beta-511 polymorphism is one of the determinants of successful eradication of H. pylori using triple therapy with a PPI, amoxicillin, and clarithromycin, together with CYP2C19 genotype and bacterial resistance to clarithromycin.	Clarithromycin	230-244	interleukin 1 beta	Homo sapiens	13-21
24936100-14	2004	CONCLUSIONS: In this pilot study of patients with corticosteroid-dependent asthma, 6-week clarithromycin 500 mg BID was clinically effective in allowing a reduction in prednisone dosage, without worsening pulmonary function, QOL, or asthmatic symptoms.	Clarithromycin	90-104	BH3 interacting domain death agonist	Homo sapiens	112-115
14715050-10	2004	Drug interactions related to the CYP3A4 pathway were generally less severe, and involved high-potency antipsychotics coadministered with inhibitors such as clarithromycin.	Clarithromycin	156-170	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	33-39
14674677-7	2003	The results of this study document that both erythromycin and clarithromycin significantly inhibit the HERG potassium current at clinically relevant concentrations.	Clarithromycin	62-76	potassium voltage-gated channel subfamily H member 2	Homo sapiens	103-107
14570755-9	2003	When a macrolide antibiotic, clarithromycin, was administered to a healthy volunteer in a dose of 200 mg every 12 h for 6 days, the inhibitory effects of clarithromycin on the in vivo CYP3A activity were clearly seen by the 6beta-hydroxylation clearance of endogenous cortisol but not by the urinary ratio 6beta-OHF/F.	Clarithromycin	29-43	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	184-189
14600366-4	2003	The CPA values for channel 3 of the sensor predicted well the bitterness of clarithromycin powder suspensions and their filtered solutions.	Clarithromycin	76-90	carboxypeptidase A1	Homo sapiens	4-7
14570755-9	2003	When a macrolide antibiotic, clarithromycin, was administered to a healthy volunteer in a dose of 200 mg every 12 h for 6 days, the inhibitory effects of clarithromycin on the in vivo CYP3A activity were clearly seen by the 6beta-hydroxylation clearance of endogenous cortisol but not by the urinary ratio 6beta-OHF/F.	Clarithromycin	154-168	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	184-189
12897563-4	2003	Further, the effects of clarithromycin, a 14-member ring macrolide, on IL-8 gene expression and nuclear factor-kappa B (NF-kappa B) activation in adenoidal fibroblasts were evaluated.	Clarithromycin	24-38	C-X-C motif chemokine ligand 8	Homo sapiens	71-75
12960287-3	2003	The clinical range of macrolides (i.e., erythromycin, roxithromycin, and clarithromycin) preferentially inhibited nuclear factor-kappaB activation mediated by reactive oxygen intermediates, inducing cAMP-dependent signaling [i.e., cAMP and cAMP-responsive element-binding protein (CREB)] by "primed" but not "resting" leukocytes.	Clarithromycin	73-87	cAMP responsive element binding protein 1	Homo sapiens	240-279
12960287-3	2003	The clinical range of macrolides (i.e., erythromycin, roxithromycin, and clarithromycin) preferentially inhibited nuclear factor-kappaB activation mediated by reactive oxygen intermediates, inducing cAMP-dependent signaling [i.e., cAMP and cAMP-responsive element-binding protein (CREB)] by "primed" but not "resting" leukocytes.	Clarithromycin	73-87	cAMP responsive element binding protein 1	Homo sapiens	281-285
12818892-0	2003	Clarithromycin inhibits overproduction of muc5ac core protein in murine model of diffuse panbronchiolitis.	Clarithromycin	0-14	mucin 5, subtypes A and C, tracheobronchial/gastric	Mus musculus	42-48
12888117-8	2003	The above data suggested that metabolism of clarithromycin decreased significantly in rats with PCM as compared to control due to significantly decreased level of CYP3A23 in the rats.	Clarithromycin	44-58	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	163-170
12888117-9	2003	By cysteine supplementation (rats with PCMC), some pharmacokinetic parameters of clarithromycin (AUC, CL, CL(NR) and V(max)) were restored fully to control levels because CYP3A23 level was completely returned to control level in rats with PCMC.	Clarithromycin	81-95	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	171-178
12932253-0	2003	Panniculitis secondary to extravasation of clarithromycin in a patient with alpha 1-antitrypsin deficiency (phenotype PiZ).	Clarithromycin	43-57	serpin family A member 1	Homo sapiens	76-95
12897563-11	2003	Treatment of cells with the NF-kappa B inhibitor N-tosyl-(L)-phenylalanine chloromethyl ketone, as well as with clarithromycin, reduced expression of IL-8 and NF-kappa B activity in a dose-dependent manner.	Clarithromycin	112-126	nuclear factor kappa B subunit 1	Homo sapiens	28-38
12897563-11	2003	Treatment of cells with the NF-kappa B inhibitor N-tosyl-(L)-phenylalanine chloromethyl ketone, as well as with clarithromycin, reduced expression of IL-8 and NF-kappa B activity in a dose-dependent manner.	Clarithromycin	112-126	C-X-C motif chemokine ligand 8	Homo sapiens	150-154
12897563-11	2003	Treatment of cells with the NF-kappa B inhibitor N-tosyl-(L)-phenylalanine chloromethyl ketone, as well as with clarithromycin, reduced expression of IL-8 and NF-kappa B activity in a dose-dependent manner.	Clarithromycin	112-126	nuclear factor kappa B subunit 1	Homo sapiens	159-169
12897563-13	2003	The inhibitory effects of clarithromycin on NF-kappa B activation and IL-8 production in adenoidal fibroblasts might explain, in part, the mechanism of this drug in improving otitis media with effusion.	Clarithromycin	26-40	nuclear factor kappa B subunit 1	Homo sapiens	44-54
12897563-13	2003	The inhibitory effects of clarithromycin on NF-kappa B activation and IL-8 production in adenoidal fibroblasts might explain, in part, the mechanism of this drug in improving otitis media with effusion.	Clarithromycin	26-40	C-X-C motif chemokine ligand 8	Homo sapiens	70-74
12586018-10	2003	CagA protein was more frequent in patients with clarithromycin-sensitive strains (p < 0.001).	Clarithromycin	48-62	S100 calcium binding protein A8	Homo sapiens	0-4
12848773-6	2003	RESULTS: Oral coadministration of clarithromycin resulted in a 1.7-fold increase of the area under the digoxin plasma concentration-time curve [mean AUC(0,24) +/- SD 23 +/- 5.2 vs. 14 +/- 2.9 microg x L(-1) x h; 95% confidence interval (CI) on the difference 7.0, 12; P = 0.002] and in a reduction of the nonglomerular renal clearance of digoxin [mean ClRng(0, 24) +/- SD 34 +/- 39 vs. 57 +/- 41 mL min-1; 95% CI on the difference 7.2, 45; P = 0.03].	Clarithromycin	34-48	CD59 molecule (CD59 blood group)	Homo sapiens	399-404
12828861-3	2003	However, individuals who carry the Q9E-hMiRP1 variant are predisposed to developing the LQTS only after clarithromycin administration.	Clarithromycin	104-118	potassium voltage-gated channel subfamily E regulatory subunit 2	Homo sapiens	39-45
12828861-6	2003	Furthermore, the possible use of clarithromycin to control the conduction effects of overexpressed Q9E-hMiRP1 pharmacologically was another attractive feature.	Clarithromycin	33-47	potassium voltage-gated channel subfamily E regulatory subunit 2	Homo sapiens	103-109
12828861-10	2003	Patchclamp studies demonstrated that cells transfected with Q9E-hMiRP1 plasmid DNA exhibited significantly reduced potassium currents but only with clarithromycin administration.	Clarithromycin	148-162	potassium voltage-gated channel subfamily E regulatory subunit 2	Homo sapiens	64-70
12776812-11	2003	CONCLUSIONS: Our case and the previous case suggest that HSP may represent a potential adverse effect of clarithromycin, clinicians should be alerted to this potentially severe side effect of such a widely used drug.	Clarithromycin	105-119	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	57-60
14679759-0	2003	[Suppressive mechanism of clarithromycin on lipopolysaccharide-induced IL-8 production in human monocytes by mediating AP-1 and NF-kappaB].	Clarithromycin	26-40	C-X-C motif chemokine ligand 8	Homo sapiens	71-75
15618724-0	2003	CYP isoforms involved in the metabolism of clarithromycin in vitro: comparison between the identification from disappearance rate and that from formation rate of metabolites.	Clarithromycin	43-57	peptidylprolyl isomerase G	Homo sapiens	0-3
12949438-6	2003	Serious cases by coadministration of CYP3A inhibitors resulting in acute hepatitis, hypotension, rhabdomyolyis, torsade de pointes, sedation, or ergotism are presented: interactions with azole antifungals (ketoconazole, itraconazole, fluconazole), HIV protease inhibitors (ritonavir, indinavir, saquinavir, nelfinavir), macrolide antibiotics (clarithromycin, erythromycin), and grapefruit juice.	Clarithromycin	343-357	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	37-42
15618724-1	2003	To clarify whether CYP2C19 is involved in the overall metabolism of clarithromycin (CAM) or not, in vitro studies using human liver microsomes and recombinant CYPs were performed by an approach based on the disappearance rate of parent compound from the incubation mixture.	Clarithromycin	68-82	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	19-26
15618724-1	2003	To clarify whether CYP2C19 is involved in the overall metabolism of clarithromycin (CAM) or not, in vitro studies using human liver microsomes and recombinant CYPs were performed by an approach based on the disappearance rate of parent compound from the incubation mixture.	Clarithromycin	84-87	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	19-26
15618724-4	2003	The CL(int) of CAM was markedly reduced by selective inhibitors of CYP3A4 (ketoconazole and troleandomycin) and by polyclonal antibodies raised against CYP3A4/5 in human liver microsomes.	Clarithromycin	15-18	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	67-73
15618724-4	2003	The CL(int) of CAM was markedly reduced by selective inhibitors of CYP3A4 (ketoconazole and troleandomycin) and by polyclonal antibodies raised against CYP3A4/5 in human liver microsomes.	Clarithromycin	15-18	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	152-160
15618724-5	2003	Among the 11 isoforms of recombinant human CYP, only CYP3A4 revealed the metabolic activity for the disappearance of CAM.	Clarithromycin	117-120	peptidylprolyl isomerase G	Homo sapiens	43-46
15618724-5	2003	Among the 11 isoforms of recombinant human CYP, only CYP3A4 revealed the metabolic activity for the disappearance of CAM.	Clarithromycin	117-120	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	53-59
15618724-8	2003	The findings suggest that CYP3A4 plays a predominant role in the overall metabolic clearance of CAM as well as in the formation of 14-(R)-hydroxy-CAM and N-demethyl-CAM.	Clarithromycin	96-99	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	26-32
12583550-9	2002	On the contrary, results with both animal models demonstrate that bacterial killing and survival are significantly higher among clarithromycin-treated mice when the antibiotic is administered less frequently and the highest Cmax/MIC ratio is achieved.	Clarithromycin	128-142	microphthalmia Japan	Mus musculus	229-232
12200967-8	2002	The effect of the antibiotics on the mRNA expression of alkaline phosphatase (ALP) and type I procollagen (COL) was examined in Pel cells exposed for 48 h to RXM, CAM, AZM, and EM, which exhibited strong, moderate, and weak cytocidal activity.	Clarithromycin	163-166	alkaline phosphatase, placental	Homo sapiens	56-76
12390102-5	2002	In addition, the eradication rates for clarithromycin-sensitive strains with RAC and LAC were 98% and 89%, respectively, and for clarithromycin-resistant strains with RAC and LAC were 8.1% and 0%, respectively.	Clarithromycin	39-53	AKT serine/threonine kinase 1	Homo sapiens	77-80
12390102-5	2002	In addition, the eradication rates for clarithromycin-sensitive strains with RAC and LAC were 98% and 89%, respectively, and for clarithromycin-resistant strains with RAC and LAC were 8.1% and 0%, respectively.	Clarithromycin	129-143	AKT serine/threonine kinase 1	Homo sapiens	167-170
12368623-7	2002	RESULTS: Clarithromycin and prednisolone each produced significant reductions in interleukin-5, interleukin-8, and granulocyte-macrophage colony-stimulating factor production.	Clarithromycin	9-23	interleukin 5	Homo sapiens	81-94
12368623-7	2002	RESULTS: Clarithromycin and prednisolone each produced significant reductions in interleukin-5, interleukin-8, and granulocyte-macrophage colony-stimulating factor production.	Clarithromycin	9-23	C-X-C motif chemokine ligand 8	Homo sapiens	96-109
12368623-7	2002	RESULTS: Clarithromycin and prednisolone each produced significant reductions in interleukin-5, interleukin-8, and granulocyte-macrophage colony-stimulating factor production.	Clarithromycin	9-23	colony stimulating factor 2	Homo sapiens	115-163
12124305-10	2002	The clearance values for CYP3A7-catalyzed metabolite formation at low substrate concentrations were substantially lower than for CYP3A4 or CYP3A5, except for clarithromycin, 4-OH triazolam, and N-desmethyl diltiazem (CYP3A5 - CYP3A7).	Clarithromycin	158-172	cytochrome P450 family 3 subfamily A member 7	Homo sapiens	25-31
12167449-1	2002	To elucidate the mechanisms involved in the action of new macrolides on chronic sinusitis, we examined the effects of clarithromycin (CAM) and roxiythromycin (RXM) on the expression of adhesion molecules (L-selectin and Mac-1) on peripheral blood neutrophils of individuals with chronic sinusitis.	Clarithromycin	118-132	selectin L	Homo sapiens	205-215
12167449-4	2002	These observations suggest that the new macrolides such as CAM and RXM may affect the functions of neutrophils in chronic sinusitis by modulating the expression of L-selectin and Mac-1 molecules on neutrophils, thereby attenuating the adhesion of neutrophils.	Clarithromycin	59-62	selectin L	Homo sapiens	164-174
12167449-4	2002	These observations suggest that the new macrolides such as CAM and RXM may affect the functions of neutrophils in chronic sinusitis by modulating the expression of L-selectin and Mac-1 molecules on neutrophils, thereby attenuating the adhesion of neutrophils.	Clarithromycin	59-62	integrin subunit alpha M	Homo sapiens	179-184
12065733-6	2002	Mechanistic studies showed that inhibition of HERG current by clarithromycin did not require activation of the channel and was both voltage- and time-dependent.	Clarithromycin	62-76	potassium voltage-gated channel subfamily H member 2	Homo sapiens	46-50
12096007-6	2002	Lung weight and protein concentration in bronchoalveolar lavage fluid (BALF) were significantly higher in the clarithromycin group between 3 and 9 h. Moreover, we detected higher levels of tumour necrosis factor-alpha (TNF-alpha) and nitric oxide (NO) in the BALF of these mice.	Clarithromycin	110-124	tumor necrosis factor	Mus musculus	219-228
12019067-6	2002	ErmN monomethylation predictably confers high resistance to the lincosamides clindamycin and lincomycin, intermediate resistance to the macrolides clarithromycin and erythromycin, and low resistance to the streptogramin B pristinamycin IA.	Clarithromycin	147-161	ermin	Homo sapiens	0-4
12065339-12	2002	However, the PCR-positive subjects who received clarithromycin demonstrated a reduction in TNF-alpha (p = 0.006), IL-5 (p = 0.007), and IL-12 (p = 0.004) mRNA in BAL and TNF-alpha mRNA in airway tissue (p = 0.0009).	Clarithromycin	48-62	tumor necrosis factor	Homo sapiens	91-100
12003967-0	2002	Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors.	Clarithromycin	0-14	C-X-C motif chemokine ligand 8	Homo sapiens	53-66
12065339-12	2002	However, the PCR-positive subjects who received clarithromycin demonstrated a reduction in TNF-alpha (p = 0.006), IL-5 (p = 0.007), and IL-12 (p = 0.004) mRNA in BAL and TNF-alpha mRNA in airway tissue (p = 0.0009).	Clarithromycin	48-62	interleukin 5	Homo sapiens	114-118
12065339-12	2002	However, the PCR-positive subjects who received clarithromycin demonstrated a reduction in TNF-alpha (p = 0.006), IL-5 (p = 0.007), and IL-12 (p = 0.004) mRNA in BAL and TNF-alpha mRNA in airway tissue (p = 0.0009).	Clarithromycin	48-62	tumor necrosis factor	Homo sapiens	170-179
12065339-13	2002	The PCR-negative subjects who received clarithromycin only demonstrated a reduction in TNF-alpha (p = 0.01) and IL-12 (p = 0.002) mRNA in BAL and TNF-alpha mRNA in airway tissue (p = 0.004).	Clarithromycin	39-53	tumor necrosis factor	Homo sapiens	87-96
12065339-13	2002	The PCR-negative subjects who received clarithromycin only demonstrated a reduction in TNF-alpha (p = 0.01) and IL-12 (p = 0.002) mRNA in BAL and TNF-alpha mRNA in airway tissue (p = 0.004).	Clarithromycin	39-53	tumor necrosis factor	Homo sapiens	146-155
12003967-0	2002	Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors.	Clarithromycin	0-14	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	105-109
12003967-0	2002	Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors.	Clarithromycin	0-14	nuclear factor kappa B subunit 1	Homo sapiens	114-124
12003967-5	2002	Clarithromycin suppressed this production in a dose-dependent manner in both monocytes and THP-1 cells (49.3-75.0% inhibition at 10 mg/L).	Clarithromycin	0-14	GLI family zinc finger 2	Homo sapiens	91-96
12003967-6	2002	A luciferase reporter gene assay with plasmids containing a serially deleted IL-8 promoter fragment showed that both the activator protein-1 (AP-1) and/or the nuclear factor-kappa B (NF-kapp aB) binding sequences were responsible for the LPS and clarithromycin responsiveness of the IL-8 promoter.	Clarithromycin	246-260	C-X-C motif chemokine ligand 8	Homo sapiens	77-81
12003967-6	2002	A luciferase reporter gene assay with plasmids containing a serially deleted IL-8 promoter fragment showed that both the activator protein-1 (AP-1) and/or the nuclear factor-kappa B (NF-kapp aB) binding sequences were responsible for the LPS and clarithromycin responsiveness of the IL-8 promoter.	Clarithromycin	246-260	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	121-140
12003967-6	2002	A luciferase reporter gene assay with plasmids containing a serially deleted IL-8 promoter fragment showed that both the activator protein-1 (AP-1) and/or the nuclear factor-kappa B (NF-kapp aB) binding sequences were responsible for the LPS and clarithromycin responsiveness of the IL-8 promoter.	Clarithromycin	246-260	nuclear factor kappa B subunit 1	Homo sapiens	159-181
12003967-6	2002	A luciferase reporter gene assay with plasmids containing a serially deleted IL-8 promoter fragment showed that both the activator protein-1 (AP-1) and/or the nuclear factor-kappa B (NF-kapp aB) binding sequences were responsible for the LPS and clarithromycin responsiveness of the IL-8 promoter.	Clarithromycin	246-260	nuclear factor kappa B subunit 1	Homo sapiens	183-193
12003967-8	2002	Moreover, LPS and clarithromycin regulated three other promoters that have either the NF-kappa B or the AP-1 binding sequences: two synthetic (pAP-1-Luc and pNF-kappa B-Luc) and one naturally occurring (ELAM-Luc).	Clarithromycin	18-32	nuclear factor kappa B subunit 1	Homo sapiens	86-96
12003967-8	2002	Moreover, LPS and clarithromycin regulated three other promoters that have either the NF-kappa B or the AP-1 binding sequences: two synthetic (pAP-1-Luc and pNF-kappa B-Luc) and one naturally occurring (ELAM-Luc).	Clarithromycin	18-32	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	104-108
12003967-8	2002	Moreover, LPS and clarithromycin regulated three other promoters that have either the NF-kappa B or the AP-1 binding sequences: two synthetic (pAP-1-Luc and pNF-kappa B-Luc) and one naturally occurring (ELAM-Luc).	Clarithromycin	18-32	PDGFA associated protein 1	Homo sapiens	143-148
12003967-9	2002	Our results indicate that clarithromycin modified inflammation by sup-pressing IL-8 production and that clarithromycin may affect the expression of other genes through AP-1 and NF-kappa B.	Clarithromycin	26-40	C-X-C motif chemokine ligand 8	Homo sapiens	79-83
12003967-9	2002	Our results indicate that clarithromycin modified inflammation by sup-pressing IL-8 production and that clarithromycin may affect the expression of other genes through AP-1 and NF-kappa B.	Clarithromycin	104-118	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	168-172
11979867-0	2002	[Clarithromycin (CAM)].	Clarithromycin	1-15	calmodulin 3	Homo sapiens	17-20
12003337-7	2002	In experiment 1, giving CLA prevented an increase in blood heterophil to lymphocyte ratio 7 h after a single injection of LPS, and increases in plasma ceruloplasmin and alpha 1 acid glycoprotein (AGP) 24 h after the injection, but not 7 h after the injection.	Clarithromycin	24-27	ceruloplasmin	Gallus gallus	151-164
12003337-7	2002	In experiment 1, giving CLA prevented an increase in blood heterophil to lymphocyte ratio 7 h after a single injection of LPS, and increases in plasma ceruloplasmin and alpha 1 acid glycoprotein (AGP) 24 h after the injection, but not 7 h after the injection.	Clarithromycin	24-27	orosomucoid 1 (ovoglycoprotein)	Gallus gallus	169-194
12619516-1	2002	The results of the treatment of community-acquired pneumonia with clarithromycin (500 mg bid for 6-8 days) at 172 patients (military recruits aged 18-25) are presented.	Clarithromycin	66-80	BH3 interacting domain death agonist	Homo sapiens	89-92
11814768-1	2002	The effect of the macrolide antibiotics, clarithromycin, midecamycin acetate and josamycin, on the generation of Th1- and Th2-type cytokines by mitogen-stimulated human T lymphocytes was compared with that of fosfomycin.	Clarithromycin	41-55	negative elongation factor complex member C/D	Homo sapiens	113-116
11742432-1	2001	Clarithromycin 500 mg po bid or azithromycin 1200 mg po weekly is recommended as first line prophylaxis for Mycobacterium avium complex (MAC) in patients with HIV infection whose CD4 counts are <50 cells/microL.	Clarithromycin	0-14	CD4 molecule	Homo sapiens	179-182
11808341-6	2002	The ATP-driven efflux pump P-glycoprotein appeared to be an interaction site between digoxin and clarithromycin or itraconazole in the kidney.	Clarithromycin	97-111	ATP binding cassette subfamily B member 1	Homo sapiens	27-41
11786660-8	2001	After 3 months of CAM treatment, serum levels of IL-6 significantly decreased.	Clarithromycin	18-21	interleukin 6	Homo sapiens	49-53
11786660-11	2001	Furthermore, CAM-treated patients whose serum IL-6 levels were decreased after 3 months of treatment survived longer: there was a statistically significant correlation between the decrease in serum IL-6 and survival time.	Clarithromycin	13-16	interleukin 6	Homo sapiens	46-50
11786660-11	2001	Furthermore, CAM-treated patients whose serum IL-6 levels were decreased after 3 months of treatment survived longer: there was a statistically significant correlation between the decrease in serum IL-6 and survival time.	Clarithromycin	13-16	interleukin 6	Homo sapiens	198-202
11709199-0	2001	Up-regulation by clarithromycin of alpha(1)-acid glycoprotein expression in liver and primary cultured hepatocytes.	Clarithromycin	17-31	orosomucoid 1	Rattus norvegicus	35-61
11709199-7	2001	Of these five, clarithromycin (CAM) was the most potent inducer of AGP, which reached a maximum level between 3 to 7 days after administration.	Clarithromycin	15-29	orosomucoid 1	Rattus norvegicus	67-70
11709199-7	2001	Of these five, clarithromycin (CAM) was the most potent inducer of AGP, which reached a maximum level between 3 to 7 days after administration.	Clarithromycin	31-34	orosomucoid 1	Rattus norvegicus	67-70
11709199-8	2001	CAM increased the steady-state level of AGP mRNA in liver as well as protein level in serum in a dose-dependent manner.	Clarithromycin	0-3	orosomucoid 1	Rattus norvegicus	40-43
11709199-9	2001	In addition, CAM increased AGP mRNA levels in primary cultured hepatocytes.	Clarithromycin	13-16	orosomucoid 1	Rattus norvegicus	27-30
11709199-10	2001	In the luciferase promoter assay, CAM potentiated dexamethasone-increased promoter activity of the AGP gene, which contained the glucocorticoid response element, in cultured rat hepatocytes, although CAM itself had no effect on its activity.	Clarithromycin	34-37	orosomucoid 1	Rattus norvegicus	99-102
11709199-14	2001	These findings suggest that CAM may cause transcriptional induction of AGP, at least in part, via a glucocorticoid-mediated mechanism.	Clarithromycin	28-31	orosomucoid 1	Rattus norvegicus	71-74
11836874-6	2001	The concomitant use of statins with drugs that inhibit CYP3A4 (cyclosporin, erythromycin, clarithromycin, itraconazole, and ketoconazole), may result in increased plasma concentrations of HMG-CoA reductase inhibitors leading occasionally to myotoxicity.	Clarithromycin	90-104	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	55-61
11759110-0	2001	Erythromycin and clarithromycin modulation of growth factor-induced expression of heparanase mRNA on human lung cancer cells in vitro.	Clarithromycin	17-31	heparanase	Homo sapiens	82-92
11759110-5	2001	In addition, we examined the effect of erythromycin (EM) and clarithromycin (CAM), which are 14-membered ring macrolide antibiotics that act as biological response modifiers, on the expression of heparanase mRNA induced by growth factors.	Clarithromycin	61-75	heparanase	Homo sapiens	196-206
11759110-5	2001	In addition, we examined the effect of erythromycin (EM) and clarithromycin (CAM), which are 14-membered ring macrolide antibiotics that act as biological response modifiers, on the expression of heparanase mRNA induced by growth factors.	Clarithromycin	77-80	heparanase	Homo sapiens	196-206
11408563-2	2001	In infected mice, CAM at 20 mg/mouse/day significantly elevated the levels of IL-12 and interferon-gamma on days 2 and 3, respectively, after infection in the bronchoalveolar lavage fluid (BALF), but the levels in the sera were not affected.	Clarithromycin	18-21	interferon gamma	Mus musculus	88-120
11481305-2	2001	Clarithromycin resistance (MIC 1 mg/L) was 2.27% (IC95 0.05-12.02) in 1991-1993, 20.98% (IC95 12.72-31.46) in 1994-1996 and 28.33% (IC95 20.48-37.28) in 1997-1999 (P < 0.01).	Clarithromycin	0-14	regulator of MON1-CCZ1	Homo sapiens	27-32
11678058-5	2001	A review of recent literature suggests that clarithromycin may induce digoxin toxicity by three different mechanisms, including reduction of renal excretion of digoxin, alteration of intestinal flora, and inhibition of cytochrome P-450 in the liver.	Clarithromycin	44-58	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	219-235
11502638-12	2001	Clarithromycin treatment in asthmatic patients could reduce the edematous area as identified by alpha(2)-macroglobulin staining, which may lead to airway tissue shrinkage and cause an artificial increase in the number of blood vessels.	Clarithromycin	0-14	alpha-2-macroglobulin	Homo sapiens	96-118
11408369-1	2001	The in vivo effects of oral clarithromycin administration on the in vivo activity of cytochrome P450 1A2, 2C9, and 2D6 were determined.	Clarithromycin	28-42	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	85-104
11408986-7	2001	This case indicates that levofloxacin and clarithromycin inhibited theophylline metabolic pathways catalyzed by both CYP1A2 and CYP3A4 and resulted in the decrease in theophylline clearance.	Clarithromycin	42-56	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	117-123
11408986-7	2001	This case indicates that levofloxacin and clarithromycin inhibited theophylline metabolic pathways catalyzed by both CYP1A2 and CYP3A4 and resulted in the decrease in theophylline clearance.	Clarithromycin	42-56	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	128-134
11115481-3	2000	Thus, the purpose of this case report is to describe the effects of prolonged treatment with clarithromycin, 500 mg bid, in reducing prednisone requirements in three elderly patients with prednisone-dependent asthma.	Clarithromycin	93-107	BH3 interacting domain death agonist	Homo sapiens	116-119
11354392-7	2001	Of the 124 patients treated with clarithromycin IR 250 mg BID, 98 (79.0%) achieved a clinical cure, and 120 (96.8%) achieved clinical success.	Clarithromycin	33-47	BH3 interacting domain death agonist	Homo sapiens	58-61
11197581-9	2001	DISCUSSION: Clarithromycin is a potent inhibitor of CYP3A4, the major enzyme responsible for simvastatin metabolism.	Clarithromycin	12-26	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	52-58
11482742-6	2001	Proton pump inhibitor (PPI)-based triple therapy regimens including clarithromycin, amoxicillin and/or nitroimidazoles are highly effective and well tolerated in elderly patients, particularly if therapy is of a short duration and low doses of both the PPI and clarithromycin are used.	Clarithromycin	68-82	ATPase H+/K+ transporting subunit alpha	Homo sapiens	0-11
11482742-6	2001	Proton pump inhibitor (PPI)-based triple therapy regimens including clarithromycin, amoxicillin and/or nitroimidazoles are highly effective and well tolerated in elderly patients, particularly if therapy is of a short duration and low doses of both the PPI and clarithromycin are used.	Clarithromycin	261-275	ATPase H+/K+ transporting subunit alpha	Homo sapiens	0-11
12760488-0	2001	Disposition and functions of clarithromycin in human THP-1 monocytes during stimulated and unstimulated conditions.	Clarithromycin	29-43	GLI family zinc finger 2	Homo sapiens	53-58
12760488-3	2001	Herein is a study with clarithromycin using human THP-1 monocytes, a phagocytic cell which has not been studied to date.	Clarithromycin	23-37	GLI family zinc finger 2	Homo sapiens	50-55
12760488-9	2001	Examination showed that initially clarithromycin treatment triggered the release of NO, H2O2, IL-1 and TNFalpha from the monocytes, known mediators of inflammation, but also mediators which cause bacterial cell death or apoptosis.	Clarithromycin	34-48	tumor necrosis factor	Homo sapiens	103-111
12760488-11	2001	Treatment from 2-4 hr with clarithromycin appeared to reverse this process in that the chemical mediator release was reduced along with the activities of hydrolytic enzymes, e.g. NAG and cathepsin D with no evidence of lipid peroxidation and protective SOD enzyme activity elevation.	Clarithromycin	27-41	NBAS subunit of NRZ tethering complex	Homo sapiens	179-182
12760488-11	2001	Treatment from 2-4 hr with clarithromycin appeared to reverse this process in that the chemical mediator release was reduced along with the activities of hydrolytic enzymes, e.g. NAG and cathepsin D with no evidence of lipid peroxidation and protective SOD enzyme activity elevation.	Clarithromycin	27-41	cathepsin D	Homo sapiens	187-198
12760488-13	2001	The normal bacterial static killing effects of clarithromycin was evident at 24 but not 2 hr in both extracellular free bacteria and those bacteria phagocytosed by the THP-1 monocytes.	Clarithromycin	47-61	GLI family zinc finger 2	Homo sapiens	168-173
11151867-8	2000	The 15% of patients in the combined studies with baseline clarithromycin resistance had significantly lower rates of eradication than those with susceptible strains (EAC: 45 vs. 89%; EC: 13 vs. 61%).	Clarithromycin	58-72	CYLD lysine 63 deubiquitinase	Homo sapiens	166-169
11284926-6	2000	The nature of the side-chain substituting the C11-C12 carbamate residue is responsible for enhancing the in vitro and in vivo activities in comparison with clarithromycin, for the pharmacodynamic and pharmacokinetic properties, for the intracellular features, and for tolerance.	Clarithromycin	156-170	RNA polymerase III subunit K	Homo sapiens	46-49
11389120-0	2001	The effect of azithromycin and clarithromycin on ex vivo interleukin-8 (IL-8) release from whole blood and IL-8 production by human alveolar macrophages.	Clarithromycin	31-45	C-X-C motif chemokine ligand 8	Homo sapiens	57-70
11389120-1	2001	We investigated the effects of azithromycin and clarithromycin, two antibiotics that possess a broad spectrum of antimicrobial activity (including antimycobacterial activity), on interleukin-8 (IL-8) release from human whole blood leucocytes and lung macrophages.	Clarithromycin	48-62	C-X-C motif chemokine ligand 8	Homo sapiens	179-192
11389120-1	2001	We investigated the effects of azithromycin and clarithromycin, two antibiotics that possess a broad spectrum of antimicrobial activity (including antimycobacterial activity), on interleukin-8 (IL-8) release from human whole blood leucocytes and lung macrophages.	Clarithromycin	48-62	C-X-C motif chemokine ligand 8	Homo sapiens	194-198
11389120-3	2001	Incubation of alveolar macrophages with different concentrations of azithromycin or clarithromycin modified IL-8 production: it increased at a drug concentration of 4 mg/L and decreased at concentration of 400 mg/L.	Clarithromycin	84-98	C-X-C motif chemokine ligand 8	Homo sapiens	108-112
11389120-4	2001	Our findings suggest that azithromycin and clarithromycin may alter IL-8 production, thus enhancing the clinical effectiveness of these antibiotics.	Clarithromycin	43-57	C-X-C motif chemokine ligand 8	Homo sapiens	68-72
11296180-9	2001	Treatment with clarithromycin combined with two or three other antibiotics, including ethambutol, rifampicin, ofloxacin, or ciprofloxacin, for at least 6 months resulted in a significant fall in plasma HBD-2 concentrations in responders, but not in nonresponders.	Clarithromycin	15-29	defensin beta 4A	Homo sapiens	202-207
11322176-7	2001	Both clarithromycin and itraconazole inhibit the CYP3A4 mediated formation of (S)-2",6"-pipecoloxylidide from ropivacaine.	Clarithromycin	5-19	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	49-55
11439889-0	2001	[Calcium dependent effect of clarithromycin on IL-8 production in cultured human epidermal cells].	Clarithromycin	29-43	C-X-C motif chemokine ligand 8	Homo sapiens	47-51
11120942-0	2001	Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells.	Clarithromycin	0-14	nuclear factor kappa B subunit 1	Homo sapiens	24-33
11120942-4	2001	Flow cytometry revealed that clarithromycin suppresses NF-kappaB activation induced by TNF-alpha in U-937 and Jurkat cells in a concentration-related manner.	Clarithromycin	29-43	nuclear factor kappa B subunit 1	Homo sapiens	55-64
11120942-4	2001	Flow cytometry revealed that clarithromycin suppresses NF-kappaB activation induced by TNF-alpha in U-937 and Jurkat cells in a concentration-related manner.	Clarithromycin	29-43	tumor necrosis factor	Homo sapiens	87-96
11120942-5	2001	Western blot analysis also demonstrated that clarithromycin inhibits NF-kappaB activation induced by TNF-alpha in U-937, Jurkat, and A549 cells and PBMC and by SEA in PBMC.	Clarithromycin	45-59	nuclear factor kappa B subunit 1	Homo sapiens	69-78
11120942-5	2001	Western blot analysis also demonstrated that clarithromycin inhibits NF-kappaB activation induced by TNF-alpha in U-937, Jurkat, and A549 cells and PBMC and by SEA in PBMC.	Clarithromycin	45-59	tumor necrosis factor	Homo sapiens	101-110
11120942-7	2001	The chloramphenicol acetyltransferase assay indicated that NF-kappaB-dependent reporter gene expression is suppressed in U-937 cells pretreated with clarithromycin.	Clarithromycin	149-163	nuclear factor kappa B subunit 1	Homo sapiens	59-68
11120942-8	2001	These findings are consistent with the idea that clarithromycin suppresses the production of proinflammatory cytokines via inhibition of NF-kappaB activation.	Clarithromycin	49-63	nuclear factor kappa B subunit 1	Homo sapiens	137-146
10930442-6	2000	Furthermore, we show that an inhibitor of NF-kappa B activation, clarithromycin (CAM), can inhibit TNF-alpha-induced activation of NF-kappa B and restore T(3)-dependent induction of 5"-DI mRNA and enzyme activity.	Clarithromycin	65-79	nuclear factor kappa B subunit 1	Homo sapiens	42-52
11012550-0	2000	Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin.	Clarithromycin	113-127	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	63-90
11012620-4	2000	Clarithromycin significantly inhibited the production of IL-1beta and TNF-alpha in the lung (P<0.01).	Clarithromycin	0-14	interleukin 1 beta	Mus musculus	57-65
11012620-4	2000	Clarithromycin significantly inhibited the production of IL-1beta and TNF-alpha in the lung (P<0.01).	Clarithromycin	0-14	tumor necrosis factor	Mus musculus	70-79
10997945-4	2000	Other cytochrome P450 (CYP) 3A4 inhibitors, cimetidine, erythromycin, and clarithromycin, also inhibited the metabolism of cisapride and mosapride.	Clarithromycin	74-88	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	6-21
11000734-12	2000	In the ALC and MLC subgroups (i.e., patients who received clarithromycin), the eradication failure rate was significantly higher for patients with CR isolates than for those with clarithromycin-susceptible isolates (100% vs 11%, p < 0.05).	Clarithromycin	58-72	allantoicase	Homo sapiens	7-10
11000734-12	2000	In the ALC and MLC subgroups (i.e., patients who received clarithromycin), the eradication failure rate was significantly higher for patients with CR isolates than for those with clarithromycin-susceptible isolates (100% vs 11%, p < 0.05).	Clarithromycin	58-72	modulator of VRAC current 1	Homo sapiens	15-18
11000734-12	2000	In the ALC and MLC subgroups (i.e., patients who received clarithromycin), the eradication failure rate was significantly higher for patients with CR isolates than for those with clarithromycin-susceptible isolates (100% vs 11%, p < 0.05).	Clarithromycin	179-193	allantoicase	Homo sapiens	7-10
11000734-12	2000	In the ALC and MLC subgroups (i.e., patients who received clarithromycin), the eradication failure rate was significantly higher for patients with CR isolates than for those with clarithromycin-susceptible isolates (100% vs 11%, p < 0.05).	Clarithromycin	179-193	modulator of VRAC current 1	Homo sapiens	15-18
10950845-2	2000	Rates for loss of CYP3A4 enzymatic activity resulting from metabolic intermediate complex formation and the concentration dependencies thereof were determined in vitro for clarithromycin, fluoxetine, and N-desmethyl diltiazem, which is the primary metabolite of diltiazem.	Clarithromycin	172-186	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	18-24
10950845-4	2000	Based on the predicted rates combined with published rates for in vivo CYP3A degradation, our model predicts that fluoxetine, clarithromycin, and the primary metabolite of diltiazem reduce the steady-state concentration of liver CYP3A4 to approximately 72, 39, or 21% of initial levels, respectively.	Clarithromycin	126-140	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	71-76
10950845-4	2000	Based on the predicted rates combined with published rates for in vivo CYP3A degradation, our model predicts that fluoxetine, clarithromycin, and the primary metabolite of diltiazem reduce the steady-state concentration of liver CYP3A4 to approximately 72, 39, or 21% of initial levels, respectively.	Clarithromycin	126-140	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	229-235
10950845-7	2000	The major implication of this work is that fluoxetine, clarithromycin, and the primary metabolite of diltiazem, at clinically relevant concentrations, inactivate CYP3A4 enzymatic activity at rates sufficient to affect in vivo concentrations of CYP3A4 and thereby affect the clearance of compounds eliminated by this pathway.	Clarithromycin	55-69	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	162-168
10950845-7	2000	The major implication of this work is that fluoxetine, clarithromycin, and the primary metabolite of diltiazem, at clinically relevant concentrations, inactivate CYP3A4 enzymatic activity at rates sufficient to affect in vivo concentrations of CYP3A4 and thereby affect the clearance of compounds eliminated by this pathway.	Clarithromycin	55-69	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	244-250
10930442-6	2000	Furthermore, we show that an inhibitor of NF-kappa B activation, clarithromycin (CAM), can inhibit TNF-alpha-induced activation of NF-kappa B and restore T(3)-dependent induction of 5"-DI mRNA and enzyme activity.	Clarithromycin	65-79	tumor necrosis factor	Homo sapiens	99-108
10930442-6	2000	Furthermore, we show that an inhibitor of NF-kappa B activation, clarithromycin (CAM), can inhibit TNF-alpha-induced activation of NF-kappa B and restore T(3)-dependent induction of 5"-DI mRNA and enzyme activity.	Clarithromycin	65-79	nuclear factor kappa B subunit 1	Homo sapiens	131-141
10930442-6	2000	Furthermore, we show that an inhibitor of NF-kappa B activation, clarithromycin (CAM), can inhibit TNF-alpha-induced activation of NF-kappa B and restore T(3)-dependent induction of 5"-DI mRNA and enzyme activity.	Clarithromycin	81-84	nuclear factor kappa B subunit 1	Homo sapiens	42-52
10930442-6	2000	Furthermore, we show that an inhibitor of NF-kappa B activation, clarithromycin (CAM), can inhibit TNF-alpha-induced activation of NF-kappa B and restore T(3)-dependent induction of 5"-DI mRNA and enzyme activity.	Clarithromycin	81-84	tumor necrosis factor	Homo sapiens	99-108
10930442-6	2000	Furthermore, we show that an inhibitor of NF-kappa B activation, clarithromycin (CAM), can inhibit TNF-alpha-induced activation of NF-kappa B and restore T(3)-dependent induction of 5"-DI mRNA and enzyme activity.	Clarithromycin	81-84	nuclear factor kappa B subunit 1	Homo sapiens	131-141
10926350-7	2000	The macrolide antibacterials clarithromycin, erythromycin and troleandomycin are inhibitors of CYP3A4 and should not be used in conjunction with cisapride.	Clarithromycin	29-43	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-101
10722500-1	2000	The P450 enzyme, CYP3A4, extensively metabolizes both amprenavir and clarithromycin.	Clarithromycin	69-83	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	17-23
10875487-7	2000	RESULTS: After 8 weeks of treatment with clarithromycin, patients" symptoms, blood and sputum eosinophils counts and sputum ECP levels were significantly decreased compared with both placebo and baseline.	Clarithromycin	41-55	ribonuclease A family member 3	Homo sapiens	124-127
10923859-11	2000	Rifalazil-32-hydroxylation in microsomes was completely inhibited by CYP3A4-specific inhibitors (fluconazole, ketoconazole, miconazole, troleandomycin) and drugs metabolized by CYP3A4 such as cyclosporin A and clarithromycin, indicating that the enzyme responsible for the rifalazil-32-hydroxylation is CYP3A4.	Clarithromycin	210-224	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-75
10103198-3	1999	We studied the effect of erythromycin, clarithromycin, josamycin, and other antibiotics on the release by eosinophils of interleukin-8 (IL-8), a potent chemokine for inflammatory cells, including eosinophils themselves.	Clarithromycin	39-53	C-X-C motif chemokine ligand 8	Homo sapiens	121-134
10615065-0	2000	Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells.	Clarithromycin	33-47	C-X-C motif chemokine ligand 8	Homo sapiens	0-13
10615065-3	2000	In the present study we investigated the effects of clarithromycin (CAM) on interleukin (IL)-8 gene expression and protein levels, using the human bronchial epithelial cell line BET-1A.	Clarithromycin	52-66	C-X-C motif chemokine ligand 8	Homo sapiens	76-94
10704650-1	2000	In this study we examined in 100 patients testing positive for Helicobacter pylori infection whether successful eradication therapy with pantoprazole, clarithromycin, and metronidazole alters fibrinogen and other acute phase response markers.	Clarithromycin	151-165	fibrinogen beta chain	Homo sapiens	192-202
10615065-3	2000	In the present study we investigated the effects of clarithromycin (CAM) on interleukin (IL)-8 gene expression and protein levels, using the human bronchial epithelial cell line BET-1A.	Clarithromycin	68-71	C-X-C motif chemokine ligand 8	Homo sapiens	76-94
10615065-8	2000	TNF-alpha-induced promoter activity in this segment showed a significant repression by CAM.	Clarithromycin	87-90	tumor necrosis factor	Homo sapiens	0-9
10615065-11	2000	In accord with promoter analyses, an electrophoretic mobility shift assay showed that CAM repressed AP-1 binding in TNF-alpha-treated BET-1A cells; however, TNF-alpha induced both AP-1 and NF-kappaB binding activities in BET-1A cells.	Clarithromycin	86-89	tumor necrosis factor	Homo sapiens	116-125
10615065-12	2000	These data suggest that macrolides such as CAM repress IL-8 gene transcription mainly via the AP-1 binding site in human bronchial epithelial cells.	Clarithromycin	43-46	C-X-C motif chemokine ligand 8	Homo sapiens	55-59
10668858-6	2000	Clinically important CYP3A4 inhibitors include itraconazole, ketoconazole, clarithromycin, erythromycin, nefazodone, ritonavir and grapefruit juice.	Clarithromycin	75-89	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	21-27
10867834-2	2000	We examined the in vivo and in vitro effects of 14-membered macrolide antibiotics erythromycin (EM) and clarithromycin (CAM) on interleukin (IL)-8 secretion from human nasal epithelial cells.	Clarithromycin	104-118	C-X-C motif chemokine ligand 8	Homo sapiens	128-146
10867834-2	2000	We examined the in vivo and in vitro effects of 14-membered macrolide antibiotics erythromycin (EM) and clarithromycin (CAM) on interleukin (IL)-8 secretion from human nasal epithelial cells.	Clarithromycin	120-123	C-X-C motif chemokine ligand 8	Homo sapiens	128-146
10867834-7	2000	When cells were preincubated with 10(-4) M CAM for 7 days, the IL-1 beta-induced secretion of IL-8 decreased significantly.	Clarithromycin	43-46	interleukin 1 beta	Homo sapiens	63-72
10867834-7	2000	When cells were preincubated with 10(-4) M CAM for 7 days, the IL-1 beta-induced secretion of IL-8 decreased significantly.	Clarithromycin	43-46	C-X-C motif chemokine ligand 8	Homo sapiens	94-98
10646728-4	2000	RESULTS: Northern blot analysis revealed that clarithromycin suppressed IL-1 beta gene expression in human nasal epithelial cells stimulated by H. influenzae endotoxin (HIE).	Clarithromycin	46-60	interleukin 1 beta	Homo sapiens	72-81
10646728-5	2000	Intercellular adhesion molecule-1 gene expression in nasal fibroblasts stimulated by IL-1 beta was also suppressed by clarithromycin.	Clarithromycin	118-132	intercellular adhesion molecule 1	Homo sapiens	0-33
10646728-5	2000	Intercellular adhesion molecule-1 gene expression in nasal fibroblasts stimulated by IL-1 beta was also suppressed by clarithromycin.	Clarithromycin	118-132	interleukin 1 beta	Homo sapiens	85-94
10646728-6	2000	Furthermore, electrophoretic mobility shift assay demonstrated that clarithromycin reduced DNA-binding activity of NF-kappa B in both human nasal epithelial cells and fibroblasts stimulated by HIE or IL-1 beta, respectively.	Clarithromycin	68-82	nuclear factor kappa B subunit 1	Homo sapiens	115-125
10646728-6	2000	Furthermore, electrophoretic mobility shift assay demonstrated that clarithromycin reduced DNA-binding activity of NF-kappa B in both human nasal epithelial cells and fibroblasts stimulated by HIE or IL-1 beta, respectively.	Clarithromycin	68-82	interleukin 1 beta	Homo sapiens	200-209
10600094-5	1999	The time course suggested a possible interaction between clarithromycin and itraconazole, presumably through itraconazole"s effects on cytochrome P450 3A4 activity.	Clarithromycin	57-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	135-154
10543765-1	1999	In vitro treatment with clarithromycin inhibited the expression of the matrix metalloproteinase-9, transforming growth factor beta, and tumor necrosis factor alpha genes in 13762NF rat mammary adenocarcinoma cells.	Clarithromycin	24-38	matrix metallopeptidase 9	Rattus norvegicus	71-97
10543765-1	1999	In vitro treatment with clarithromycin inhibited the expression of the matrix metalloproteinase-9, transforming growth factor beta, and tumor necrosis factor alpha genes in 13762NF rat mammary adenocarcinoma cells.	Clarithromycin	24-38	tumor necrosis factor	Rattus norvegicus	136-163
10589373-4	1999	Clarithromycin is primarily metabolised by cytochrome P450 (CYP) 3A isozymes and has an active metabolite, 14-hydroxyclarithromycin.	Clarithromycin	0-14	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-67
10589373-12	1999	Clarithromycin can increase the steady-state concentrations of drugs that are primarily depend upon CYP3A metabolism (e.g., astemidole, cisapride, pimozide, midazolam and triazolam).	Clarithromycin	0-14	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	100-105
10589373-14	1999	Potent inhibitors of CYP3A (e.g., omeprazole and ritonavir) may also alter the metabolism of clarithromycin and its metabolites.	Clarithromycin	93-107	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	21-26
10511062-0	1999	Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans.	Clarithromycin	11-25	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	73-80
10511062-2	1999	Omeprazole and clarithromycin are metabolized by CYP2C19 and CYP3A4.	Clarithromycin	15-29	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	49-56
10511062-2	1999	Omeprazole and clarithromycin are metabolized by CYP2C19 and CYP3A4.	Clarithromycin	15-29	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	61-67
11720625-3	1999	However, clarithromycin is thought to be less frequently associated with drug induced TdP, because it inactivates hepatic cytochrome P-450 to a lesser extent than erythromycin.	Clarithromycin	9-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	122-138
10383920-8	1999	However, rokitamycin, LMA7, erythromycin, and clarithromycin inhibited the CYP3A4-catalyzed triazolam alpha-hydroxylation with IC50 (Ki) values of 5.8 (2.0), 40, 33 (20), and 56 (43) microM, respectively.	Clarithromycin	46-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-81
10103198-3	1999	We studied the effect of erythromycin, clarithromycin, josamycin, and other antibiotics on the release by eosinophils of interleukin-8 (IL-8), a potent chemokine for inflammatory cells, including eosinophils themselves.	Clarithromycin	39-53	C-X-C motif chemokine ligand 8	Homo sapiens	136-140
10103198-5	1999	Only 14-member macrolides (erythromycin and clarithromycin) showed a concentration-dependent suppressive effect on IL-8 release (control, 100%; erythromycin at 1 microgram/ml, 67.82% +/- 3.45% [P < 0.01]; clarithromycin at 5 micrograms/ml, 56.81% +/- 9.61% [P < 0.01]).	Clarithromycin	44-58	C-X-C motif chemokine ligand 8	Homo sapiens	115-119
9951426-2	1999	We recently reported 2 fatal cases in patients taking pimozide and clarithromycin and we have shown that clarithromycin inhibits CYP3A-mediated metabolism of pimozide in vitro.	Clarithromycin	67-81	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	129-134
10206083-2	1999	The aim of this study was to examine the relationship between genetic polymorphism of CYP2C19 and metabolism of omeprazole administrated as a single dose or as repeated-doses, which were in both cases co-administered with clarithromycin.	Clarithromycin	222-236	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	86-93
9972380-8	1999	There is evidence that clarithromycin, a relatively new macrolide antibiotic, also inhibits the isoenzyme CYP3A4.	Clarithromycin	23-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	106-112
9951426-0	1999	Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6).	Clarithromycin	10-24	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	128-147
10452116-1	1999	AIM: To study the antagonistic effect of selective neuronal nitric-oxide synthase (nNOS) inhibitor 7-nitroindazole on the long-term potentiation (LTP) induced by l-clausenamide (Cla) in rat hippocampus in vivo.	Clarithromycin	178-181	nitric oxide synthase 1	Rattus norvegicus	51-81
10452116-1	1999	AIM: To study the antagonistic effect of selective neuronal nitric-oxide synthase (nNOS) inhibitor 7-nitroindazole on the long-term potentiation (LTP) induced by l-clausenamide (Cla) in rat hippocampus in vivo.	Clarithromycin	178-181	nitric oxide synthase 1	Rattus norvegicus	83-87
10452116-5	1999	CONCLUSION: Nitric oxide produced by nNOS plays a role in the induction of Cla-induced LTP in hippocampus.	Clarithromycin	75-78	nitric oxide synthase 1	Rattus norvegicus	37-41
10223590-6	1999	Clarithromycin exhibited moderate levels of microbicidal activity against M. intracellulare residing in peritoneal macrophages, THP-1 cells and A-549 cells.	Clarithromycin	0-14	GLI family zinc finger 2	Homo sapiens	128-133
10223590-7	1999	The profiles of clarithromycin-mediated killing or inhibition of the intracellular organisms in A-549 and THP-1 cells were similar to those observed for organisms within peritoneal macrophages.	Clarithromycin	16-30	GLI family zinc finger 2	Homo sapiens	106-111
10221415-5	1999	The results with IL-6 and TNF-alpha in the clarithromycin studies were most striking.	Clarithromycin	43-57	interleukin 6	Homo sapiens	17-21
10221415-5	1999	The results with IL-6 and TNF-alpha in the clarithromycin studies were most striking.	Clarithromycin	43-57	tumor necrosis factor	Homo sapiens	26-35
9951426-2	1999	We recently reported 2 fatal cases in patients taking pimozide and clarithromycin and we have shown that clarithromycin inhibits CYP3A-mediated metabolism of pimozide in vitro.	Clarithromycin	105-119	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	129-134
9935275-11	1999	Clarithromycin is a weak inducer of CYP and exhibits fewer drug-drug interactions than erythromycin.	Clarithromycin	0-14	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	36-39
9951426-13	1999	Clarithromycin inhibited CYP3A-mediated pimozide metabolism and the resulting elevation in plasma concentrations may increase the risk of pimozide cardiotoxicity.	Clarithromycin	0-14	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	25-30
9874281-0	1998	Effect of clarithromycin on alpha1-acid glycoprotein levels in normal and diabetic rats.	Clarithromycin	10-24	orosomucoid 1	Rattus norvegicus	28-52
10067059-7	1999	RFP induces cytochrome P450 3A in the liver to decrease the activities of many drugs, such as cyclosporin A, tacrolimus, protease inhibitor, itraconazole, and clarithromycin.	Clarithromycin	159-173	tripartite motif containing 27	Homo sapiens	0-3
9881659-4	1998	Treatment with CAM increased the AGP concentration only.	Clarithromycin	15-18	orosomucoid 1	Rattus norvegicus	33-36
9881659-8	1998	These results suggested that the influence of CAM on the pharmacokinetic properties of pindolol in CAM-treated rats can be explained by protein binding which, in turn, may be associated with variations in AGP concentration.	Clarithromycin	46-49	orosomucoid 1	Rattus norvegicus	205-208
9881659-8	1998	These results suggested that the influence of CAM on the pharmacokinetic properties of pindolol in CAM-treated rats can be explained by protein binding which, in turn, may be associated with variations in AGP concentration.	Clarithromycin	99-102	orosomucoid 1	Rattus norvegicus	205-208
10069109-0	1999	[Sensitivity of group A beta-hemolytic Streptococcus isolated from pediatric pharyngotonsillitis to erythromycin and clarithromycin: a primary care multicenter study].	Clarithromycin	117-131	amyloid beta precursor protein	Homo sapiens	22-28
9874281-2	1998	In this study, we show that clarithromycin (CAM), a 14-membered macrolide antibiotic, causes an increase in the serum levels of AGP in a dose-dependent manner.	Clarithromycin	28-42	orosomucoid 1	Rattus norvegicus	128-131
9874281-2	1998	In this study, we show that clarithromycin (CAM), a 14-membered macrolide antibiotic, causes an increase in the serum levels of AGP in a dose-dependent manner.	Clarithromycin	44-47	orosomucoid 1	Rattus norvegicus	128-131
9874281-3	1998	AGP levels peak at 48h after a single administration with CAM In order to elucidate the mechanism of AGP induction by CAM, the effects of CAM, phenobarbital (PB), ethynylestradiol (EE2) and dexamethasone (DEX) treatments on APP fluctuation patterns were examined.	Clarithromycin	118-121	orosomucoid 1	Rattus norvegicus	0-3
9874281-3	1998	AGP levels peak at 48h after a single administration with CAM In order to elucidate the mechanism of AGP induction by CAM, the effects of CAM, phenobarbital (PB), ethynylestradiol (EE2) and dexamethasone (DEX) treatments on APP fluctuation patterns were examined.	Clarithromycin	118-121	orosomucoid 1	Rattus norvegicus	101-104
9874281-3	1998	AGP levels peak at 48h after a single administration with CAM In order to elucidate the mechanism of AGP induction by CAM, the effects of CAM, phenobarbital (PB), ethynylestradiol (EE2) and dexamethasone (DEX) treatments on APP fluctuation patterns were examined.	Clarithromycin	118-121	orosomucoid 1	Rattus norvegicus	0-3
9874281-3	1998	AGP levels peak at 48h after a single administration with CAM In order to elucidate the mechanism of AGP induction by CAM, the effects of CAM, phenobarbital (PB), ethynylestradiol (EE2) and dexamethasone (DEX) treatments on APP fluctuation patterns were examined.	Clarithromycin	118-121	orosomucoid 1	Rattus norvegicus	101-104
9874281-4	1998	In addition, modulation of the AGP induction by CAM, PB, EE2 and DEX in the diabetic state was examined.	Clarithromycin	48-51	orosomucoid 1	Rattus norvegicus	31-34
9874281-5	1998	In contrast to treatment by PB, CAM treatment increased alpha2-macroglobulin levels to a much lesser extent than that observed during inflammation.	Clarithromycin	32-35	alpha-2-macroglobulin	Rattus norvegicus	56-76
9874281-7	1998	In addition, AGP induction by CAM, EE2 and DEX were attenuated in streptozotocin-induced diabetic rats, whereas the PB-induced increase in AGP levels was potentiated in diabetic rats.	Clarithromycin	30-33	orosomucoid 1	Rattus norvegicus	13-16
9874281-9	1998	These results suggest that CAM increases AGP levels via a mechanism which may be different from PB and typical inflammatory pathways.	Clarithromycin	27-30	orosomucoid 1	Rattus norvegicus	41-44
9695727-3	1998	Because P-glycoprotein could play an important role in the renal secretion of digoxin, we hypothesized that clarithromycin decreases renal digoxin excretion by inhibiting P-glycoprotein-mediated transport.	Clarithromycin	108-122	ATP binding cassette subfamily B member 1	Homo sapiens	8-22
9728893-0	1998	The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.	Clarithromycin	90-104	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-48
9728893-1	1998	OBJECTIVE: To assess the relative contribution of intestinal and hepatic CYP3A inhibition to the interaction between the prototypic CYP3A substrates midazolam and clarithromycin.	Clarithromycin	163-177	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	73-78
9695727-3	1998	Because P-glycoprotein could play an important role in the renal secretion of digoxin, we hypothesized that clarithromycin decreases renal digoxin excretion by inhibiting P-glycoprotein-mediated transport.	Clarithromycin	108-122	ATP binding cassette subfamily B member 1	Homo sapiens	171-185
9695727-6	1998	These results suggest that clarithromycin may inhibit the P-glycoprotein-mediated tubular secretion of digoxin, and this interaction mechanism may contribute to an increase in the serum digoxin concentration.	Clarithromycin	27-41	ATP binding cassette subfamily B member 1	Homo sapiens	58-72
9696194-9	1998	In the subgroup treated with clarithromycin, G-CSF was also associated with increased survival (377 days vs 252 days, P<0.01).	Clarithromycin	29-43	colony stimulating factor 3	Homo sapiens	45-50
9701415-0	1998	Erythromycin and clarithromycin attenuate cytokine-induced endothelin-1 expression in human bronchial epithelial cells.	Clarithromycin	17-31	endothelin 1	Homo sapiens	59-71
9701415-6	1998	Erythromycin and clarithromycin uniquely suppressed mRNA levels as well as the release of ET- at therapeutic and non-cytotoxic concentrations (percentage inhibition of ET-1 protein release: 26.4+/-5.22% and 31.2+/-7.45%, respectively, at 10(-6) M).	Clarithromycin	17-31	endothelin 1	Homo sapiens	168-172
9701415-7	1998	Furthermore, erythromycin and clarithromycin inhibited ET-1 expression in bronchoepithelial cells from patients with chronic, stable asthma.	Clarithromycin	30-44	endothelin 1	Homo sapiens	55-59
9696194-13	1998	Addition of G-CSF to a regimen of clarithromycin and ethambutol may increase survival in DMAC and should be studied prospectively.	Clarithromycin	34-48	colony stimulating factor 3	Homo sapiens	12-17
9444409-6	1998	The level of IL-8 was significantly higher in the lavage fluid of patients with uterine endometritis than in the controls (p < 0.001), and decreased by CAM treatment (p < 0.01).	Clarithromycin	155-158	C-X-C motif chemokine ligand 8	Homo sapiens	13-17
9640482-5	1998	Clarithromycin inhibits CYP3A4, the isoenzyme responsible for the metabolism of cisapride.	Clarithromycin	0-14	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	24-30
9640482-6	1998	Concomitant administration of cisapride with agents known to inhibit CYP3A4 (i.e., azole antifungals, erythromycin, clarithromycin) may result in elevated cisapride concentrations.	Clarithromycin	116-130	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-75
9420030-6	1997	Cross-resistance to clarithromycin and erythromycin, which was transferred by natural transformation from the Cla(r) Ery(r) donor strain H. pylori E to the Cla(s) Ery(s) recipient strain H. pylori UA802, was associated with an single A-to-G transition mutation at position 2142 of both copies of the 23S rRNA in UA802 Cla(r) Ery(r) mutants.	Clarithromycin	20-34	selectin P ligand	Homo sapiens	110-113
9597486-0	1998	[Effect of clarithromycin administration on interferon-gamma and interleukin 12 mRNA expression in the tumor tissue of non-small-cell lung cancer].	Clarithromycin	11-25	interferon gamma	Homo sapiens	44-60
9420030-6	1997	Cross-resistance to clarithromycin and erythromycin, which was transferred by natural transformation from the Cla(r) Ery(r) donor strain H. pylori E to the Cla(s) Ery(s) recipient strain H. pylori UA802, was associated with an single A-to-G transition mutation at position 2142 of both copies of the 23S rRNA in UA802 Cla(r) Ery(r) mutants.	Clarithromycin	20-34	selectin P ligand	Homo sapiens	156-159
9420030-6	1997	Cross-resistance to clarithromycin and erythromycin, which was transferred by natural transformation from the Cla(r) Ery(r) donor strain H. pylori E to the Cla(s) Ery(s) recipient strain H. pylori UA802, was associated with an single A-to-G transition mutation at position 2142 of both copies of the 23S rRNA in UA802 Cla(r) Ery(r) mutants.	Clarithromycin	20-34	selectin P ligand	Homo sapiens	156-159
9420030-7	1997	The transformation frequency for Cla(r) and Ery(r) was found to be approximately 2 x 10(-6) transformants per viable cell, and the MICs of both clarithromycin and erythromycin for the Cla(r) Ery(r) mutants were equal to those for the donor isolate.	Clarithromycin	144-158	selectin P ligand	Homo sapiens	184-187
9386357-4	1997	It was also found that rifamycins in combination with clarithromycin could have a good bactericidal effect in the PAM-model of the infection.	Clarithromycin	54-68	peptidylglycine alpha-amidating monooxygenase	Homo sapiens	114-117
9230759-4	1997	EM and clarithromycin (CAM) uniquely suppressed mRNA levels as well as the release of IL-8 at the therapeutic and noncytotoxic concentrations (% inhibition of IL-8 protein release: 25.0 +/- 5.67% and 37.5 +/- 8.99%, respectively, at 10(-6) M).	Clarithromycin	7-21	C-X-C motif chemokine ligand 8	Homo sapiens	86-90
9440054-10	1997	In alternative, omeprazole, clarithromycin, amoxicillin (OCA) has been also suggested to overcome the problem of metronidazole resistance, however recent studies seem to indicate that resistance to metronidazole does not seem to significantly influence outcome of OCT.	Clarithromycin	28-42	plexin A2	Homo sapiens	264-267
9296238-6	1997	Clarithromycin 500 mg bid was started for an acute exacerbation of bronchitis 10 days after the last INR was obtained and was continued for 14 days of therapy.	Clarithromycin	0-14	BH3 interacting domain death agonist	Homo sapiens	22-25
9292586-7	1997	RESULTS: For patients with AIDS and those having CD4 counts <75 cells/mm3, azithromycin, clarithromycin, and rifabutin prophylaxis increased lifetime per person MAC-related costs by $994, $2,117, and $2,185 U.S., respectively.	Clarithromycin	92-106	CD4 molecule	Homo sapiens	49-52
9230759-4	1997	EM and clarithromycin (CAM) uniquely suppressed mRNA levels as well as the release of IL-8 at the therapeutic and noncytotoxic concentrations (% inhibition of IL-8 protein release: 25.0 +/- 5.67% and 37.5 +/- 8.99%, respectively, at 10(-6) M).	Clarithromycin	7-21	C-X-C motif chemokine ligand 8	Homo sapiens	159-163
9230759-4	1997	EM and clarithromycin (CAM) uniquely suppressed mRNA levels as well as the release of IL-8 at the therapeutic and noncytotoxic concentrations (% inhibition of IL-8 protein release: 25.0 +/- 5.67% and 37.5 +/- 8.99%, respectively, at 10(-6) M).	Clarithromycin	23-26	C-X-C motif chemokine ligand 8	Homo sapiens	159-163
8501007-2	1993	Selective methylation at the C-6 hydroxyl group of erythromycin A oxime derivatives and preparation of clarithromycin.	Clarithromycin	103-117	complement C6	Homo sapiens	29-32
8764523-4	1996	The incidence of CE in patients with CD4 counts < 50/mm3 treated with clarithromycin prophylaxis for MAC was compared with patients not receiving clarithromycin prophylaxis.	Clarithromycin	73-87	CD4 molecule	Homo sapiens	37-40
9099936-0	1996	Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells.	Clarithromycin	21-35	CD276 molecule	Homo sapiens	39-61
8741708-5	1996	Oral administration of clarithromycin at a daily dose of 1-10 mg/day for 2 weeks dose-dependently inhibited IL-8 (5 mg/ kg)-induced decrease in mucus score, with the maximal inhibition being 54 +/- 11% (p < 0.001) in the trachea and 48 +/- 8% (p < 0.01) in the main bronchi.	Clarithromycin	23-37	interleukin-8	Cavia porcellus	108-112
7820984-0	1994	[Effects of intravenous administration of clarithromycin on plasma levels of gastrin and group I pepsinogen].	Clarithromycin	42-56	gastrin	Homo sapiens	77-84
7820984-3	1994	The above study was aimed at ascertaining in a group of dyspeptic patients whether clarithromycin, a structural analogue of erythromycin, is apt to modify certain functional parameters of gastric secretion, above all the patterns of gastrin and PG-I secretion.	Clarithromycin	83-97	gastrin	Homo sapiens	233-240
7820984-3	1994	The above study was aimed at ascertaining in a group of dyspeptic patients whether clarithromycin, a structural analogue of erythromycin, is apt to modify certain functional parameters of gastric secretion, above all the patterns of gastrin and PG-I secretion.	Clarithromycin	83-97	biglycan	Homo sapiens	245-249
7820984-4	1994	A 20-minute intravenous clarithromycin infusion (1.5 mg/kg) in fasting subjects has brought about a significant reduction (at 20 and 45 minutes from the start of infusion) of circulating gastrin (about 23%) and, after a meal, a 69% increase.	Clarithromycin	24-38	gastrin	Homo sapiens	187-194
7820984-6	1994	These findings suggest that in vivo and at the doses used in our experiment clarithromycin has no influence on plasma PG-I release and is apt to modify the fasting and postprandial gastrin releasing pattern.	Clarithromycin	76-90	gastrin	Homo sapiens	181-188
8280403-8	1993	Gastrointestinal reactions represent the most frequent disturbance, occurring in 15 to 20% of patients on erythromycins and in 5% or fewer patients treated with some recently developed macrolide derivatives that seldom or never induce endogenous release of motilin, such as roxithromycin, clarithromycin, dirithromycin, azithromycin and rikamycin (rokitamycin).	Clarithromycin	289-303	motilin	Homo sapiens	257-264
9597458-0	1997	[Effects and actions of EM (erythromycin), CAM (clarithromycin), and JM (josamycin) on IL-4 and IL-5 production by monocytes].	Clarithromycin	43-46	interleukin 4	Homo sapiens	87-91
9597458-0	1997	[Effects and actions of EM (erythromycin), CAM (clarithromycin), and JM (josamycin) on IL-4 and IL-5 production by monocytes].	Clarithromycin	48-62	interleukin 4	Homo sapiens	87-91
9597458-0	1997	[Effects and actions of EM (erythromycin), CAM (clarithromycin), and JM (josamycin) on IL-4 and IL-5 production by monocytes].	Clarithromycin	48-62	interleukin 5	Homo sapiens	96-100
9131953-4	1997	RESULTS: Cytochrome P4503A (CYP3A) activity was reduced in all subjects by a mean level of 26% following clarithromycin treatment.	Clarithromycin	105-119	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	9-15
9131953-4	1997	RESULTS: Cytochrome P4503A (CYP3A) activity was reduced in all subjects by a mean level of 26% following clarithromycin treatment.	Clarithromycin	105-119	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	28-33
9131953-6	1997	CONCLUSIONS: As clarithromycin was shown to inhibit CYP3A activity in all subjects tested, we recommend that a high degree of caution be exercised when clarithromycin is administered to patients receiving cyclosporine therapy or other drugs known to be eliminated by CYP3A-mediated metabolism.	Clarithromycin	16-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	52-57
8971305-17	1996	CONCLUSIONS: In the elderly, triple therapy with omeprazole+metronidazole+clarithromycin for 1 week is well tolerated and highly effective; anti-H. pylori antibody and PGC serum levels decrease soon after anti-H. pylori therapy only in patients cured of H. pylori infection.	Clarithromycin	74-88	progastricsin	Homo sapiens	168-171
8977529-6	1996	RESULTS: Aminophylline (AM), methylprednisolone (MP), erythromycin (EM), and clarithromycin (CAM) suppressed the IL-5 induced prolongation of eosinophil survival in a dose-dependent manner.	Clarithromycin	77-91	interleukin 5	Homo sapiens	113-117
8977529-6	1996	RESULTS: Aminophylline (AM), methylprednisolone (MP), erythromycin (EM), and clarithromycin (CAM) suppressed the IL-5 induced prolongation of eosinophil survival in a dose-dependent manner.	Clarithromycin	93-96	interleukin 5	Homo sapiens	113-117
9099936-10	1996	Both spontaneous and up-regulated expression of ICAM-1, LFA-3 and VCAM-1 by IFN-gamma, IL-1beta or 12-o-tetradecanoyl phorbol 13-acetate (TPA) were markedly suppressed by clarithromycin in a dose-dependent manner at concentrations between 0.1 and 10 microg/ml.	Clarithromycin	171-185	intercellular adhesion molecule 1	Homo sapiens	48-54
9099936-10	1996	Both spontaneous and up-regulated expression of ICAM-1, LFA-3 and VCAM-1 by IFN-gamma, IL-1beta or 12-o-tetradecanoyl phorbol 13-acetate (TPA) were markedly suppressed by clarithromycin in a dose-dependent manner at concentrations between 0.1 and 10 microg/ml.	Clarithromycin	171-185	CD58 molecule	Homo sapiens	56-61
9099936-10	1996	Both spontaneous and up-regulated expression of ICAM-1, LFA-3 and VCAM-1 by IFN-gamma, IL-1beta or 12-o-tetradecanoyl phorbol 13-acetate (TPA) were markedly suppressed by clarithromycin in a dose-dependent manner at concentrations between 0.1 and 10 microg/ml.	Clarithromycin	171-185	vascular cell adhesion molecule 1	Homo sapiens	66-72
9099936-10	1996	Both spontaneous and up-regulated expression of ICAM-1, LFA-3 and VCAM-1 by IFN-gamma, IL-1beta or 12-o-tetradecanoyl phorbol 13-acetate (TPA) were markedly suppressed by clarithromycin in a dose-dependent manner at concentrations between 0.1 and 10 microg/ml.	Clarithromycin	171-185	interferon gamma	Homo sapiens	76-85
9099936-10	1996	Both spontaneous and up-regulated expression of ICAM-1, LFA-3 and VCAM-1 by IFN-gamma, IL-1beta or 12-o-tetradecanoyl phorbol 13-acetate (TPA) were markedly suppressed by clarithromycin in a dose-dependent manner at concentrations between 0.1 and 10 microg/ml.	Clarithromycin	171-185	interleukin 1 beta	Homo sapiens	87-95
9099936-14	1996	As clarithromycin suppressed HLA-DR and costimulatory molecule expression was enhanced by IFN-gamma, autologous T cell proliferation was markedly inhibited by clarithromycin.	Clarithromycin	3-17	CD276 molecule	Homo sapiens	40-62
9099936-14	1996	As clarithromycin suppressed HLA-DR and costimulatory molecule expression was enhanced by IFN-gamma, autologous T cell proliferation was markedly inhibited by clarithromycin.	Clarithromycin	3-17	interferon gamma	Homo sapiens	90-99
9099936-15	1996	Clarithromycin has a considerable immunosuppressive effect on synoviocytes by inhibiting costimulatory molecule expression, cytokine production and antigen-specific T cell proliferation induced by synoviocytes.	Clarithromycin	0-14	CD276 molecule	Homo sapiens	89-111
7763252-2	1995	Among those tested, erythromycin (EM) and clarithromycin (CAM) uniquely suppressed mRNA levels as well as the release of IL-6 at the therapeutic and non-cytotoxic concentration (10(-6)M).	Clarithromycin	42-56	interleukin 6	Homo sapiens	121-125
8097709-1	1993	Clarithromycin and its metabolites have been examined for their abilities to induce specific form(s) of cytochrome P-450 and metabolite complex formation in rats.	Clarithromycin	0-14	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	104-120
8097709-3	1993	Clarithromycin and N-demethyl clarithromycin, but not decladinosyl clarithromycin, produced a metabolite complex with cytochrome P-450 in vivo.	Clarithromycin	0-14	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	118-134
8097709-4	1993	Activities of testosterone 2 beta- and 6 beta-hydroxylases were increased by administration of clarithromycin and N-demethyl clarithromycin when these activities were measured in the presence of ferricyanide, but not significant induction was observed when measured in the absence of ferricyanide.	Clarithromycin	95-109	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	14-58
8097709-8	1993	Clarithromycin and its N-modified metabolites were able to induce 3A1 and form a metabolite complex with cytochrome P-450 in vivo in varying extents.	Clarithromycin	0-14	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	105-121
34626662-6	2022	Erythromycin and clarithromycin can be considered ubiquitous with mean concentrations of 2.5 +- 2.3 ngL-1 and 5.7 +- 4.6 ngL-1 respectively, and the presence of sulfamethoxazole and trimethoprim was also noticeable with maximum concentrations of 78.3 ngL-1 for sulfamethoxazole.	Clarithromycin	17-31	leucine rich repeat containing 4C	Homo sapiens	100-113
1629568-3	1992	SOD activity in the gastric mucosa was assayed by the inhibition of CLA-dependent chemiluminescence in highly diluted tissue homogenates.	Clarithromycin	68-71	superoxide dismutase 1	Homo sapiens	0-3
1684980-12	1991	There is a progressive increase in serum concentrations of clarithromycin and 14-OH-(R)-clarithromycin with renal impairment so that doses may need to be reduced in severe impairment (glomerular filtration rate less than 30 ml min-1).	Clarithromycin	59-73	CD59 molecule (CD59 blood group)	Homo sapiens	227-232
2142274-7	1990	Clarithromycin was active on Haemophilus at concentrations of 4 to 64 micrograms/ml (mode 16); MICs for beta-lactamase producing strains were comparable to those of strains not producing.	Clarithromycin	0-14	beta-lactamase	Staphylococcus aureus	104-118
1535292-8	1992	In pH 1.39, CAM degraded with a T1/2 of 17 min while EM kinetics corresponded to a T1/2 of 3 s. Therefore, CAM was 340-fold more stable in pH 1.39 and markedly more stable in the acidic solution than EM.	Clarithromycin	12-15	interleukin 1 receptor like 1	Homo sapiens	32-42
1535292-8	1992	In pH 1.39, CAM degraded with a T1/2 of 17 min while EM kinetics corresponded to a T1/2 of 3 s. Therefore, CAM was 340-fold more stable in pH 1.39 and markedly more stable in the acidic solution than EM.	Clarithromycin	107-110	interleukin 1 receptor like 1	Homo sapiens	32-42
1535292-8	1992	In pH 1.39, CAM degraded with a T1/2 of 17 min while EM kinetics corresponded to a T1/2 of 3 s. Therefore, CAM was 340-fold more stable in pH 1.39 and markedly more stable in the acidic solution than EM.	Clarithromycin	107-110	interleukin 1 receptor like 1	Homo sapiens	83-92
12907132-4	2003	The LPS-enhanced PGE2 synthesis and the expression of cPLA2 and COX-2 mRNAs were inhibited by clarithromycin, azithromycin and dexamethasone in PMNLs and MNLs.	Clarithromycin	94-108	phospholipase A2 group IVA	Homo sapiens	54-59
12907132-4	2003	The LPS-enhanced PGE2 synthesis and the expression of cPLA2 and COX-2 mRNAs were inhibited by clarithromycin, azithromycin and dexamethasone in PMNLs and MNLs.	Clarithromycin	94-108	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	64-69
12907132-5	2003	The mRNA expression of COX-1 in PMNLs was decreased by clarithromycin and azithromycin.	Clarithromycin	55-69	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	23-28
34626662-6	2022	Erythromycin and clarithromycin can be considered ubiquitous with mean concentrations of 2.5 +- 2.3 ngL-1 and 5.7 +- 4.6 ngL-1 respectively, and the presence of sulfamethoxazole and trimethoprim was also noticeable with maximum concentrations of 78.3 ngL-1 for sulfamethoxazole.	Clarithromycin	17-31	leucine rich repeat containing 4C	Homo sapiens	121-126
34626662-6	2022	Erythromycin and clarithromycin can be considered ubiquitous with mean concentrations of 2.5 +- 2.3 ngL-1 and 5.7 +- 4.6 ngL-1 respectively, and the presence of sulfamethoxazole and trimethoprim was also noticeable with maximum concentrations of 78.3 ngL-1 for sulfamethoxazole.	Clarithromycin	17-31	leucine rich repeat containing 4C	Homo sapiens	251-256
34988253-1	2022	Clarithromycin (CYP inhibitor) can be used instead of azithromycin for nontuberculous mycobacteria therapy in patients requiring CYP substrates to mitigate rifampin"s CYP induction.	Clarithromycin	0-14	peptidylprolyl isomerase G	Homo sapiens	16-19
34619548-8	2021	SMK is a well-known factor that markedly enhances theophylline clearance through the induction of CYP1A enzymes, while CAM has been reported to inhibit CYP3A4.	Clarithromycin	119-122	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	152-158
34977105-14	2021	Granulosain I and RAP showed significant synergistic effect on AML, CLA, and LEV, but no significant effect on MTZ was observed.	Clarithromycin	68-71	LDL receptor related protein associated protein 1	Homo sapiens	18-21
34865299-5	2021	RESULTS: Antibiotic resistance to clarithromycin increased by 3.7% per year (IRR 1.037, p=0.014) over 20 years, with a corresponding 5.0% annual increase in minimum inhibitory concentration (MIC) (OR 1.050, p<0.001).	Clarithromycin	34-48	insulin receptor related receptor	Homo sapiens	77-80
34636179-11	2021	Interleukin-6 (IL-6) and IL-8 production by stimulated ECs were unaltered by incubation with macrolides, whereas Clarithromycin exposure significantly decreased IL-6 gene expression.	Clarithromycin	113-127	C-X-C motif chemokine ligand 8	Homo sapiens	25-29
34363189-7	2021	Clarithromycin use was associated with decreases in circulating C-reactive protein, tumour necrosis factor-alpha and interleukin (IL)-6; by increase of production of interferon-gamma and decrease of production of interleukin-6 by mononuclear cells; and by suppression of SARS-CoV-2 viral load.	Clarithromycin	0-14	C-reactive protein	Homo sapiens	64-82
34363189-7	2021	Clarithromycin use was associated with decreases in circulating C-reactive protein, tumour necrosis factor-alpha and interleukin (IL)-6; by increase of production of interferon-gamma and decrease of production of interleukin-6 by mononuclear cells; and by suppression of SARS-CoV-2 viral load.	Clarithromycin	0-14	interleukin 6	Homo sapiens	117-135
34636179-11	2021	Interleukin-6 (IL-6) and IL-8 production by stimulated ECs were unaltered by incubation with macrolides, whereas Clarithromycin exposure significantly decreased IL-6 gene expression.	Clarithromycin	113-127	interleukin 6	Homo sapiens	161-165
34363189-7	2021	Clarithromycin use was associated with decreases in circulating C-reactive protein, tumour necrosis factor-alpha and interleukin (IL)-6; by increase of production of interferon-gamma and decrease of production of interleukin-6 by mononuclear cells; and by suppression of SARS-CoV-2 viral load.	Clarithromycin	0-14	interferon gamma	Homo sapiens	166-182
34275626-5	2021	In the present study, we used undifferentiated bovine mammary epithelial cells (MAC-T cells) and treated them with t10,c12 CLA for 6 h. We found that SREBP1 protein expression declined over 56% when cells were treated with 60 microM or greater concentration of t10,c12 CLA.	Clarithromycin	269-272	sterol regulatory element binding transcription factor 1	Bos taurus	150-156
34363189-7	2021	Clarithromycin use was associated with decreases in circulating C-reactive protein, tumour necrosis factor-alpha and interleukin (IL)-6; by increase of production of interferon-gamma and decrease of production of interleukin-6 by mononuclear cells; and by suppression of SARS-CoV-2 viral load.	Clarithromycin	0-14	interleukin 6	Homo sapiens	213-226
34888378-0	2021	Clinical Effect of Clarithromycin Combined with Tinidazole on Helicobacter pylori-Related Gastritis and Its Influence on COX-2 Expression.	Clarithromycin	19-33	prostaglandin-endoperoxide synthase 2	Homo sapiens	121-126
34888378-2	2021	We attempted to investigate the role of clarithromycin with tinidazole on Helicobacter pylori-related gastritis from the aspects of clinical effect and COX-2 expression.	Clarithromycin	40-54	prostaglandin-endoperoxide synthase 2	Homo sapiens	152-157
34888378-7	2021	Clarithromycin combined with tinidazole can effectively improve the clinical effect of Helicobacter pylori-related gastritis and reduce the expression level of COX-2.	Clarithromycin	0-14	prostaglandin-endoperoxide synthase 2	Homo sapiens	160-165
34721043-0	2021	Influence of Cytochrome P450 2C19 Genotype on Helicobacter pylori Proton Pump Inhibitor-Amoxicillin-Clarithromycin Eradication Therapy: A Meta-Analysis.	Clarithromycin	100-114	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	13-33
34260894-10	2021	In addition, the reduced DABE-dabigatran PBPK model predicted successfully the extent of DDI with verapamil and clarithromycin as P-gp inhibitors.	Clarithromycin	112-126	ATP binding cassette subfamily B member 1	Homo sapiens	130-134
34440230-9	2021	The mutant-transfected HAC15 cells increased the expression of CYP11B2 and aldosterone secretion, which was partially suppressed by clarithromycin and nifedipine but not roxithromycin treatment.	Clarithromycin	132-146	cytochrome P450 family 11 subfamily B member 2	Homo sapiens	63-70
34719987-2	2021	METHODS: Five databases (PubMed, Google Scholar, Trip, Medline, and Clinical Key) were searched to identify randomized clinical trials with patients exposed to azithromycin or clarithromycin in combination with a beta-lactam.	Clarithromycin	176-190	TRAF interacting protein	Homo sapiens	49-53
34467456-0	2021	Evidence-Based Guidelines for Drug Interaction Studies: Model-Informed Time Course of Intestinal and Hepatic CYP3A4 Inhibition by Clarithromycin.	Clarithromycin	130-144	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	109-115
34467456-2	2021	This study utilised validated physiologically based pharmacokinetic (PBPK) software to define the optimal dose, frequency, and duration of clarithromycin to achieve optimal characterisation of CYP3A4 inhibition in a study population.	Clarithromycin	139-153	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	193-199
34467456-3	2021	The Simcyp  Simulator (Version 19.0) was used to simulate clarithromycin-mediated CYP3A4 inhibition in healthy virtual cohorts.	Clarithromycin	58-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	82-88
34467456-6	2021	Literature review identified 500 mg twice daily for 5 days as the most common clarithromycin dosing protocol for CYP3A4 inhibition studies.	Clarithromycin	78-92	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	113-119
34467456-7	2021	On simulation, clarithromycin 500 mg twice daily resulted in the largest steady-state inhibition of hepatic (percent mean inhibition (95%CI) = 80 (77-83)) and small intestine (94 (94-95)) CYP3A4 activity (as compared to 500 mg once daily, 400 mg once/twice daily, or 250 mg once/twice daily).	Clarithromycin	15-29	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	188-194
34467456-9	2021	The study presented herein supports that clarithromycin dosing protocol of 500 mg twice daily for 5 days is sufficient to achieve maximal hepatic and small intestine CYP3A4 inhibition.	Clarithromycin	41-55	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	166-172
34458952-14	2021	Clarithromycin application remarkably attenuated CEPT1 and CHPT1 gene expression, which participate in the last step in the synthesis of glycerophospholipids; 4.	Clarithromycin	0-14	choline/ethanolaminephosphotransferase 1	Mus musculus	49-54
34458952-14	2021	Clarithromycin application remarkably attenuated CEPT1 and CHPT1 gene expression, which participate in the last step in the synthesis of glycerophospholipids; 4.	Clarithromycin	0-14	choline phosphotransferase 1	Mus musculus	59-64
34302035-8	2021	The MP-evolved strains showed cross-resistance to rifampicin and clarithromycin owing to the acquisition of a mutation in the intergenic region of the Rv2864c ortholog, which encodes a penicillin-binding protein, at an early stage.	Clarithromycin	65-79	penicillin-binding lipoprotein	Mycobacterium tuberculosis H37Rv	151-158
34097497-2	2021	MAB_2355c was identified previously as a possible new factor that confers the intrinsic resistance of 194 clinical M. abscessus isolates to clarithromycin.	Clarithromycin	140-154	MAB_2355c	Mycobacterium abscessus	0-9
34221265-12	2021	Cost per effectiveness was higher for clarithromycin (CE=3,250,170 IRR) than for furazolidone (CE=2,988,488 IRR), and ICER showed that 5.1 Million IRR per participant is needed to eradicate H. pylori.	Clarithromycin	38-52	insulin receptor related receptor	Homo sapiens	67-70
35440370-5	2022	RESULTS: Co-incubation of clarithromycin with spike protein-stimulated healthy volunteer PBMCs ex vivo resulted in an increase in CD8+ (p = 0.004) and CD4+ (p = 0.007) IL-2, with a decrease in CD8+ (p = 0.032) and CD4+ (p = 0.007) IL-10.	Clarithromycin	26-40	interleukin 10	Homo sapiens	231-236
35440370-5	2022	RESULTS: Co-incubation of clarithromycin with spike protein-stimulated healthy volunteer PBMCs ex vivo resulted in an increase in CD8+ (p = 0.004) and CD4+ (p = 0.007) IL-2, with a decrease in CD8+ (p = 0.032) and CD4+ (p = 0.007) IL-10.	Clarithromycin	26-40	CD8a molecule	Homo sapiens	130-133
34193275-6	2021	Then, the rats were administered DGX orally (40 mug/kg), after some of them were orally administered clarithromycin (CAM; 10 mg/kg), a P-gp inhibitor.	Clarithromycin	101-115	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	135-139
35440370-5	2022	RESULTS: Co-incubation of clarithromycin with spike protein-stimulated healthy volunteer PBMCs ex vivo resulted in an increase in CD8+ (p = 0.004) and CD4+ (p = 0.007) IL-2, with a decrease in CD8+ (p = 0.032) and CD4+ (p = 0.007) IL-10.	Clarithromycin	26-40	CD4 molecule	Homo sapiens	151-154
35440370-6	2022	The addition of amoxicillin to clarithromycin resulted in an increase in CD8+ IL-6 (p = 0.010), decrease in CD8+ (p = 0.014) and CD4+ (p = 0.022) TNF-alpha, and decrease in CD8+ IFN-alpha (p = 0.038).	Clarithromycin	31-45	CD8a molecule	Homo sapiens	73-76
35440370-5	2022	RESULTS: Co-incubation of clarithromycin with spike protein-stimulated healthy volunteer PBMCs ex vivo resulted in an increase in CD8+ (p = 0.004) and CD4+ (p = 0.007) IL-2, with a decrease in CD8+ (p = 0.032) and CD4+ (p = 0.007) IL-10.	Clarithromycin	26-40	interleukin 2	Homo sapiens	168-172
35440370-5	2022	RESULTS: Co-incubation of clarithromycin with spike protein-stimulated healthy volunteer PBMCs ex vivo resulted in an increase in CD8+ (p = 0.004) and CD4+ (p = 0.007) IL-2, with a decrease in CD8+ (p = 0.032) and CD4+ (p = 0.007) IL-10.	Clarithromycin	26-40	CD8a molecule	Homo sapiens	193-196
35440370-5	2022	RESULTS: Co-incubation of clarithromycin with spike protein-stimulated healthy volunteer PBMCs ex vivo resulted in an increase in CD8+ (p = 0.004) and CD4+ (p = 0.007) IL-2, with a decrease in CD8+ (p = 0.032) and CD4+ (p = 0.007) IL-10.	Clarithromycin	26-40	CD4 molecule	Homo sapiens	214-217
35440370-6	2022	The addition of amoxicillin to clarithromycin resulted in an increase in CD8+ IL-6 (p = 0.010), decrease in CD8+ (p = 0.014) and CD4+ (p = 0.022) TNF-alpha, and decrease in CD8+ IFN-alpha (p = 0.038).	Clarithromycin	31-45	interleukin 6	Homo sapiens	78-82
35440370-6	2022	The addition of amoxicillin to clarithromycin resulted in an increase in CD8+ IL-6 (p = 0.010), decrease in CD8+ (p = 0.014) and CD4+ (p = 0.022) TNF-alpha, and decrease in CD8+ IFN-alpha (p = 0.038).	Clarithromycin	31-45	CD8a molecule	Homo sapiens	108-111
35440370-6	2022	The addition of amoxicillin to clarithromycin resulted in an increase in CD8+ IL-6 (p = 0.010), decrease in CD8+ (p = 0.014) and CD4+ (p = 0.022) TNF-alpha, and decrease in CD8+ IFN-alpha (p = 0.038).	Clarithromycin	31-45	CD4 molecule	Homo sapiens	129-132
35440370-6	2022	The addition of amoxicillin to clarithromycin resulted in an increase in CD8+ IL-6 (p = 0.010), decrease in CD8+ (p = 0.014) and CD4+ (p = 0.022) TNF-alpha, and decrease in CD8+ IFN-alpha (p = 0.038).	Clarithromycin	31-45	tumor necrosis factor	Homo sapiens	146-155
35440370-6	2022	The addition of amoxicillin to clarithromycin resulted in an increase in CD8+ IL-6 (p = 0.010), decrease in CD8+ (p = 0.014) and CD4+ (p = 0.022) TNF-alpha, and decrease in CD8+ IFN-alpha (p = 0.038).	Clarithromycin	31-45	CD8a molecule	Homo sapiens	173-176
35440370-6	2022	The addition of amoxicillin to clarithromycin resulted in an increase in CD8+ IL-6 (p = 0.010), decrease in CD8+ (p = 0.014) and CD4+ (p = 0.022) TNF-alpha, and decrease in CD8+ IFN-alpha (p = 0.038).	Clarithromycin	31-45	interferon alpha 1	Homo sapiens	178-187
35487253-6	2022	As well, OCT combined with MTZ/CLR restored the integrity of gastric mucosa damaged by H. pylori via elevating the expression of Muc5ac and somatostatin receptor 2, decreasing inflammation and increasing the number of chorionic or glands.	Clarithromycin	31-34	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	129-135
35579824-6	2022	The relative contributions of different cytochromes P450 (CYPs), mainly CYP3A4 and CYP2B6, involved in esketamine/noresketamine clearance was captured correctly in the IN-PBPK model using the DDI clinical studies of intranasal esketamine with clarithromycin and rifampicin and a published DDI study of oral esketamine with ticlopidine.	Clarithromycin	243-257	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	72-78
35616006-5	2022	However, asciminib exposure was slightly increased in subjects receiving an itraconazole capsule (~3%) or clarithromycin (~35%), another strong CYP3A inhibitor.	Clarithromycin	106-120	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	144-149
35487253-6	2022	As well, OCT combined with MTZ/CLR restored the integrity of gastric mucosa damaged by H. pylori via elevating the expression of Muc5ac and somatostatin receptor 2, decreasing inflammation and increasing the number of chorionic or glands.	Clarithromycin	31-34	somatostatin receptor 2	Homo sapiens	140-163
2527301-0	1989	Effects of clarithromycin on cytochrome P-450.	Clarithromycin	11-25	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	29-45
35002447-3	2022	H. pylori clarithromycin resistance has been associated with point mutations in 23srRNA, the most prominent of which are A2143 and A2144G.	Clarithromycin	10-24	mitochondrially encoded 12S RNA	Homo sapiens	82-87
2527301-5	1989	Nevertheless, clarithromycin formed cytochrome P-450 Fe(II)-metabolite complexes with microsomes from dexamethasone-treated rats in vitro, or after administration to dexamethasone-treated rats in vivo.	Clarithromycin	14-28	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	36-52
2527301-8	1989	We conclude that clarithromycin and roxithromycin induce cytochrome P-450p, but do not form complexes with this isoenzyme, although they do form complexes with other glucocorticoid-inducible isoenzymes.	Clarithromycin	17-31	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	57-74
2534682-0	1989	Immunological and anti-inflammatory effects of clarithromycin: inhibition of interleukin 1 production of murine peritoneal macrophages.	Clarithromycin	47-61	interleukin 1 complex	Mus musculus	77-90
3030158-1	1986	The Cypridina luciferin analog, 2-methyl-6-phenyl-3,7-dihydroimidazo[1,2-a]pyrazin-3-one (CLA), in Hanks" balanced salt solution, emitted a weak luminescence which was not affected by superoxide dismutase or catalase and was not augmented by resting human granulocytes.	Clarithromycin	90-93	catalase	Homo sapiens	208-216
3030158-3	1986	The light emission by CLA in the presence of activated granulocytes was inhibited by superoxide dismutase, but not by catalase or benzoate.	Clarithromycin	22-25	catalase	Homo sapiens	118-126
7291237-8	1981	The increase in water intake in CLA rats appears to be partly mediated by angiotensin II.	Clarithromycin	32-35	angiotensinogen	Rattus norvegicus	74-88
33991350-2	2021	Being a cytochrome P450 (CYP) 3A substrate, pharmacokinetic interactions of bedaquiline are anticipated with clarithromycin (a CYP3A inhibitor), which is routinely used in PNTM treatment.	Clarithromycin	109-123	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	8-32
33595670-3	2021	We show here that Clarithromycin impairs both the frequencies and number of interleukin (IL)-17 producing T helper (Th) 17 cells within the lungs of mice infected with a macrolide-resistant S. pneumoniae serotype 15A strain.	Clarithromycin	18-32	interleukin 17A	Mus musculus	76-95
34013847-3	2021	The plasma concentrations ratios of alpha-hydroxytriazolam and 4-hydroxytriazolam to triazolam in portal blood were significantly decreased by multiple administration of clarithromycin in CYP3A-humanised mice.These results suggest that intestinal CYP3A activity was inhibited by macrolide antibiotics in CYP3A-humanised mice in vitro and in vivo.	Clarithromycin	170-184	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	188-193
34013847-3	2021	The plasma concentrations ratios of alpha-hydroxytriazolam and 4-hydroxytriazolam to triazolam in portal blood were significantly decreased by multiple administration of clarithromycin in CYP3A-humanised mice.These results suggest that intestinal CYP3A activity was inhibited by macrolide antibiotics in CYP3A-humanised mice in vitro and in vivo.	Clarithromycin	170-184	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	247-252
34013847-3	2021	The plasma concentrations ratios of alpha-hydroxytriazolam and 4-hydroxytriazolam to triazolam in portal blood were significantly decreased by multiple administration of clarithromycin in CYP3A-humanised mice.These results suggest that intestinal CYP3A activity was inhibited by macrolide antibiotics in CYP3A-humanised mice in vitro and in vivo.	Clarithromycin	170-184	cytochrome P450, family 3, subfamily a, polypeptide 11	Mus musculus	247-252
33991350-2	2021	Being a cytochrome P450 (CYP) 3A substrate, pharmacokinetic interactions of bedaquiline are anticipated with clarithromycin (a CYP3A inhibitor), which is routinely used in PNTM treatment.	Clarithromycin	109-123	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	127-132
33829412-0	2021	Clarithromycin Ameliorates Early Brain Injury After Subarachnoid Hemorrhage via Suppressing Periostin-Related Pathways in Mice.	Clarithromycin	0-14	periostin, osteoblast specific factor	Mus musculus	92-101
33859206-2	2021	Here, we present the results of a retrospective observational study of clarithromycin resistance (Cla-res) in 4744 H. pylori-infected patients from Central Hungary.	Clarithromycin	71-85	selectin P ligand	Homo sapiens	98-101
33829412-3	2021	Clarithromycin (CAM) is a worldwide antibiotic that can inhibit periostin expression.	Clarithromycin	0-14	periostin, osteoblast specific factor	Mus musculus	64-73
33829412-3	2021	Clarithromycin (CAM) is a worldwide antibiotic that can inhibit periostin expression.	Clarithromycin	16-19	periostin, osteoblast specific factor	Mus musculus	64-73
33829412-10	2021	An intracerebroventricular injection of recombinant periostin blocked the neuroprotective effects of CAM in SAH mice (n = 6, respectively; p < 0.05).	Clarithromycin	101-104	periostin, osteoblast specific factor	Mus musculus	52-61
28520375-4	2012	In CYP2D6 poor metabolizers who are taking concomitant strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin), a quarter of the usual dose should be used (Table 1) (2).	Clarithromycin	101-115	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	3-9
33663821-10	2021	Supplementation with CLA affected the muscle concentrations of 22 metabolites on d 70 including 10 long-chain (>C22) sphingomyelin (SM), hydroxysphingomyelin [SM(OH)], PC-aa, and PC-ae along with 9 long-chain (>C16) lysoPC-a and 3 metabolites related to amino acids (spermine, citrulline, and Asp).	Clarithromycin	21-24	aspartoacylase	Bos taurus	293-296
33576040-7	2021	Moreover, the four compounds were found to be less active and safer against hIMPDH2 than the reference drugs, with IC50  > 17.17 microM, which makes sure that their selectivity is toward HpIMPDH and reverse to that of amoxicillin and clarithromycin.	Clarithromycin	234-248	inosine monophosphate dehydrogenase 2	Homo sapiens	76-83
28520375-4	2012	In CYP2D6 poor metabolizers who are taking concomitant strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin), a quarter of the usual dose should be used (Table 1) (2).	Clarithromycin	101-115	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-68
33348240-8	2021	A significant correlation between sildenafil CL/F and metabolic markers of CYP3A activity was observed after clarithromycin administration.	Clarithromycin	109-123	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	75-80
33348240-10	2021	Endogenous markers well reflected the CYP3A inhibition of clarithromycin, suggesting possible utility in DDI study with moderate to strong CYP3A inhibition; however, there are limitations in predicting intestinal CYP3A mediated DDI.	Clarithromycin	58-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-43
33348240-10	2021	Endogenous markers well reflected the CYP3A inhibition of clarithromycin, suggesting possible utility in DDI study with moderate to strong CYP3A inhibition; however, there are limitations in predicting intestinal CYP3A mediated DDI.	Clarithromycin	58-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	139-144
33348240-10	2021	Endogenous markers well reflected the CYP3A inhibition of clarithromycin, suggesting possible utility in DDI study with moderate to strong CYP3A inhibition; however, there are limitations in predicting intestinal CYP3A mediated DDI.	Clarithromycin	58-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	139-144
33552084-7	2020	In this model, the combination of E-CRP and clarithromycin drastically reduced bacteremia and increased survival of mice when compared to the protective effects of either E-CRP or clarithromycin alone.	Clarithromycin	44-58	C-reactive protein, pentraxin-related	Mus musculus	173-176
33552084-7	2020	In this model, the combination of E-CRP and clarithromycin drastically reduced bacteremia and increased survival of mice when compared to the protective effects of either E-CRP or clarithromycin alone.	Clarithromycin	180-194	C-reactive protein	Homo sapiens	36-39
33552084-8	2020	E-CRP was more effective in reducing bacteremia in mice treated with clarithromycin than in untreated mice.	Clarithromycin	69-83	C-reactive protein, pentraxin-related	Mus musculus	2-5
32967779-5	2020	The observed differences were associated with different inhibitory/inactivation potentials of troleandomycin, erythromycin, clarithromycin and azithromycin, suggesting CYP3A4 Template also as a tool for drug-interaction mechanisms.	Clarithromycin	124-138	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	168-174
33341955-4	2021	The coadministration of tegoprazan with amoxicillin/clarithromycin increased Css,max (2.2-fold) and AUCtau (2.7-fold) of tegoprazan and M1 (2.1- and 2.2-fold for Css,max and AUCtau , respectively) compared to administration of tegoprazan alone.	Clarithromycin	52-66	cytidine monophosphate N-acetylneuraminic acid synthetase	Homo sapiens	77-80
33341955-4	2021	The coadministration of tegoprazan with amoxicillin/clarithromycin increased Css,max (2.2-fold) and AUCtau (2.7-fold) of tegoprazan and M1 (2.1- and 2.2-fold for Css,max and AUCtau , respectively) compared to administration of tegoprazan alone.	Clarithromycin	52-66	cytidine monophosphate N-acetylneuraminic acid synthetase	Homo sapiens	162-165
33341955-5	2021	The Css,max and AUCtau of 14-OH-clarithromycin increased by 1.7- and 1.8-fold, respectively, on the other hand disposition of amoxicillin and clarithromycin were not significantly changed.	Clarithromycin	32-46	cytidine monophosphate N-acetylneuraminic acid synthetase	Homo sapiens	4-7
33550966-2	2021	The present work is an effort for a computational target to block the spike proteins (S) and ACE2 receptor proteins with Macrolide antibiotics like Azithromycin, (AZM), Clarithromycin (CLAM) and Erythromycin (ERY) along with RNA-dependent RNA polymerase (RdRp).	Clarithromycin	169-183	angiotensin converting enzyme 2	Homo sapiens	93-97
33550966-2	2021	The present work is an effort for a computational target to block the spike proteins (S) and ACE2 receptor proteins with Macrolide antibiotics like Azithromycin, (AZM), Clarithromycin (CLAM) and Erythromycin (ERY) along with RNA-dependent RNA polymerase (RdRp).	Clarithromycin	185-189	angiotensin converting enzyme 2	Homo sapiens	93-97
33550966-6	2021	Interaction of CLAM and ERY presented low binding energy (-6.8 and -6.6) with the ACE2 receptor.	Clarithromycin	15-19	angiotensin converting enzyme 2	Homo sapiens	82-86
33173988-2	2020	We previously reported that macrolide antibiotics such as azithromycin (AZM) and clarithromycin (CAM) potently inhibit autophagic flux and that combining AZM or CAM with the epidermal growth factor receptor inhibitors enhanced their antitumor effect against various cancer cells.	Clarithromycin	81-95	epidermal growth factor receptor	Homo sapiens	174-206
33173988-2	2020	We previously reported that macrolide antibiotics such as azithromycin (AZM) and clarithromycin (CAM) potently inhibit autophagic flux and that combining AZM or CAM with the epidermal growth factor receptor inhibitors enhanced their antitumor effect against various cancer cells.	Clarithromycin	97-100	epidermal growth factor receptor	Homo sapiens	174-206
33173988-2	2020	We previously reported that macrolide antibiotics such as azithromycin (AZM) and clarithromycin (CAM) potently inhibit autophagic flux and that combining AZM or CAM with the epidermal growth factor receptor inhibitors enhanced their antitumor effect against various cancer cells.	Clarithromycin	161-164	epidermal growth factor receptor	Homo sapiens	174-206
32958515-4	2020	The highest-ranked drug was the macrolide antibiotic Clarithromycin, which has previously been reported to have anti-inflammatory effects in aseptic conditions.Clarithromycin"s effects were validated in several experiments: it influenced NF-kappaB mediated transcription in murine peritoneal macrophages and intestinal enteroids; it suppressed NF-kappaB protein shuttling in murine reporter enteroids; it suppressed NF-kappaB (p65) DNA binding in the small intestine of mice exposed to LPS, and it reduced the severity of dextran sulphate sodium-induced colitis in C57BL/6 mice.	Clarithromycin	53-67	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	238-247
32628085-3	2020	Some of the exposure-enhancing effects of clarithromycin may originate from its inhibitory potential toward OATP1B1, because the estimated effects of itraconazole (also a P450 3A4 inhibitor) were only minor.Simulations using the current PBPK model in groups of virtual subjects with or without renal or hepatic impairment revealed modified pharmacokinetic profiles for pemafibrate following co-administration of typical P450 inhibitors.	Clarithromycin	42-56	solute carrier organic anion transporter family member 1B1	Homo sapiens	108-115
32657910-9	2020	The final model of theophylline clearance was as follows: CL/F (L/hr/kg) = 0.0484 x 1.40 x 0.861 x 0.889 x 0.557.Smoking is a well-known factor that markedly enhances CL/F through the induction of CYP1A enzymes, whereas CAM has been reported to inhibit CYP3A4.	Clarithromycin	220-223	cytokine receptor like factor 1	Homo sapiens	58-62
32958515-4	2020	The highest-ranked drug was the macrolide antibiotic Clarithromycin, which has previously been reported to have anti-inflammatory effects in aseptic conditions.Clarithromycin"s effects were validated in several experiments: it influenced NF-kappaB mediated transcription in murine peritoneal macrophages and intestinal enteroids; it suppressed NF-kappaB protein shuttling in murine reporter enteroids; it suppressed NF-kappaB (p65) DNA binding in the small intestine of mice exposed to LPS, and it reduced the severity of dextran sulphate sodium-induced colitis in C57BL/6 mice.	Clarithromycin	53-67	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	344-353
32958515-4	2020	The highest-ranked drug was the macrolide antibiotic Clarithromycin, which has previously been reported to have anti-inflammatory effects in aseptic conditions.Clarithromycin"s effects were validated in several experiments: it influenced NF-kappaB mediated transcription in murine peritoneal macrophages and intestinal enteroids; it suppressed NF-kappaB protein shuttling in murine reporter enteroids; it suppressed NF-kappaB (p65) DNA binding in the small intestine of mice exposed to LPS, and it reduced the severity of dextran sulphate sodium-induced colitis in C57BL/6 mice.	Clarithromycin	53-67	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	344-353
32958515-4	2020	The highest-ranked drug was the macrolide antibiotic Clarithromycin, which has previously been reported to have anti-inflammatory effects in aseptic conditions.Clarithromycin"s effects were validated in several experiments: it influenced NF-kappaB mediated transcription in murine peritoneal macrophages and intestinal enteroids; it suppressed NF-kappaB protein shuttling in murine reporter enteroids; it suppressed NF-kappaB (p65) DNA binding in the small intestine of mice exposed to LPS, and it reduced the severity of dextran sulphate sodium-induced colitis in C57BL/6 mice.	Clarithromycin	53-67	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	427-430
32958515-4	2020	The highest-ranked drug was the macrolide antibiotic Clarithromycin, which has previously been reported to have anti-inflammatory effects in aseptic conditions.Clarithromycin"s effects were validated in several experiments: it influenced NF-kappaB mediated transcription in murine peritoneal macrophages and intestinal enteroids; it suppressed NF-kappaB protein shuttling in murine reporter enteroids; it suppressed NF-kappaB (p65) DNA binding in the small intestine of mice exposed to LPS, and it reduced the severity of dextran sulphate sodium-induced colitis in C57BL/6 mice.	Clarithromycin	160-174	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	238-247
32958515-4	2020	The highest-ranked drug was the macrolide antibiotic Clarithromycin, which has previously been reported to have anti-inflammatory effects in aseptic conditions.Clarithromycin"s effects were validated in several experiments: it influenced NF-kappaB mediated transcription in murine peritoneal macrophages and intestinal enteroids; it suppressed NF-kappaB protein shuttling in murine reporter enteroids; it suppressed NF-kappaB (p65) DNA binding in the small intestine of mice exposed to LPS, and it reduced the severity of dextran sulphate sodium-induced colitis in C57BL/6 mice.	Clarithromycin	160-174	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	344-353
32958515-4	2020	The highest-ranked drug was the macrolide antibiotic Clarithromycin, which has previously been reported to have anti-inflammatory effects in aseptic conditions.Clarithromycin"s effects were validated in several experiments: it influenced NF-kappaB mediated transcription in murine peritoneal macrophages and intestinal enteroids; it suppressed NF-kappaB protein shuttling in murine reporter enteroids; it suppressed NF-kappaB (p65) DNA binding in the small intestine of mice exposed to LPS, and it reduced the severity of dextran sulphate sodium-induced colitis in C57BL/6 mice.	Clarithromycin	160-174	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	344-353
32958515-4	2020	The highest-ranked drug was the macrolide antibiotic Clarithromycin, which has previously been reported to have anti-inflammatory effects in aseptic conditions.Clarithromycin"s effects were validated in several experiments: it influenced NF-kappaB mediated transcription in murine peritoneal macrophages and intestinal enteroids; it suppressed NF-kappaB protein shuttling in murine reporter enteroids; it suppressed NF-kappaB (p65) DNA binding in the small intestine of mice exposed to LPS, and it reduced the severity of dextran sulphate sodium-induced colitis in C57BL/6 mice.	Clarithromycin	160-174	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	427-430
32958515-5	2020	Clarithromycin also suppressed NF-kappaB (p65) nuclear translocation in human intestinal enteroids.Conclusions: These findings demonstrate that in-silico drug repositioning algorithms can viably be allied to laboratory validation assays in the context of inflammatory bowel disease; and that further clinical assessment of clarithromycin in the management of inflammatory bowel disease is required.	Clarithromycin	0-14	nuclear factor kappa B subunit 1	Homo sapiens	31-40
32958515-5	2020	Clarithromycin also suppressed NF-kappaB (p65) nuclear translocation in human intestinal enteroids.Conclusions: These findings demonstrate that in-silico drug repositioning algorithms can viably be allied to laboratory validation assays in the context of inflammatory bowel disease; and that further clinical assessment of clarithromycin in the management of inflammatory bowel disease is required.	Clarithromycin	0-14	RELA proto-oncogene, NF-kB subunit	Homo sapiens	42-45
32951003-7	2020	Furthermore, treatment with (+)-CLA reduced the mRNA level of prostaglandin endoperoxide synthase 2 while it increased the protein level of glutathione peroxidase 4 in hepatocytes and mouse liver, confirming that the inhibition of ferroptosis contributes to the protective effect of (+)-CLA on drug-induced liver damage.	Clarithromycin	32-35	prostaglandin-endoperoxide synthase 2	Mus musculus	62-99
33226983-0	2020	Genetic and pharmacological relationship between P-glycoprotein and increased cardiovascular risk associated with clarithromycin prescription: An epidemiological and genomic population-based cohort study in Scotland, UK.	Clarithromycin	114-128	ATP binding cassette subfamily B member 1	Homo sapiens	49-63
33226983-3	2020	To the best of our knowledge, no studies have examined whether this association might be mediated via P-glycoprotein (P-gp), a major pathway for clarithromycin metabolism.	Clarithromycin	145-159	ATP binding cassette subfamily B member 1	Homo sapiens	102-116
33226983-3	2020	To the best of our knowledge, no studies have examined whether this association might be mediated via P-glycoprotein (P-gp), a major pathway for clarithromycin metabolism.	Clarithromycin	145-159	ATP binding cassette subfamily B member 1	Homo sapiens	118-122
33226983-4	2020	The aim of this study was to examine CV risk following prescription of clarithromycin versus amoxicillin and in particular, the association with P-gp, a major pathway for clarithromycin metabolism.	Clarithromycin	71-85	ATP binding cassette subfamily B member 1	Homo sapiens	145-149
33226983-4	2020	The aim of this study was to examine CV risk following prescription of clarithromycin versus amoxicillin and in particular, the association with P-gp, a major pathway for clarithromycin metabolism.	Clarithromycin	171-185	ATP binding cassette subfamily B member 1	Homo sapiens	145-149
33226983-10	2020	Clarithromycin use was significantly associated with increased risk of CV hospitalization compared with amoxicillin at both 0-14 days (HR 1.31; 95% CI 1.17-1.46, p < 0.001) and 30 days to 1 year (HR 1.13; 95% CI 1.06-1.19, p < 0.001), with the association at 0-14 days modified by use of P-gp inhibitors or substrates (interaction p-value: 0.029).	Clarithromycin	0-14	ATP binding cassette subfamily B member 1	Homo sapiens	288-292
33226983-13	2020	CONCLUSIONS: In this study, we observed that the increased risk of CV events with clarithromycin compared with amoxicillin was associated with an interaction with P-glycoprotein.	Clarithromycin	82-96	ATP binding cassette subfamily B member 1	Homo sapiens	163-177
32951003-7	2020	Furthermore, treatment with (+)-CLA reduced the mRNA level of prostaglandin endoperoxide synthase 2 while it increased the protein level of glutathione peroxidase 4 in hepatocytes and mouse liver, confirming that the inhibition of ferroptosis contributes to the protective effect of (+)-CLA on drug-induced liver damage.	Clarithromycin	32-35	glutathione peroxidase 4	Mus musculus	140-164
32559772-0	2020	Comparative Study of the Effect of Macrolide Antibiotics Erythromycin, Clarithromycin, and Azithromycin on the ERG1 Gene Expression in H9c2 Cardiomyoblast Cells.	Clarithromycin	71-85	potassium voltage-gated channel subfamily H member 2	Rattus norvegicus	111-115
32936818-0	2020	Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy.	Clarithromycin	98-112	prolyl endopeptidase	Mus musculus	27-30
32559772-3	2020	The aim of this study was to compare the effects of erythromycin, clarithromycin and azithromycin on cell viability and expression of ERG1 gene in H9c2 cells.	Clarithromycin	66-80	potassium voltage-gated channel subfamily H member 2	Rattus norvegicus	134-138
32929360-12	2020	Furthermore, DHA, but not MTX, reduced the presence of CD8+CLA+, CD8+CD69+ or CD8+CD103+ TRM cells in mouse skin.	Clarithromycin	59-62	CD8a molecule	Homo sapiens	55-58
32391435-2	2020	Our findings indicate that the antibiotic clarithromycin can target hERG1 and modulate autophagy to promote the death of chemoresistant colorectal cancer cells.	Clarithromycin	42-56	potassium voltage-gated channel subfamily H member 2	Homo sapiens	68-73
32274687-2	2020	Clarithromycin, a strong inhibitor of CYP3A4 and P-glycoprotein, dramatically increases colchicine"s half-life, augmenting the risk of a life-threatening adverse reaction when used inadvertently with colchicine.	Clarithromycin	0-14	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-44
32274687-2	2020	Clarithromycin, a strong inhibitor of CYP3A4 and P-glycoprotein, dramatically increases colchicine"s half-life, augmenting the risk of a life-threatening adverse reaction when used inadvertently with colchicine.	Clarithromycin	0-14	ATP binding cassette subfamily B member 1	Homo sapiens	49-63
28861755-0	2020	Clarithromycin decreases rhinovirus replication and cytokine production in nasal epithelial cells from subjects with bronchial asthma: effects on IL-6, IL-8 and IL-33.	Clarithromycin	0-14	interleukin 6	Homo sapiens	146-150
28861755-0	2020	Clarithromycin decreases rhinovirus replication and cytokine production in nasal epithelial cells from subjects with bronchial asthma: effects on IL-6, IL-8 and IL-33.	Clarithromycin	0-14	C-X-C motif chemokine ligand 8	Homo sapiens	152-156
28861755-0	2020	Clarithromycin decreases rhinovirus replication and cytokine production in nasal epithelial cells from subjects with bronchial asthma: effects on IL-6, IL-8 and IL-33.	Clarithromycin	0-14	interleukin 33	Homo sapiens	161-166
28861755-6	2020	Pretreatment with clarithromycin also decreased IL-33 production, which was detected after infection.	Clarithromycin	18-32	interleukin 33	Homo sapiens	48-53
28861755-7	2020	Pretreatment with clarithromycin decreased the expression of intercellular adhesion molecule-1, the receptor for RV14, after infection, the number and fluorescence intensity of the acidic endosomes through which RV RNA enters the cytoplasm, and the activation of nuclear factor kappa-B proteins in nuclear extracts.	Clarithromycin	18-32	intercellular adhesion molecule 1	Homo sapiens	61-94
31628882-6	2020	The 16 cases of statin-clarithromycin adverse drug reactions (rhabdomyolysis (n = 14) or less severe clinical myopathy) involved a CYP3A4-metabolized statin (simvastatin, lovastatin or atorvastatin).	Clarithromycin	23-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	131-137
31635898-4	2020	and reagents (dexamethasone (DEX), clarithromycin (CAM) and curcumin (CUM)) on HIF-1alpha expression in cultured normal nasal epithelial cells (NECs) were also evaluated.	Clarithromycin	35-49	hypoxia inducible factor 1 subunit alpha	Homo sapiens	79-89
31635898-4	2020	and reagents (dexamethasone (DEX), clarithromycin (CAM) and curcumin (CUM)) on HIF-1alpha expression in cultured normal nasal epithelial cells (NECs) were also evaluated.	Clarithromycin	51-54	hypoxia inducible factor 1 subunit alpha	Homo sapiens	79-89
31635898-8	2020	Both CAM and CUM showed an additive effect with DEX in inhibiting HIF-1alpha expression (P &lt; 0.05).	Clarithromycin	5-8	hypoxia inducible factor 1 subunit alpha	Homo sapiens	66-76
31677184-8	2020	Program eradication rates using clarithromycin-based triple therapy were suboptimal (73.7%, 95% CI: 70.0-77.4%); the habits of smoking (1.70-fold, 95% CI: 1.01-2.39) and betel nut chewing (1.54-fold, 95% CI: 0.93-2.16) were associated with the higher risk of treatment failure.	Clarithromycin	32-46	NUT midline carcinoma family member 1	Homo sapiens	176-179
32231201-0	2020	Correction: Clarithromycin inhibits autophagy in colorectal cancer by regulating the hERG1 potassium channel interaction with PI3K.	Clarithromycin	12-26	potassium voltage-gated channel subfamily H member 2	Homo sapiens	85-90
32074497-7	2020	PAM is highly effective in clarithromycin-resistant cases (70.4% versus 48.2%, RR = 0.65, p = 0.002) and that PAC showed significant efficacy in metronidazole-resistant cases (87.3% versus 58.6%, RR = 1.43, p = 0.0006).	Clarithromycin	27-41	peptidylglycine alpha-amidating monooxygenase	Homo sapiens	0-3
32123164-0	2020	Clarithromycin inhibits autophagy in colorectal cancer by regulating the hERG1 potassium channel interaction with PI3K.	Clarithromycin	0-14	potassium voltage-gated channel subfamily H member 2	Homo sapiens	73-78
32123164-4	2020	Because Cla is known to bind human Ether-a-go-go Related Gene 1 (hERG1) K+ channels, we studied if its effects depended on hERG1 and its conformational states.	Clarithromycin	8-11	potassium voltage-gated channel subfamily H member 2	Homo sapiens	65-70
32123164-4	2020	Because Cla is known to bind human Ether-a-go-go Related Gene 1 (hERG1) K+ channels, we studied if its effects depended on hERG1 and its conformational states.	Clarithromycin	8-11	potassium voltage-gated channel subfamily H member 2	Homo sapiens	123-128
32123164-5	2020	By availing of hERG1 mutants with different gating properties, we found that fluorescently labelled Cla preferentially bound to the closed channels.	Clarithromycin	100-103	potassium voltage-gated channel subfamily H member 2	Homo sapiens	15-20
32123164-6	2020	Furthermore, by sequestering the channel in the closed conformation, Cla inhibited the formation of a macromolecular complex between hERG1 and the p85 subunit of PI3K.	Clarithromycin	69-72	potassium voltage-gated channel subfamily H member 2	Homo sapiens	133-138
32123164-9	2020	We conclude that Cla affects the autophagic flux by impairing the signaling pathway linking hERG1 and PI3K.	Clarithromycin	17-20	potassium voltage-gated channel subfamily H member 2	Homo sapiens	92-97
32148980-13	2020	Review of 6 previously reported and current case of clarithromycin-associated ALF revealed that patients had AST and ALT values in the thousands.	Clarithromycin	52-66	solute carrier family 17 member 5	Homo sapiens	109-112
32104016-7	2020	qRT-PCR analysis showed that the increased expression of the efflux pump genes, MAB_2355c, MAB_1409c and MAB_1846, as well as their positive regulatory gene whiB7, consistently correlated with increased clarithromycin resistance.	Clarithromycin	203-217	MAB_2355c	Mycobacterium abscessus	80-89
32104016-7	2020	qRT-PCR analysis showed that the increased expression of the efflux pump genes, MAB_2355c, MAB_1409c and MAB_1846, as well as their positive regulatory gene whiB7, consistently correlated with increased clarithromycin resistance.	Clarithromycin	203-217	MAB_1409c	Mycobacterium abscessus	91-100
31791943-3	2020	However, it has been debated whether clarithromycin and azithromycin differ in the extent to which they induce erm(41)-mediated macrolide resistance.	Clarithromycin	37-51	ETS variant transcription factor 5b	Danio rerio	111-114
31791943-6	2020	Visualization of fluorescent bacilli in infected zebrafish demonstrates that azithromycin and clarithromycin activate erm(41) expression in vivo That azithromycin induces a more rapid expression of erm(41) was confirmed by measuring the beta-galactosidase activity of a reporter strain in which lacZ was placed under the control of the erm (41) promoter.	Clarithromycin	94-108	ETS variant transcription factor 5b	Danio rerio	118-121
31791943-6	2020	Visualization of fluorescent bacilli in infected zebrafish demonstrates that azithromycin and clarithromycin activate erm(41) expression in vivo That azithromycin induces a more rapid expression of erm(41) was confirmed by measuring the beta-galactosidase activity of a reporter strain in which lacZ was placed under the control of the erm (41) promoter.	Clarithromycin	94-108	ETS variant transcription factor 5b	Danio rerio	198-201
31791943-6	2020	Visualization of fluorescent bacilli in infected zebrafish demonstrates that azithromycin and clarithromycin activate erm(41) expression in vivo That azithromycin induces a more rapid expression of erm(41) was confirmed by measuring the beta-galactosidase activity of a reporter strain in which lacZ was placed under the control of the erm (41) promoter.	Clarithromycin	94-108	ETS variant transcription factor 5b	Danio rerio	198-201